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ABSTRACT
There is considerable evidence indicating an 
association between aflatoxin ingestion and liver cancer in 
humans. The development of methods that would permit the 
monitoring of aflatoxin exposure in individuals would 
provide useful information in assessing human risk from 
this toxin. In this study, an ELISA technique, using a 
polyclonal antibody raised against aflatoxin Bi in the 
rabbit, was developed for monitoring the levels of 
aflatoxin excreted in human urine samples. Urine could not 
be used directly in the assay because high blanks were 
observed from the presence of some aflatoxin-like 
substances. A 'clean-up' procedure using Sep-Pak C13 
cartridges and immunoaffinity columns was developed. The 
methods were validated using ^H-AFBp in both buffer and 
presumed uncontaminated human urine samples from 
Europeans. As AFBi itself is unlikely to be found in human 
samples, urine from marmoset monkeys treated with l^c-AFBi 
were also used in the validation processes as they are 
likely to contain a spectrum of aflatoxin metabolites 
similar to those in human urine. The levels of AFB^ 
equivalents were monitored by both radioactive counting and 
ELISA. The radioactive measurements demonstrated that the 
overall recovery of the ELISA method was approximately 
50%. The failure to detect all of the aflatoxin
contamination in the urine may be due to the inability of 
the antibody to detect most of the polar aflatoxin
metabolites.
When the ELISA method was used in monitoring
aflatoxin excreted in patients with or without liver 
disease from Thailand, a range of aflatoxin levels in the 
urine samples were obtained. Since in Thailand, liver 
fluke infection, caused by Opisthorchis viverrini is a 
serious health problem in the area where there is high
contamination with aflatoxin in food and a high incidence
of liver cancer, the interaction between liver fluke 
infection and aflatoxin ingestion was also studied using 
hamster as an animal model. The results indicated that 
liver fluke infection may alter the pattern of aflatoxin 
metabolites excreted in hamster urine, which in turn could 
affect the results obtained from the ELISA.
Measurements by the ELISA method of aflatoxin excreted 
in urine samples from Thai vegetarians; who are a 
population at high risk of exposure to aflatoxin suggested 
that this group of people excreted higher levels of 
aflatoxin, but a further study with a greater number of 
subjects would be necessary to confirm this finding.
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LIST OF ABBREVIATIONS
AFBi Aflatoxin Bi
AFB2 Aflatoxin B2
AFGi Aflatoxin Gi
AFG2 Aflatoxin G2
AFL Aflatoxicol
AFMi Aflatoxin Mi
AFPi Aflatoxin Pi
AFQi Aflatoxin Qi
AFBi*-Cys 8 , 9-Dihydro-8- (S-cysteinyl)-9-hydroxy
aflatoxin Bi
AFBi-Cys-Gly 8 ,9-Dihydro-8-(S-cysteinyl-glycyl)-9-
hydroxy aflatoxin Bi
AFBi-dhd 8 ,9-Dihydro-8,9-dihydroxy aflatoxin Bi
AFBi-FAPy 8 ,9-Dihydro-8-(N5-formyl-2',5',6 '-triamino-
4'-oxo-N^-pyrimidyl)-9-hydroxy aflatoxin Bi
AFBi-GSH 8 ,9-Dihydro-8-(S-glutathionyl)-9-hydroxy
aflatoxin Bi
AFBi-Gua 8 ,9-Dihydro-8-(N7-guanyl)-9-hydroxy
aflatoxin Bi
AFBi-NAcCys 8 ,9-Dihydro-8-(S-Cysteinyl)-(N-acetyl)-9-
hydroxy aflatoxin Bi
AFB2a 8 ,9-Dihydro-8-hydroxy aflatoxin Bi
AFLHi Aflatoxicol of AFQi
AFLMi Aflatoxicol of AFMi
BSA Bovine serum albumin
DMSO Dimethyl sulphoxide
ELISA Enzyme-linked immunosorbent assay
GSH Reduced glutathione
HBV Hepatitis B virus
HPLC High performance liquid chromatography
PBS Phosphate-buffered saline
PHC Primary hepatocellular carcinoma
RIA Radioimmunoassay
TLC Thin-layer chromatography
Tween 20 Polyoxyethylenesorbitan monolaurate
UALS Urinary aflatoxin-like substances
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CHAPTER 1
General Introduction
1
Aflatoxins were first discovered in the early 1960's 
following the outbreak of 'Turkey X disease' in the South 
and East of England. This disease was characterized by 
subcutaneous haemorrhage, weight loss, lethargy and death 
in turkeys. Postmortem examination revealed acute hepatic 
necrosis with generalised bile duct proliferation. There 
were losses of other birds, including ducklings, and also 
swine, cattle and sheep. They all had similar symptoms to 
the turkeys. The common factor in the death of these 
animals was shown to be the use in animal feedstuffs of 
batches of groundnut meal which had been imported from 
Brazil (see Goldblatt, 1969). The groundnut meal was found 
to be heavily contaminated with a fungus which, using 
subsequently imported toxic groundnuts, was identified as 
Aspergillus flavus (Sargeant et al., 1961). A toxic
substance was extracted which produced .the same results in 
ducklings as the groundnut meal and this mycotoxin was 
given the name "aflatoxin".
When conditions of humidity and temperature permit, 
aflatoxins are formed on stored foodstuffs by species 
of Aspergillus (Stoloff, 1977). The aflatoxins
are a group of secondary metabolites produced by some 
strains of Aspergillus flavus and Aspergillus parasiticus. 
Aflatoxins have been found as natural contaminants in many 
types of food, e.g. peanut, cottonseed meal, corn and rice 
(Wogan, 1968; Shank et al., 1972a,b), particularly in
tropical countries.
2
1.1 CHEMICAL STRUCTURES AND PROPERTIES
Aflatoxins are highly substituted coumarins containing 
a fused dihydrofurofuran moiety. There are four main 
naturally occurring aflatoxins (Figure 1.1). AFB^ and AFB2 
were so designated because of their strong blue fluores­
cence under UV light, whereas AFGi and AFG2 fluoresced 
greenish yellow (Nesbitt et al., 1962; Asao et al., 1965). 
The B toxins can be characterized by the fusion of a 
cyclopentenone ring to the lactone ring of the coumarin 
structure; the G toxins contain an additional fused lactone 
ring instead. AFB^ and, to a somewhat lesser extent, AFG^ 
were responsible for the extreme biological potency of 
aflatoxin-contaminated meals and crude fractions derived 
from toxigenic A. flavus cultures. These two toxins 
possess an unsaturated bond at the 8,9-position on the 
terminal furan ring. The much less potent AFB2 and AFG2 
are saturated at this position (Asao et al., 1965).
The aflatoxins are soluble in methanol, chloroform, 
dimethyl sulphoxide, dimethylformamide and other organic 
solvents. They are also soluble in ethanol and propylene 
glycol but less so and only sparingly soluble in water 
(10-30 pg/ml) (Busby and Wogan, 1984). Although aflatoxins 
are quite stable in food and feedstuffs, they are rapidly 
deactivated by extremes of pH (< 3 or > 10), oxidizing 
agents, or exposure to UV light in the presence of oxygen 
(Stoloff, 1977). A thorough review of the chemistry of 
aflatoxins is given by Heathcote and Hibbert (1978).
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1.2 CONTAMINATION OF FOOD BY AFLATOXINS
A great many different food have been shown to be 
contaminated by aflatoxins. Food most commonly implicated 
are peanuts, maize, cassava, dried fish, rice and some
alcoholic beverages fermented from maize (see Busby and 
Wogan, 1984). Milk from some village dairies has been
found to contain high levels of AFM^ (Suzanger et al.,
1976). In a study carried out in Sudan, it was found that 
some women excreted aflatoxins in breast-milk at levels
similar to or higher than those considered safe in animal
milk, for human consumption; (Coulter et al., 1984).
Human populations may be exposed to aflatoxins by the 
consumption of commodities that have been directly con­
taminated by toxigenic strains of A. flavus or A. 
parasiticus during growth, harvest or storage. Secondary 
exposure may occur by the consumption of products, e.g. 
meat and other edible tissues, milk and dairy products and 
eggs, derived from animals that have consumed aflatoxin- 
contaminated feeds (Busby and Wogan, 1984). The risk of 
exposure to aflatoxins is apparently less in techno­
logically developed countries than in developing ones. 
This may be because of inadequate food storage facilities 
and preservation techniques, combined with the naturally 
warm, humid weather, generally unhygienic environmental 
conditions and ignorance which provide an atmosphere 
conducive to the growth of fungus and consequently to the 
elaboration of aflatoxins on foodstuffs (see Denning, 
1987).
Many ways of removing aflatoxins from food have been 
devised, either intentionally or by long traditional means 
of food handling (Sauer, 1978). The most effective means 
of lowering aflatoxin contamination in the developing
countries is by preventing insect and chemical damage to
crops, picking during the dry season (if possible) and 
ensuring adequate drying of crops and storage of crops in a 
cool, dry atmosphere protected from insect infestation.
1.3 METABOLISM OF AFLATOXINS
AFBi is actively metabolized in a variety of animal
species. Figure 1.2 shows an overall scheme of AFB^ 
metabolism. The relative importance of each individual
pathway varies substantially (depending on the animal 
species and the experimental conditions. Essentially, the 
initial metabolism of AFB^ involves three; principal types 
of reactions: (a) hydroxylation, (b) epoxidation and (c)
ketoreduction. The former two reactions are believed to be 
carried out principally by a microsomal mixed-function 
oxidase system, the latter by a cytosolic NADPH-dependent 
reductase. In most animal species the hydroxylated AFB^ 
metabolites may undergo phase II metabolism by conjugating 
with glucuronic acid or sulphate (see Busby and Wogan, 
1984; Woo et al, 1988).
There have been a large number of studies on the 
metabolism of AFB^ in different species (see Busby and 
Wogan, 1984; Neal, 1987). Unfortunately, many of the
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7
earlier investigations used species whose primary metabolic 
pathways have subsequently been found to be different from 
man's and are, therefore, of limited help in understanding 
the relationship between metabolism and toxicity in man 
(Hsieh et al. , 1977). The monkey apparently possesses
similar pathways of aflatoxin metabolism to the human and, 
therefore, information available from studies involving 
this species is relevant to the human situation. In the 
last decade, there has been a large number of studies of 
the metabolism of aflatoxins in in vitro systems using a 
variety of human tissue preparations. These have mainly 
involved the presumed target tissue, the liver, used in 
various forms from subcellular fractions to isolated 
hepatocytes and tissue explants. In many of these studies, 
assays using the corresponding animal tissues have been 
carried out, in parallel with the human studies, to enable 
the assessment of relative susceptibilities (see Neal, 
1987).
The human hepatic metabolism of aflatoxins will 
largely depend on the cytochrome P450 content, which is 
controlled by exogenous and endogenous factors. Amongst 
endogenous determinants, which may be viewed as analogous 
to the strain differences which occur within animal 
species, there is increasing evidence for polymorphism in 
the cytochrome P450 content of human liver, in which the 
types of cytochrome present, or their activities, are 
genetically segregated into specific cohorts within general 
population (Idle and Smith, 1979; Ritchie and Idle, 1982).
8
In addition to the genetically determined factors 
related to the individual species of cytochromes which 
affect the susceptibility of humans to aflatoxins, there is 
the influence of environmental or exogenous factors. 
General dietary sufficiency or insufficiency is known to 
affect general cytochrome P450 levels in animals and 
presumably would similarly affect humans. A comparison of 
the effects of low and sufficient protein diets on the type 
of aflatoxin-induced lesions in rats (Madhavan and 
Gopaland, 1965) could reflect, in part, the effects of 
these diets on the levels of drug metabolizing systems. 
Also, in humans the influence of dietary constituents, 
tobacco smoking and alcohol intake will modify the 
intrinsic capacity to metabolize environmental pollutants, 
including the aflatoxins.
In human microsomal systems, a frequently reported 
major route of AFBi metabolism is by hydroxylation in the 
cyclopentenone ring to form AFQi (Masri et al., 1974;
Roebuck and Wogan, 1977; Moss and Neal, 1985), although in 
one study, AFMi anc^  AFPi were the principal metabolites 
observed (Merrill and Campbell, 1974). The high metabolic 
production of AFQi in vitro appears to be a feature of 
primates, similar results having been obtained using 
hepatic microsome fractions from rhesus and marmoset 
monkeys (Masri et al. , 1974; G.E. Neal, personal
communication). Details of studies involving AFQi are 
given in Chapter 3.
Another feature of the in vitro primary microsomal 
metabolism of AFBi by human liver is an overall high rate
9
of metabolic conversion which can be compared with the high 
rate of metabolism observed in avian species (Moss and 
Neal, 1985) . Human microsomal AFBi metabolism results in 
relative levels of production of AFQi anc^  AFBi-dhd of 
60-90% and 10-20% respectively, whereas using avian 
microsomes the production of these metabolites is 0% and 
85-95% respectively (Moss and Neal, 1985; Neal et. al., 
1986). With few exceptions, AFMi ^as generally been 
reported to be a minor microsomal metabolite in human liver 
systems, although some individual variation in its 
production has been indicated (Moss and Neal, 1985). AFMi 
probably comprises 1-4% of consumed AFBi (Campbell et al. , 
1970? Sun and Chu, 1984) but despite the low level of 
production, AFMi appears to be the only primary metabolite 
of AFBi to be excreted in an unconjugated form and, 
therefore, it may be useful in assessing aflatoxin 
consumption (Denning, 1987).
Reports of the formation of AFPi, from AFBi by a 
mixed-function oxidase catalysed O-demethylation process, 
in iri vitro human microsomal incubations have varied from 
AFPi being a principal metabolite to its being a minor 
product, if present at all (Merrill and Campbell, 1974; 
Roebuck and Wogan, 1977? Moss and Neal, 1985). Even within 
individual studies, the level of formation of AFPi relative 
to AFQi has varied between individual samples from 1:4 to 
1:54 (Roebuck and Wogan, 1977). AFPi frequently found 
as the p-glucuronide or sulphate conjugates in the urine or 
bile of animals treated with AFBi, especially in rhesus
10
monkeys (Bassir and Emafo, 1970; Dalezios and Wogan, 1972).
These conjugates are readily hydrolysed by 3-glucuronidase
or sulphatase because the conjugation is on the phenol ring------
(Martin et al., 1978). A significant excretion in the 
urine of AFPi, either in free or conjugated by humans, 
would therefore be readily detectable.
The metabolism of AFBj, to AFB2a ky human cytosols has 
also been reported but AFB2a would appear to be a minor 
metabolite, and a misidentification of AFB^-dhd cannot be 
excluded (Patterson and Roberts, 1972; Neal et al., 1981).
The metabolism of AFBi to AFL by human cytosol fractions 
has also been demonstrated (Salhab and Edwards, 1977). It 
was also detected in the sera of children in the Sudan 
(Hendrickse et al., 1982). AFLHi has been reported to be a 
major metabolite of AFBi in in vitro systems when both 
microsomal hydroxylase and cytosolic reductase of human- or 
monkey-derived fractions are present (Salhab and Hsieh,
1975). AFL is metabolized to AFBi anc^  AFLMi to AFMp in 
the presence of human microsomes and NADP (Salhab et al. ,
1977).
The AFBi activating capacity of human microsomal 
systems jLn vitro, assessed by the production of AFBi“dhd 
(assayed by the Tris complex), indicated that 10-20% of the 
soluble AFBi metabolites are formed via epoxidation (Moss 
and Neal, 1985). However, it has been found that the rapid 
metabolism of AFBi ky human microsomes with NADPH is 
accompanied by only a low recovery of AFBi as soluble 
metabolites, and it is possible either that Tris buffer
11
does not compete effectively with macromolecular binding 
for the AFB^-dhd formed, or that a higher binding of 
activated AFBp to protein or RNA takes place via the 
AFBi-epoxide in human microsomes than in microsomes from 
animal species (Moss and Neal, 1985). Binding of 3h-aFB^ 
to ribosomal RNA added to in vitro human liver microsomal 
incubations have been reported (Swenson et al., 1974).
In in vivo experiments, the binding of labelled AFBi 
to nucleic acid via AFBi-epoxide has a higher specific 
activity than binding to protein (Swenson et al., 1977),
which indicates that the conversion of non-covalently bound 
epoxide to AFBi~dhd, followed by Schiff base binding to 
protein, is limited by the high level of binding to nucleic 
acid at the stage of AFBi-epoxide formation. If the lower 
recovery of soluble AFBi metabolites when human microsomes 
are incubated with AFBi is due to a high covalent binding 
of AFBi-epoxide, then these incubations might more 
accurately reflect the in vivo (high nucleic acid binding) 
situation (Neal, 1987).
Factors affecting differences between in vitro and in 
vivo behaviour also presumably involve the cellular 
architecture itself. A considerable individual variation 
in AFBi activation capacity of human liver has been 
observed using fresh biopsy samples incubated with labelled 
AFBi'.' Binding to DNA varies between 0.7 and 8.5 ng AFBi 
bound/mg DNA, which is intermediate between the levels 
found in the AFBi sensitive hamster and resistant mouse 
(Booth et al. / 1981). AFBi-epoxide which would appear to
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be a highly reactive species has not been isolated 
successfully but it can be generated chemically (Martin and 
Garner, 1977). This AFBi-epoxide can combine with guanine 
bases in DNA to produce alterations in DNA. DNA binding 
has been demonstrated in human epithelial lung cells using 
tissue culture (Wang and Cerutti, 1979) and in human 
bronchus and colon explants (Autrup et aJL. , 1979). In a
study of the capacity to form AFBi~DNA adducts in cultured 
human organs when incubated with AFBi, both the AFBi-Gua 
adduct and the imidazole ring-opened, AFBi-FAPy adduct, 
were found (Autrup and Harris, 1983). The ratios between 
these adducts varied in the different tissues and could 
indicate a role for enzymatic ring opening in addition to 
the non-enzymatic reaction. Recently the AFBi~Gua adduct 
has been detected in urine among residents in Kenya (Autrup 
et al. 1985).
As can be seen in Figure 1.2 following the formation 
of the AFBi“8,9-oxide, the only pathway of detoxification, 
other than possible macromolecular binding not involving a 
toxic response, is via glutathione conjugation (AFBi~GSH). 
Recent experiments suggest that the human potential for 
this means of detoxification is small, as very little
AFBi-GSH is produced (Moss and Neal, 1985). The presence
of AFBi mercapturate has not been reported in human 
systems. In this connection the reported low level of 
AFBi~GSH conjugating capacity in human cytosols might be 
relevant. Despite a similar low level of AFBi-GSH
conjugating capacity in marmoset monkey liver cytosol
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fractions, the presence of the mercapturate has been 
detected in the urine of these animals treated with AFBi 
(Moss et al., 1985).
Since most of the excreted AFB^ is in the form of 
water-soluble non-primary microsomal metabolites, a 
knowledge of the conjugation of primary metabolites to 
secondary metabolites by human tissue systems is clearly of 
importance in terms of monitoring. But many of the in 
vitro studies have examined the primary metabolites of 
aflatoxins in which the metabolism leads to the production 
of chloroform-soluble rather than insoluble, unbound 
metabolites (Roebuck and Wogan, 1977). Despite the fact 
that, from microsomal studies, AFQ^ would appear to be the 
major human hepatic AFBi metabolite, no conjugate of AFQi 
has been rigorously characterized to date, or reported in 
urine samples.
1.4 HUMAN DISEASES POSSIBLY RELATED TO EXPOSURE TO
AFLATOXINS
Aflatoxins are among the few chemically identified and 
widely disseminated environmental carcinogens for which 
quantitative estimations of human exposure have been 
systematically sought. Significant differences in
responsiveness are known to exist among animal species, but 
less is known about the human response. The character and 
intensity of the human response might vary depending on 
factors such as age, sex, nutritional status, concurrent
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exposure to other agents, genetic factors, concurrent 
illness (e.g. viral hepatitis or parasitic infestation), as 
well as the level and duration of exposure to aflatoxins
(Wogan, 1975).
1.4.1 Acute aflatoxicosis
Acute aflatoxicosis is probably only recognized in 
connection with an outbreak of poisoning in specific
communities and as such is rare. The evidence for acute
aflatoxicosis has been reported from Taiwan (Ling et al. , 
1967), Uganda (Serck-Hanssen, 1970) and Kenya (Ngindu et 
al., 1982). The syndrome was characterized by vomiting,
abdominal pain, pulmonary oedema, and fatty infiltration
and necrosis of the liver. More extensive documentation of
an outbreak of putative aflatoxin poisoning was provided in 
1974 from Western India (Krishnamachari et a_l., 1975). The 
causative agent appears to have been a particular crop of
maize which was contaminated by Aspergillus flavus due to
wet storage conditions resulting from unseasonal heavy
rains. The major symptom evident was jaundice. Males were 
affected twice as commonly as females. Out of a total of 
397 patients, 106 died. Several samples of the maize had 
high levels of aflatoxin contamination (6.25 to 15.6 mg 
aflatoxin/kg maize) and it was calculated that consumption 
of aflatoxins could have been in the range of 2.6 mg daily 
for several weeks. The actual involvement of aflatoxin 
ingestion in the onset of disease was strongly supported by 
the pathological evidence. Liver pathology indicated the
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presence of multinucleate giant cells with extensive bile 
duct proliferation, these lesions showing striking 
similarity to those induced in the livers of experimental 
animals exposed to aflatoxins (Butler, 1964). Death was 
due to gastrointestinal haemorrhage.
1.4.2 Hepatocellular carcinoma
There is a considerable body of evidence implicating 
aflatoxins as an important aetiologic factor in human liver 
cancer (see Busby and Wogan, 1984; Denning, 1987). 
Epidemiological studies established a positive association 
between the geographic distribution of areas of high liver 
cancer incidence and that of prevalence of aflatoxin 
contamination of foodstuffs. Although the evidence gives 
no information concerning the latent period and does not 
constitute definitive scientific proof of a principal 
aetiologic role for aflatoxins in human liver cancer, 
nevertheless, the evidence for involvement of aflatoxins 
appears to be strong.
Epidemiological data regarding aflatoxin contamination 
of food and the incidence of hepatocellular carcinoma as 
well as monitoring of aflatoxin and its metabolites in both 
urine and serum are now available from Uganda (Alpert et. 
al., 1968a,b; 1971), Swaziland (Keen and Martin, 1971;
Peers et al., 1976, 1987), Kenya (Peers and Linsell, 1973; 
Autrup et al. , 1983, 1987), Mozambique (Prates and Torres, 
1965; van Rensburg et al., 1974, 1985), Transkei (van
Rensburg et al., 1985), Nigeria (Denning et al., 1988), the
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Philippines (Campbell et al. , 1970; Campbell and Salamat,
1971; Bulatao-Jayme et al. , 1982), Thailand (Shank et al. , 
1972a-e), and China (Hu ^t al. , 1983; Zhu et al. , 1987;
Gan et cQ. , 1988).
A dose-response relationship between aflatoxin 
consumption and liver cancer incidence has been provided by 
Peers and Linsell (1977) by combining the data from four 
separate field studies in Kenya (Peers and Linsell, 1973), 
Thailand (Shank et al^, 1972c-d), Mozambique (van Rensburg, 
1974) and Swaziland (Peers et a_l. , 1976). The summary of 
data shown in Table 1.1 demonstrated a high degree of 
positive correlation between estimated daily intake of 
aflatoxin [expressed as ng/kg body weight/day (X)] on one 
hand, and the adult incidence rate of liver cancer 
[expressed as cases per 10  ^ adult/year (Y)], on the other 
hand. The correlation equation was given as Y = 7.6 log 
X-3.6 (significant at p <0.001).
These data provide strong circumstantial evidence of a 
putative causal relationship between aflatoxin ingestion 
and liver cancer incidence in humans. Although this 
evidence does not constitute proof that aflatoxins are the 
cause of human liver cell carcinoma, these data, together 
with the extensive animal data on aflatoxin 
carcinogenicity, are sufficient to associate exposure to 
the carcinogen with elevated risk of this form of cancer 
(Busby and Wogan, 1984).
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Table 1.1
Summary of data supporting a dose-response relationship between 
aflatoxin and primary liver cancer incidence3
Aflatoxin
intake
(ng/kg/day)b
Liver cancer
Country Area Number 
of cases (
Incidence 
no/lO^persons/yr)0
Kenya High altitude 3.5 4 1.23
Thailand Songkhla 5.0 2 2.00
Swaziland High veld 5.2 11 2.18
Kenya Middle altitude 5.9 33 2.51
Swaziland Mid veld 8.9 29 3.83
Kenya Low altitude 10.0 49 4.01
Swaziland Leborabo 15.4 4 4.27
Thailand Ratburi 45.0 6 6.00
Swaziland Low veld 43.1 42 9.18
Mozambique Inhambane 222.1 101 16.1-25.4
a Adapted from Peers and Linsell (1977). Periods covered were 1 year in 
Thailand, 3 years in Mozambique and 4 years each in Kenya and 
Swaziland
b Estimated average daily intake (excluding native beers) of aflatoxin by 
adults expressed as ng aflatoxin/kg body weight/day
c Incidence expressed as number of new case/10^ population/year
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1.4.3 Reye1s syndrome
Reye's syndrome is an acute, often fatal disease 
affecting infants and young children typified by acute 
encephalopathy accompanied by fatty degeneration of the 
viscera (Reye et aJL., 1963). The disease usually
progresses from a mild prodromal viral illness to severe 
cerebral involvement with coma. It is thought that Reye‘s 
syndrome results from a number of interacting factors, of 
which exposure to aflatoxins is possibly one. Clustering 
of Reye's syndrome has been observed in Northeast Thailand 
in predominantly rural areas, geographically and seasonally 
related to heavy contamination of market food samples with 
aflatoxins (Olson et al., 1971? Shank et al., 1971;
Bourgeois, 1975). Trace amounts of aflatoxins were 
detected in tissues, body fluids or gastrointestinal
contents of 22 out of 23 Thai patients who died from Reye's 
syndrome (Shank et al., 1971). The presence of aflatoxins 
was also demonstrated in the liver specimens of a number of 
Reye's syndrome patients in New Zealand (Becroft, 1966; 
Becroft and Webster, 1972), Czechoslovakia (Dvorackova et 
al., 1977), and the United States (Chaves-Carballo et al. , 
1976; Hogan et al., 1978); however, a dietary source of
aflatoxin was not identified in any of these cases. It
should be noted that not all Reye1s syndrome patients had
detectable amounts of aflatoxins in their tissues or body 
fluids (Ryan et al, 1979; Nelson et al. , 1980; Rogan,
1985). Moreover, no unusual clustering of Reye1s syndrome 
has been found in other countries with high frequencies of 
food contamination with aflatoxins.
1.4.4 Kwashiorkor
Protein energy malnutrition is the dominant form of 
malnutrition in childhood in certain Third World areas 
and has a wide spectrum of associated clinical disorders 
that embraces both marasmus and kwashiorkor. Nutritional 
marasmus is the childhood equivalent of chronic 
starvation. Kwashiorkor, in contrast, occurs mainly in 
recently weaned children, and is typical by oedema 
accompanied by hypoalbuminaemia (Williams, 1933, 1935;
Alleyne £t al., 1976). Skin disorders are frequently
present and an accompanying immune deficiency leads to a 
susceptibility to infection (Frank et al., 1975). The
condition is almost invariably accompanied by a fatty 
liver. Suggestions have been made that the condition is 
associated with a protein deficiency in the presence of an 
energy sufficiency in the diet but this theory is no longer 
widely supported (Gopaland, 1968). It has been demons­
trated that there are no essential differences in the 
protein/energy ratios in the diets of children who develop 
marasmus or kwashiorkor. It is postulated that kwashiorkor 
results from a 1dysadaptation' of biochemical mechanisms 
that protect essential organs such as the liver at the 
expense of less essential tissues such as muscle during 
protein energy malnutrition. The cause of this postulated 
dysadaptation remains obscure (Gopaland, 1968). Epidemio­
logical evidence has indicated that the geographical 
distribution and seasonal variation in the incidence of 
kwashiorkor parallels aflatoxin contamination of local
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foodstuffs (Hendrickse, 1984). Evidence has also been 
obtained that aflatoxins are detected more frequently, and 
at higher levels, in sera from kwashiorkor children than in 
marasmus or adequately nourished children from the same 
areas (Hendrickse et al. , 1982; Coulter et al. , 1986a; De
Vries et al., 1987). Aflatoxins have been reported to be 
present in biopsy or autopsy specimens of liver from 
kwashiorkor patients, in contrast to specimens from non- 
kwashiorkor children (Hendrickse et al. , 1983; Coulter et 
al. , 1986b; Apeaguei et al. , 1986). Urinary excretion of
aflatoxins in kwashiorkor appears to be less than in other 
groups (Hendrickse et a_l., 1983; De Vries et aly# 1987).
Although these results undoubtedly show that the 
kwashiorkor children were more at risk from the toxin, it 
is not possible to conclude, at present, whether the 
relationship exists because aflatoxins cause kwashiorkor or 
because children with kwashiorkor are unable to metabolize 
and excrete these substances (Editorial, 1984; De Vries et 
al., 1987).
1.4.5 Indian childhood cirrhosis syndrome
A direct involvement of aflatoxin ingestion in human 
hepatic cirrhosis has been proposed in the case of Indian 
childhood cirrhosis syndrome (Robinson, 1967). This is a 
disease which affects children in the Indian sub-continent, 
usually between the ages of 6 months and 6 years. A role 
for aflatoxins in the onset of this disease has been 
suggested based on the frequent contamination of local
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foodstuffs with the toxin, and the reported presence of 
aflatoxins in the urine of affected children and .in the 
milk of the mothers (Robinson, 1967; Amla et al ., 1970,
1974). It has also been reported that the accidental 
feeding of aflatoxin-contaminated protein to infants with 
kwashiorkor has led to a syndrome resembling Indian child­
hood cirrhosis, both clinically and histologically (Amla et. 
al. , 1971). The presence of highly fluorescent compounds
in the urine of Indian childhood cirrhosis patients has 
been confirmed, but to date these have not been identified 
as any known aflatoxin metabolite (Yadgin et al., 1970).
At present, therefore, the role of aflatoxin ingestion in 
the incidence of this disease remains uncertain.
1*4.6 Impaired immune function
In experimental animal model systems, aflatoxin
\
ingestion has been found to modify the immune system in 
many ways, including depressive effects on antibody 
formation, complement and phagocytosis, as well as cell- 
mediated immunity (Pier and Heddleston, 1970; Richard and 
Thurston, 1975; Pier et a±., 1977). The implications of
this in terms of an effect on human health are clearly very 
considerable. An impaired immune function could be a 
factor in the high incidence of hepatocellular carcinoma in 
areas of high viral hepatitis infection and consumption of 
aflatoxins (Prince et al. , 1975; Tabor et al., 1977). An
efficient cell-mediated immune system is required for the 
elimination of hepatitis B virus. If the immune system
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becomes impaired by aflatoxin ingestion, this could result 
in the prolonged presence of hepatitis B with the 
consequent development of the cirrhotic condition, which 
in turn could facilitate the subsequent carcinogenic 
change.
An immunosuppressive effect due to the presence of 
aflatoxins could influence the pattern of infection with 
many infectious diseases (Denning, 1987) including the 
human immunodeficiency virus (Hendrickse and Maxwell, 
1988). This area of research interest demands further 
investigation.
I.5 AETIOLOGICAL FACTORS IN HEPATOCELLULAR CARCINOMA
The incidence of primary hepatocellular carcinoma
(PHC) is highest in Africa and Asia (Waterhouse et al. , 
1982; Doll, 1986). Crude estimates indicate that probably 
more than 200,000 people die of this cancer each year (Sun 
and Wang, 1983). It appears to be a global health
problem. Studies have narrowed down the search for
causative factors and have identified the hepatitis B virus 
(HBV) (Blumberg and London, 1985) and mycotoxins, 
especially AFB^ (Linsell, 1984), to be the major candidates 
as aetiological agents for human liver cancer.
Attention has been focused on HBV because (a)
prospective epidemiological studies have shown a high 
incidence of PHC among carriers in HBV-endemic areas 
(Beasley et al. , 1981; Sakuma et al., 1982; Lu et al.,
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1983); (b) of the clinical observation that most of the
patients with PHC are carriers of hepatitis B surface 
antigen (HBsAg) and have chronic active hepatitis (Blumberg 
and London, 1981; Sakuma et al., 1982; Lu et al,, 1983;
Hino et slI, , 1984a); and (c) recently, integrated HBV
sequences have been found in the hepatocyte genome in 
patients with chronic hepatitis, with hepatocellular 
carcinoma and HBV carriers (Chakraborty et '.al., 1980;
Shafritz et al. , 1981; Brechot et al. , 1982; Hino et al. ,
1984a,b).
PHC is less common and occurs at an older age in urban 
populations than in rural populations. HBV infection at an 
early age in rural areas is considered to be the 
explanation for these observations. However, recent 
evidence suggests that other environmental factors are 
important (Harris and Sun, 1986). For example, a case 
control study of PHC patients of whom all were born and 
reared in rural areas but half had then moved to an urban 
setting was conducted by Kew et al. (1983). They concluded 
that HBV status, which was similar in both groups, was not 
responsible for the differences in incidence and age at 
onset of PHC in rural and urban populations. Similar 
conclusions have been arrived at based on data from China 
(Sun et a].., 1980).
The additional environmental factors most likely to 
increase the risk of PHC include exposure to AFBi (IARC, 
1976; Wogan, 1976; van Rensburg, 1977; Linsell, 1979; van 
Rensburg et al., 1985; Hsieh, 1986; Stora and Dvorackova,
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1987)/ consumption of alcoholic beverages (Lieber et al./ 
1979; Martini, 1980; Ohnishi et al., 1982; Bulatao-Jayme et 
al^ . / 1982; Yu et al, 1983; Austin et al. , 1986),
contaminated water (Su, 1979), low selenium levels (Yu et 
al. , 1985), occupation (Stemhagen et al., 1983), tobacco
smoking (Trichopoulos et al. , 1980; Lam et al. , 1982;
Yu et. al. , 1983; Kew et al. , 1985; Austin et al. , 1986),
and androgen therapy (Westaby et aJL. , 1983). The detail of 
aetiological factors in hepatocellular carcinoma was 
thoroughly reviewed by Bassendine (1987).
Consumption of alcoholic beverages has long been 
considered to be a major aetiological factor in the 
pathogenesis of PHC in Western countries (Tuyns and 
Obradovic, 1975; Keller, 1978; Martini, 1980; Bassendine,
1986). A recent case-control study has also suggested that 
the consumption of alcoholic beverages may be an important 
factor of PHC in the Philippines (Bulatao-Jayme et al. ,
1982). Individuals who consumed daily more than 21g of 
alcohol and more than 4 pg of AFB^ in contaminated-food 
(estimated) had a 35-fold increased relative risk of PHC. 
The results indicated that the effects of alcohol intake 
and dietary mycotoxin intake were synergistic.
Case-control studied in Greece (Trichopoulos et al. , 
1980), Hong Kong (Lam et al., 1982) and the USA (Yu et al.,
1983) have demonstrated an increased risk of PHC among 
cigarette smokers, but a recent study has failed to confirm 
this effect (Austin et al., 1986).
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In the People's Republic of China, the correlation 
between PHC incidence and estimated dietary mycotoxin 
intake is statistically higher than the correlation between 
PHC incidence and the geographical distribution of HBV 
infection (Wang et al., 1983). Whereas the incidence of
HBV infection does not vary among people living in the low- 
and high-altitude areas of Kenya, both the incidence of 
food contamination by AFBi produced by Aspergillus flavus 
and the incidence of PHC are higher in the low-lying 
regions (van Rensburg, 1977). Further indirect evidence of 
an interactive effect between HBV infection and chemical 
carcinogens comes from a study of Eskimos in Greenland, an 
area of presumed low dietary consumption of AFBi, but which 
has a high prevalence of HBV carriers. A low incidence of 
PHC was reported for this area (Melbye et aJ., 1984).
The precise roles of HBV infection and aflatoxin 
intake in the development of PHC remain to be elucidated. 
The existence of regions of low incidence for PHC, despite 
an elevated prevalence of HBV infection, may indicate that 
HBV infection acting alone has limited carcinogenic effect 
but that it needs to be potentiated by other factors. The 
clear geographical association between aflatoxin 
contamination and PHC incidence in parts of Africa and 
Asia, and the lack of an association with HBV prevalence at 
higher levels of incidence for PHC suggests that in these 
regions aflatoxin is a major determinant of risk (van 
Rensburg et al., 1985). It is of interest that areas where 
a moderate to high prevalence of HBV is accompanied by a 
low incidence of PHC tend to be either too dry, as in
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Botswana, or too cold, as in Greenland, for the growth of 
Aspergillus flavus. An aflatoxin survey in Egypt, which 
has a hot and dry climate, and a reportedly low incidence 
of PHC, revealed exceedingly low levels of contamination 
(Girgis et al., 1977).
However, epidemiological studies have firmly estab­
lished HBV infection as, at least, a probable prerequisite 
for the development of PHC in the majority of cases. The 
viral carrier status is acquired during early childhood, 
and carries a relative risk for the development of the 
tumour of over 200. Integration of HBV DNA probably acts 
as a genotoxic initiator in the multistep process of 
hepatocarcinogenesis, although the precise mechanisms
involved have not been determined. Aflatoxin ingestion may 
also have an aetiological role in some areas, probably as a 
genotoxic or epigenitic promotor to HBV-initiated 
carcinogenesis (Kew, 1986).
From the evidence being accumulated, it is postulated 
that hepatocellular carcinoma is multifactorial in origin, 
and the pattern of its aetiological associations differs 
between populations at high and low risk (Harris and Sun, 
1984; Kew, 1986). This multifactorial aetiological
hypothesis is rapidly gaining support from recent findings 
of molecular genetic investigations on the mechanism of 
hepatocarcinogenesis. It now appears highly likely that
there are synergistic effects between AFB^ and HBV in
causing PHC (Ayoola, 1984; Harris and Sun, 1984) but more 
evidence is required to determine which one is the
initiator and which one is the promotor.
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1.6 BIOCHEMICAL AND MOLECULAR EPIDEMIOLOGYOF AFLATOXINS
The primary goal of biochemical and molecular 
epidemiology is to identify individuals at high cancer risk 
by obtaining evidence of (a) high exposure to carcinogens, 
leading to pathobiological lesions in target cells, and/or 
(b) increased oncogenic susceptibility due to either 
inherited or acquired host factors. This emerging and 
multidisciplinary area of cancer research combines 
epidemiological and laboratory approaches (Perera and 
Weinstein, 1982; Harris et al., 1985).
Progress has been made in identifying chemical 
carcinogens in human body fluids and tissue samples. For 
example, both AFB^ metabolites (e.g. AFMi) (Campbell et 
al. , 1970; Sun et ajL., 1983; Wu et al.. , 1984; Groopman et
al., 1985; Sun et al. , 1986), and nucleic acid repair
products (Autrup et al., 1983, 1985, 1987; Groopman et al., 
1985) can now be measured in body fluids and by both 
immunological and chemical methods, and these products have 
been detected in urine samples from individuals ingesting 
contaminated food. Urinary excretion of AFM^ from local 
inhabitants in areas of high PHC prevalence in the People's 
Republic of China was found to be significantly elevated, 
up to 40-fold or more, over that found in people in areas 
of lower PHC incidence (Sun et al. , 1983; Wu et ad.., 1984). 
During the rainy season, in the high PHC incidence area, 
the amount of AFMi excreted in the urine may increase to a 
level of 100-fold more than that excreted in the low
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incidence area. By measurement of AFBi and AFMi, the 
conversion ratio in humans has been calculated to be 1.5-5% 
(Sun et al_. , 1983; Sun et al. , 1986; Zhu et al. , 1987) . On 
the basis of these data, it has been calculated that the 
AFBi inta^ 0 in approximately 10% of adults living in the 
high incidence area exceeds 1 mg per year. The primary 
source of contamination is corn and rice; the second is the 
local undistilled alcoholic beverage obtained from these 
grains. Since men generally eat more food and also drink 
more alcoholic beverages than women, both the 3-fold or 
more male preponderance of PHC and the age peak in the 
fourth and fifth decades of life in areas of prevalence 
(facts difficult to explain on the basis of viral aetiology 
alone) can at least partly be attributed to AFBi ingestion 
and/or alcohol consumption (Harris and Sun, 1986).
Food samples collected in Murang'a District, Kenya, 
have been demonstrated to be contaminated with AFBi, and 
also one of its putative nucleic acid repair products, 
AFBi-Gua, has been detected in human urine collected in 
this region of high cancer risk (Autrup et al., 1985,
1987). Recent findings from this continuing biochemical 
exDidemiological investigation have also shown a seasonal 
variation in that the urinary AFBi-adducts are found more 
frequently during the months of high contamination of food 
by AFBi (Autrup et al., 1985). The aflatoxin-DNA adduct
was also found in urine samples from the Guangxi Province 
of China (Groopman et al., 1985). The presence of this
AFBi~DNA base adduct in the urine is an indication not
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only of exposure to AFBi, but also of its metabolic 
activation and interaction between the ultimate 
carcinogenic form of AFBi and cellular nucleic acid in 
vivo. This further supports the hypothesis that AFBi may 
have an important role in the aetiology of human liver 
cancer (Harris and Sun, 1986).
AFBj is a procarcinogen, i.e. it requires enzymatic 
activation to an electrophilic metabolite that binds 
covalently to DNA. Interindividual differences (more than 
10-fold) have been found both in the metabolic activation 
of AFBi to form DNA adducts in cultured human hepatic 
explants (Autrup et al. , 1984) and for hepatic microsomes
to cause mutations in the Ames Salmonella assay (Harries et 
al., 1986). It would be of considerable interest to
compare the rates of metabolic activation of AFBi in 
individuals with normal livers with those in patients with 
chronic active hepatitis, a predisposing condition for 
hepatocellular carcinoma. AFBi and its metabolites have 
also been found in human sera and various human tissues, 
including liver (see Garner et al.., 1985). Promising
methodology to measure AFBi binding to serum albumin is 
being developed (Wild et a_l., 1986; Sabbioni et al. , 1987) 
and that should provide another means of monitoring AFBi 
exposure.
Measurement of AFBi modified DNA by enzyme immuno­
assays (Haugen et al. , 1981; Groopman et aJL. , 1982; Hsieh
et al., 1988) and synchronous scanning fluorimeter (Harris 
et al., 1986) in liver samples from males and females will
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be of particular interest in regard to the male 
preponderance of PHC. It will also allow the critical 
evaluation of the quantitative relationship, if one exists, 
between adduct levels and the risk of developing PHC.
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CHAPTER 2
Development of a Method to Monitor Aflatoxins 
Excreted in Human Urine Samples
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2.1 INTRODUCTION
The aflatoxins and several other mycotoxins may 
present health hazards that are far more extensive and 
serious than had been realised due to the extreme potency 
of many of these compounds. Growing concern with aflatoxin 
poisoning and their potentially hazardous effects as 
carcinogens at doses insufficient to manifest the symptoms 
of aflatoxicosis has led to a concerted effort to devise 
analytic methods for the accurate determination of 
aflatoxin in food, physiologic fluids and tissues (Langone 
and van Vunakis, 1976).
Common methods used to analyse samples for the 
presence of aflatoxins include TLC or HPLC of extracted 
samples with confirmation of identity by physicochemical 
methods such as fluorescence photon counting or mass
spectrometry with selective ion monitoring. The
methodology for measuring aflatoxin levels in food by TLC 
or HPLC is well established and there have been many
reports on the use of these two methods (Seitz, 1975? van 
Edgmond and Paulsch, 1986). However, these methods are not 
specific for the aflatoxin structure and extensive pre­
liminary 'clean-up' procedures are necessary when examining 
complex samples which can be time consuming and costly, and 
require technical skill and expensive instruments. For
these reasons, these methods are decreasingly being used in 
measurements of aflatoxin metabolites in human body fluids 
in epidemiological studies (Garner et al., 1985).
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The recent development of immunological techniques 
(Langone and van Vunakis, 1976; Poirier, 1981; Muller et 
al. , 1982) that use antibodies with a high degree of 
sensitivity and specificity against certain carcinogens 
including AFBi provides the possibility of determining 
individual exposure in relatively large human populations. 
RIA has been applied to the quantitative determination of 
circulating substances, such as hormones, drugs and 
infectious agents. The high specificity of antibodies and 
the sensitivity afford by radiolabelled tracers often 
permit the use of RIA to measure picomole levels of the 
target compound in unprocessed physiological fluids or 
other samples. However, RIA has certain practical
limitations. The short half-life of the isotopes used 
limits the shelf life of the reagents. In addition, the 
need for y-emitting isotope subjects the users of RIA to a 
radiation hazard.
Enzyme immunoassay which is also known as ELISA has 
been developed in an attempt to overcome those problems of 
RIA. ELISA is similar in design to solid-phase RIA except 
that an enzyme is used as the immunoglobulin marker instead 
of a y-emitting isotope. It is based on the reaction 
between an antigenic compound and an antibody with 
specificity for a particular part of the antigenic 
molecule. After binding of the primary antibody to the 
immobilized antigen, a second antibody (with conjugated 
enzyme) having specificity for the bound antibody is 
allowed to bind to the primary antibody. On adding a
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suitable chromogenic substrate for the bound enzyme and 
assaying the colour produced, quantitation of the bound 
antigen is achieved. There are two types of ELISA, one is 
the "non-competitive” assay in which the colour developed 
is proportional to the amount of immobilized antigen 
present on the plate (exactly as described above), while 
the other type is the "competitive" assay in which the 
colour developed is inversely related to the amount of 
antigen present in the sample. This competitive ELISA is 
used throughout these studies and is described in Section
2.2.3.1. The fact that a single molecule of enzyme is 
capable of reacting with a large number of substrate 
molecules provides for amplification and, thus, a high 
degree of sensitivity. In the sandwich type ELISA 
technique, there are two stages of amplification; the first 
one is when secondary antibody is bound to primary 
antibody, and the second stage is when substrates are bound 
to the enzymes as shown in Figure 2.1. Because stable 
enzymes such as alkaline phosphatase or peroxidase can be
used, ELISA also has the advantage of using reagents with a
long shelf life. In practice, however, the sensitivity of 
the ELISA system is at least as sensitive as, if not more 
sensitive than, RIA. ELISA methods should be concentrated 
on for routine monitoring work.
A number of reports have appeared on the generation of 
antibodies against APB^ and its metabolites (Garner et al., 
1985). The characteristics of these antibodies ve'ry much
depend on the specific immunogen used. Polyclonal
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antibodies appear to be particularly suitable for 
measurements of exposure since various aflatoxin-derived 
materials can be assayed, thus giving a more representative 
picture of the exposure. In contrast, a battery of 
monoclonal antibodies might be advantageous in determining 
at an individual level the pattern of aflatoxin metabolites 
present in the samples.
These antibodies can be used in conjunction with other 
chemical analytical techniques as non-invasive screening 
methods to monitor human exposure to aflatoxins. Useful 
screening methods will require the ability to quantify 
aflatoxin and its metabolites in readily accessible 
compartments, such as serum and urine. Earlier studies on 
aflatoxin derivatives in human samples have used techniques 
such as TLC, HPLC and immunological assay to prepare and 
analyse aflatoxin-contaminated samples (Campbell et al. , 
1970? Hendrickse et al. , 1982; Autrup et al. , 1983; Hu et
al. , 1984; Martin et al., 1984; Groopman et al., 1984;
Tsuboi et ad. , 1984; Groopman et al. , 1985? Wild et al. ,
1987). However, when attempting to apply immunological 
assays especially ELISA to human urine samples, despite the 
specific nature of the antibody reaction, the presence of 
interfering substances often gave apparent positive results 
for aflatoxins. These substances which are also known as 
urinary aflatoxin-like substances(Dragsted et al., 1988)
can be removed by extraction, dilution or concentration of 
the urine samples on Sep-Pak C^g cartridges and immuno- 
affinity columns (Martin et al., 1984; Groopman et al.,
1984).
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The objective of this study was to develop the 
procedures necessary to monitor aflatoxin levels in human 
urine samples using an ELISA technique. A polyclonal 
antibody against AFBi was use(3 in order to give a more 
representative picture of the exposure. Uncontaminated 
urine samples from Western European people which were 
presumed to be free of aflatoxin contamination were used as 
control samples. They were spiked with known concentra­
tions of AFBi, or ^h -a fBi , to validate the methods being 
developed.
2.2 MATERIALS AND METHODS
2.2.1 Materials
2.2.1.1. Aflatoxins
AFBi was purchased from Makor Chemicals Ltd.
(Jerusalem, Israel). AFB2/ AFGi# AFG2, AFMi, AFPi# AFQX, 
and AFL, were purchased from Sigma Chemicals Company
(Poole, Dorset). AFBi-Gua and AFBi~FAPy were prepared by 
activating AFBi An vitro followed by reaction with calf
thymus DNA. AFBi-GSH was prepared using activated AFBi 
with mouse cytosolic GSH-S-transferase (Moss and Neal, 
1985). AFBi-Cys-Gly, AFBi-Cys and AFBi-NAcCys were
prepared in vitro as the degradation products of AFBi-GSH 
using isolated rat kidney cells. -^C-AFBi and ^H-AFBi were 
purchased from Morevak Biochemicals (Brea, California,
USA).
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2.2.1.2 Chemicals
BSA, Tween 20, dithiothreitol, sodium cholate, 
3,3',5,5'-tetramethylbenzidine and l-ethyl-3-(3-dimethyl- 
aminopropyl)-carbodiimide were obtained from Sigma 
Chemicals Company (Poole, Dorset). DMSO of Spectrosol 
grade and gelatine were purchased from BDH Chemicals Ltd. 
(Poole, Dorset). PBS was obtained from Oxoid Ltd. 
(Basingstoke, Hants). All other chemicals and organic 
solvents used in all experiments were of analytical or HPLC 
grade.
2.2.2 Preparation of all the components necessary for 
analysing aflatoxins by ELISA
2.2.2.1 Preparation of the immunogen
AFBi bound to quail liver microsomal protein by 
metabolic activation was used as the antigen. The protein 
was solubilized from microsomal membranes and partially 
purified by technique used by Elshourbagy and Guzelian 
(1980). Quail liver microsomal pellets containing bound 
AFBi were suspended in 50 mM Tris buffer (pH 7.4) 
containing 25% glycerol (v/v), 5 mM MgCl2 , 0.1 mM EDTA, and 
0.5 mM dithiothreitol to have the concentration of 30 mg 
protein/ml, sonication being used to aid dissolution of the 
pellets. Then 50 mM potassium phosphate (pH 7.4) buffer 
containing 0.1 mM EDTA and 30% glycerol (v/v) was added to 
yield a final concentration of 7 mg protein/ml buffer. A 
10% solution of sodium cholate was added dropwise, with 
stirring, at 0-5°C to give a final concentration of 3 mg
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cholate/mg protein. After these additions, the solution 
was stirred for 20 min, a 50% (w/v) polyethylene glycol
solution was added dropwise to achieve a final polyethylene 
glycol concentration of 10%, and stirring was continued for 
an additional 20 min. The mixture was centrifuged at 
40,000 x g for 30 min. The supernatant was discarded and 
pellets were redissolved in 3 ml PBS. The protein content 
of the immunogen was determined according to the method of 
Lowry et al. (1951) using bovine serum albumin as a 
standard.
2.2.2.2 Preparation of the rabbit AFBi antiserum
Sandy half-lop female rabbits were immunized with AFB^ 
conjugate by injecting 500 ug protein of immunogen mixed 
50/50 (v/v) with Freund's complete adjuvant intramuscularly 
into front and hind limbs of each animal. Subsequent 
injections employed the solubilized protein antigen (500 pg 
protein) mixed with an equal volume of Freund's incomplete 
adjuvant. They were injected four weeks apart on three 
occasions. Ten days after the third injection, blood 
samples (30 ml) were obtained from each animal via an ear 
vein. The samples were then left at 4°C for 3 h to allow 
the complete coagulation process to take place; the serum 
was then separated by centrifugation of the clotted blood 
at 1000 x g for 20 min at room temperature. The antibody 
titre of the serum obtained was evaluated using competitive 
ELISA binding assay (see Section 2.2.3.1). A booster dose 
of 500 ug protein of immunogen mixed with equal volume of
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Freund’s incomplete adjuvant was given to the rabbits every 
6 months. The serum obtained had to be tested for antibody 
titre.
2.2.2.3 Preparation of the BSA-AFBi conjugate
BSA-AFBi for use in the ELISA technique was prepared 
according to Sizaret et aJL. (1982). The conjugate was 
synthesized by dissolving AFBi (6.5 mg) in methylene 
chloride (3 ml) in which any traces of water that might 
have been present were removed with molecular sieve beads 
type 3A (BDH Chemicals Ltd., Poole, Dorset). Chlorine gas 
was bubbled through the solution until a bright yellow 
colour appeared. The yellow colour was free chlorine in 
the solution. After drying the AFB1CI2 solution under 
vacuum, BSA (9.3 mg) in 0.01 M sodium phosphate buffer, pH
7.4 (4.5 ml) was quickly added; immediately thereafter,
DMSO (0.5 ml) was added dropwise using magnetic stirring to 
dissolve AFBiCl2 » The mixture was kept for 30 min at 37°C 
in a shaking water bath. The insoluble material was 
removed by centrifugation at 1000-1200 x g for 15 min at 
4°C. The modified BSA was then precipitated by sequential 
addition of NaCl (43 mg), ethyl acetate (6 ml) and acetone 
(12 ml) under magnetic stirring. The mixture was kept on 
ice for 30 min before being centrifuged at 1000-1200 x g, 
for 15 min at 4°C. The precipitated BSA-AFB^ conjugate was 
washed with ethanol (20 ml x 6 ) to remove unbound AFB^. 
The BSA-AFBi was dissolved in PBS (pH 7.4, 10 ml), 
sonication being used to aid dissolution of this
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conjugate. The BSA-AFBi solution was then stored at 
-40°C. The protein content of the conjugate was determined 
according to the method of Lowry et cLL. (1951) using bovine 
serum albumin as a standard. The number of molecules of 
AFBi bound to 1 molecule of BSA was determined by 
spectrophotometry (UVIKON 860; Kontron Instruments, 
Watford, Herts) at 405 nm using samples of the stock 
BSA-AFBi solution (250 pi) diluted with PBS to 1 ml.
2.2.2.4 Preparation of the ELISA plates
Flat-bottomed polystyrene microtitre plates (model 
M129E, Dynatech Laboratories Inc., Virginia, USA) were 
coated with BSA-AFB^ (5 ng) in PBS (50 ;ul) in each well. 
The outer rows of wells were not coated because in 
preliminary studies it had been found that they showed a 
much greater variation in the assay. The plates were left 
to dry overnight at 37°C. They were stored at -40°C until 
used. Coated plates could be kept at this temperature for 
extended periods without apparent loss of binding 
capacity. When plates were to be used for assay, they were 
removed from the -40°C freezer and washed 4 times with 
0.05% Tween 20 in PBS (PBS-Tween 20). Non-specific binding 
sites were blocked with 100 ;ul of 0.25% gelatine in PBS 
(PBS-gelatine) for 60 min at room temperature. The plates 
were then washed twice with PBS-Tween 20 before used.
2.2.2.5 Preparation of the immunoaffinity gel
An immunoaffinity column was prepared by the procedure
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described by Pharmacia. Freeze-dried powder (6 g) of 
AH-Sepharose 4B (Pharmacia, Milton Keynes, Herts) was 
suspended in 0.5 M NaCl (200 ml NaCl/g freeze-dried powder) 
for 30 min at room temperature. The gel was washed with 
distilled water (1200 ml) on a sintered glass filter 
(porosity G3) to remove NaCl. Water was added to 6 ml 
undiluted rabbit anti-AFB^ serum to a final volume of 18 ml 
before adding to the gel. The pH of the gel was adjusted 
to between 4.5 and 6.0 with 0.1 M HC1. The mixture was 
left stirring at room temperature using slow-moving 
propeller stirring. A solution (2 ml) of 1 M l-ethyl-3- 
(3-dimethylaminopropyl)- carbodiimide was added dropwise 
and the pH was maintained between 4.5-6.0 for 1 h. Changes 
observed in pH after 1 h were small. The reaction was 
allowed to proceed for 24 h at 4°C. The gel was washed 
alternately with 0.1 M sodium acetate/0.5 M NaCl (pH 4.6; 
1000 ml) and 0.1 M sodium hydrogen carbonate/0.5 M NaCl (pH 
8.3; 1000 ml) with water (1000 ml) in between each buffer. 
The gel was washed by each buffer for 3 times before 
suspension in PBS with 0.02% sodium azide (20 ml) to 
prevent bacterial growth. The gel was stored at 4°C until 
required.
2.2.3 General procedures used in the analysis of 
aflatoxins
The methods described in this section were used in all 
experiments unless stated otherwise.
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2.2.3.1 Competitive ELISA binding assay
Competitive binding assays were performed in glass 
tubes by adding an aliquot (200 ^ 1 ) of test solution, 
diluted in PBS, to rabbit anti-AFB^ serum diluted 1:10,000 
in PBS-gelatine (200 /il) and incubating on a shaking plate 
at 3 7°C for 60 min. Aliquots (50 ,ul) of these mixtures 
were dispensed into each well of washed microtitre plates 
in 6 replicates. The plates were sealed with plate sealing 
tape (Titertek, Flow Laboratories, Rickmansworth, Herts.) 
to prevent evaporation, and incubated at room temperature 
with continuous shaking on Vari-Shaker (Dynatech 
Laboratories Ltd., Billingshurst, Sussex) for 90 min. 
Plates were washed 5 times with PBS-Tween 20 by complete 
immersion of the plates in the washing solution. Aliquots 
(50 /ul) of anti-rabbit IgG-peroxidase conjugate (I.C.N. 
Biochemicals Ltd., High Wycombe, Bucks.) diluted 1:5000 in 
PBS-gelatine were added to each well and sealed plates were 
further incubated at room temperature for 90 min with 
continuous shaking. The plates were washed 5 times with 
PBS-Tween 20 followed by a single distilled water wash. 
The bound peroxidase was detected by adding aliquots (50 
,ul) of 3,31,5,51-tetramethylbenzidine 0.1 mg/ml in 0.1 M 
sodium acetate buffer (pH 6.0) with 0.002% H2O2 to each 
well and the plates were left at room temperature for 30 
min. The reaction was stopped with 2 M H2SO4 (50 /Ul). 
Absorbance at 450 nm was read on a Titertek Multiskan MCC 
(Flow Laboratories, Rickmansworth, Herts.).
Inhibition was calculated as a percentage of the
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absorbance where no inhibition was present in the test 
solution. Values of AFBi equivalents present in the test 
samples were calculated from a standard curve of AFB^ 
concentrations ranging from 0.01-100 ng/ml.
To check on interplate variation, on every microtitre 
plate used was included one column (6 wells) of blank or 
non-inhibited samples and one column of internal standard 
(1 ng AFBi/ml). This internal standard was then used to 
correct for the variation between the plates. The 
correction applied was to normalise the standard curve for 
the inhibition observed for 1 ng AFB^/ml for each 
individual plate.
2.2.3.2 Sep-Pak Cip cartridge
Sep-Pak Ciq cartridges (Waters Associates, Millipore 
UK, Harrow, Middx.) were pre-wetted with methanol (10 ml) 
to activate the cartridges followed by distilled water (10 
ml) to dilute the concentration of methanol. After the 
sample had been loaded onto the cartridge, it was washed 
with distilled water (3 ml). The retained materials were 
eluted with methanol (5ml). The cartridge was reactivated 
with methanol (10 ml) followed by distilled water (10 ml). 
The cartridge was reusable up to 4 times.
2 . 2.3.3 Immunoaffinity column
The column was packed with affinity gel, prepared as 
described in Section 2.2.2.5, in a 2 ml disposable plastic 
syringe giving a 1 ml bed volume as shown in Figure 2.2.
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The column was then washed with PBS (20 ml) to remove 
sodium azide added to the gel to prevent bacterial growth. 
The sample was loaded on the column and then washed with 
PBS (15 ml) before elution with 85% methanol in PBS (15 
ml). Preliminary studies demonstrated that more than 95% 
of AFBi or aflatoxin metabolites retained on the affinity 
column were eluted with the first 10 ml of methanol. This 
was a convenient volume for the subsequent evaporation in 
one tube of the Speedvac Concentrator and therefore 
facilitated one tube per sample. The column was then 
washed with PBS (20 ml) before the next sample was loaded. 
When urine samples were used, it was found that the columns 
could only be used for two samples and were then discarded.
2.2.3.4 Evaporation process
The purpose of evaporation in these experiments was to 
reduce the volume of methanol present in the samples. The 
process was carried out in the Savant Speedvac Concentrator 
(Stratech Scientific Ltd., London)at 40°C. In preliminary 
experiments it was found that the evaporation of the 
samples to dryness followed by reconstitution led to 
variable recoveries. In order to avoid this problem, a 
small volume of water (0.5 ml) was always added into each 
sample which was in 100% methanol. This provided for a 
residual aqueous solution after the rapid removal of 
methanol by evaporation in the Speedvac.
2.2.3.5 HPLC
Samples to be used in the HPLC were dissolved in
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methanol/water (1:1, v/v) and clarified by centrifugation. 
Samples were analysed using Models 6000 pumps and 660 
solvent programmer (Waters Associates, Millipore U.K., 
Harrow, Middx.) and were introduced by a Rheodyne 7120 
injector valve (Berkeley, California, USA). The column 
(100 x 4.6 mm) was laboratory-packed with Magnusphere 5 ODS 
reverse phase protected by a guard column (65 x 1.2 mm) of 
CO:Pell ODS (Whatman, Maidstone, Kent). The column was 
eluted with a linear 15-40% methanol/water gradient 
containing 0.01% phosphoric acid and 8% acetonitrile at a 
flow rate of 1.2 ml/min. The gradient elution took 8 min 
followed by maintenance of 40% methanol for another 4 min 
and then the gradient was reversed to 15% methanol in 1 
min. The machine was left to re-equilibrate at 15% 
methanol for 5 min before the next injection.
U.V. absorption was monitored at 365 nm using an LDC 
Spectromonitor III (Laboratory Data Control, Florida, 
USA). Fluorescence was also monitored by using a 
Fluorescence Detector Model 420 (Waters Associates, 
Millipore U.K., Harrow, Middx.) with the excitation band 
pass filter centred on 365 nm and long pass emission filter 
starting at 425 nm.
Fractions (1 min/l.2 ml) from the HPLC were collected 
in 5 ml plastic scintillation minivials using an LKB 
Redirac Fraction Collector (Bromma, Sweden). Normally 18 
fractions per sample were collected.
2.2.3.6. Radioactive counting
All radioactive determinations were carried out in 5
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ml plastic scintillation minivials using aliquots (1 ml) of 
sample and scintillant (4 ml) (Monofluor, National 
Diagnostic, Aylesbury, Bucks) followed by counting in a 
liquid scintillation counter (Packard Model 460, 
Pangbourne, Berks).
2.2.3.7 Creatinine assay
All human urine samples were analysed for creatinine 
concentration using "Merckotest Creatinine 3385" (E. Merck, 
Darmstadt, West Germany). Samples were diluted 1:100 as 
described in the kit. The reaction is based on the 
principle that creatinine forms a yellow-orange compound in 
alkaline solution with picric acid. All the assays were 
carried out at 25°C. The absorbance at 492 nm was read in 
a Kontron Spectrophotometer (Model UVIKON 860, Kontron 
Instruments Ltd., Watford, Herts).
2.2.4 General procedures adopted for analysing
aflatoxins in human urine samples
Human urine samples were centrifuged at 1000 x g for
10 min at room temperature to remove any precipitate
present in the samples. They were then subjected to the
procedure summarized in Figure 2.3.
2.3 Experimental protocols
2.3.1 Antibody recognition of structural analogues to
AFBi
Several structural analogues and metabolites of AFBi
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Figure 2.3 Diagram showing the procedure analysing level 
of aflatoxins in human urine samples
Human urine sample (1 ml)
v
pass through pre-wetted Sep-Pak C^g cartridge
wash with distilled water (3 ml) 
elute with 100% methanol (5 ml)
\J/
collected methanol eluate and add water (0.5 ml)
J/
evaporate to 0.5 ml and reconstitute with PBS (5 ml)
load onto immunoaffinity column (1 ml bed volume)
wash with PBS (15 ml) 
elute with 85% methanol
in PBS (15 ml)
v
collect first 10 ml methanol eluate
evaporate to 0.5ml and reconstitute to 1 ml with PBS
use appropriate volume in ELISA
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were tested in the ELISA, including AFB2# AFG]_, AFG2/ AFM]_, 
AFPi, AFQi, AFL, AFBi-Gua, AFBi-FAPy, AFBi-GSH, 
AFB^-Cys-Gly, AFBi-Cys and AFB^-NAcCys. The structures of 
these compounds are shown in Figure 2.4. They were tested 
against rabbit anti-AFB^ serum in the standard competitive 
ELISA (Section 2.2.3.1). The percentage inhibition of 
antibody binding to the coating antigen, BSA-AFB^, was 
determined for concentrations ranging from 0.01 to 100 ng 
aflatoxin analogue/ml. Inhibition curves were drawn and 
50% inhibition values for each aflatoxin analogue were 
determined.
2.3.2 Standard AFBi solutions in PBS and in urine 
sample
2.3.2.1 Analysis of standard AFBi solutions without
'clean-up1 procedures
Human urine samples from West Germany which were 
presumed to be free of contamination with aflatoxins were 
used as control samples. Standard concentrations of AFB^ 
ranging from 0.01 to 100 ng/ml were prepared in both PBS 
and these urine samples, using a stock solution of 10 /ig 
AFB^/ml. Competitive ELISA were performed (as in Section
2.2.3.1) using the 'spiked' PBS, 'spiked' and 'unspiked'
urine samples and the percentage inhibitions obtained were 
calculated with reference to the PBS control.
2.3.2.2 Analysis of standard AFBi solutions with
'clean-up' procedures
Standard concentrations of AFB^ ranging from 0.01 to 
100 ng/ml in both PBS and the uncontaminated Western urine
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samples were prepared as in Section 2.3.2.1. Four 
different urine samples were used. They were processed by 
a Sep-Pak and an affinity column using the general 
procedures for 'clean-up' of urine samples (see Section 
2.2.4). Samples were reconstituted to 1 ml PBS before 
analysing for AFBi by ELISA. Also one uncontaminated urine 
sample was spiked with the same range of AFBi 
concentrations after the sample had been passed through a 
Sep-Pak and an affinity column. Competitive binding assays 
were performed (see Section 2.2.3.1) and the percentage 
inhibitions were calculated by comparing with both PBS 
control and unspiked urine samples.
2.3.3 Methanol concentrations and ELISA
Standard concentrations of AFBi ranging from 0.01 to 
100 ng AFBi/ml were prepared in PBS, 50% methanol in PBS 
and 85% methanol in PBS using the stock solution of 10 ug 
AFBi/ml in PBS. Competitive ELISA were performed and the 
percentage inhibitions of each solution were calculated 
from PBS control.
2.3.4 Development of a method to monitor aflatoxins 
excreted in human urine samples
2.3.4.1 Sep-Pak Cia cartridge
A. Capacity of Sep-Pak Cip cartridge
A range of concentrations, 0.1, 1.0, 10.0 and 100 ng
^H-AFBi/ml (100,000 dpm/ml) was prepared in PBS and in 
uncontaminated urine sample. A sample (1 ml) of each
53
concentration was loaded onto a Sep-Pak C^g cartridge, 
washed with distilled water (3 ml) and the retained 
materials eluted with 100% methanol (5 ml). All fractions 
were collected and aliquots (1 ml) of each fraction in 
duplicate were taken to count for radioactivity. The 
percentage of the total radioactivity which was present in 
each fraction was calculated.
B . Evaporation of methanol eluate and HPLC fractions
obtained from Sep-Pak C]a cartridge
The solution containing 20 ng ^fj-AFBi/ml (10,000 
dpm/ml) was prepared in 20 ml uncontaminated urine sample. 
A sample (10 ml) was loaded onto a Sep-Pak Cj_g cartridge 
washed with distilled water (3 ml) and eluted with 100% 
methanol (5 ml). All fractions were collected and aliquots 
(1 ml) of each fraction were counted for radioactivity. 
When the nature of the labelled material which was not 
retained by the Sep-Pak was examined by HPLC, the 
unretained (2 ml) and the aqueous washing fractions (2 ml) 
from the Sep-Pak were combined and methanol (4 ml) was 
added to this combined fraction giving a total 
concentration of methanol 1:1 (v/v). In the case of the
methanol fraction from the Sep-Pak, a sample (2 ml) was 
taken and water (2 ml) was added giving a methanol 
concentration of 1:1 (v/v). Each sample (500 ,ul) was
injected into the HPLC. Fractions (1 min/1.2 ml) from the 
HPLC were collected and radioactivity was counted. In 
order to compare the distribution of radioactivity in the
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HPLC fractions obtained from the Sep-Pak, a sample with the 
original ^H-AFB^ solution, 200 ng ^H-AFBi/ml (50,000 
dpm/ml), was prepared in uncontaminated urine and the 
methanol (1 volume) was added before aliquots (500 /ll) were 
injected into the HPLC as reference.
Aliquots (2 ml) of methanol elute from the Sep-Pak
cartridge were added with water (200 ;ul) before evaporation 
to 0.5 ml and reconstitution with PBS to 2ml. The sample 
(500 ;ul) was counted for radioactivity and aliquots (500
,ul) were injected into the HPLC and fractions were
collected and also counted for radioactivity.
2.3.4.2 Immunoaffinity column
A. Capacity of affinity gel
Affinity gels were prepared by using immune and
non-immune serum (see Section 2.2.2.5). The columns were 
packed with gel suspension (0.8 ml) in 2 ml disposable 
plastic syringes giving a 0.5 ml bed volume. Two columns 
were packed; one with the immune gel, the other one with 
non-immune gel. Columns were washed with PBS (20 ml) to 
remove sodium azide. The columns were loaded with 1 ng 
^H-AFB^ in PBS (1 ml) containing 10^ dpm, and then washed 
with PBS (10 ml). Retained materials were eluted with 80% 
methanol in PBS (15 ml). Fractions (1 ml) were collected 
throughout the loading, washing and elution procedures for 
radioactive counting.
B. Characteristics of the immunoaffinity columns
Affinity gel was packed in a 2 ml disposable plastic
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syringe to a bed volume of 0.5 ml. Standard concentrations 
of 0.1, 1.0, 10.0 and 100 mg AFBi/ml were prepared in both 
PBS and uncontaminated urine samples. ^H-AFB^ was added 
to each sample to give a radioactive level of 50,000 
dpm/ml. The samples were loaded onto the columns in 
different volumes containing different amounts of ^H-AFBi. 
The volumes ranged from 0.2 to 10 ml and the amounts from 1 
to 100 ng ^H-AFBi. The columns were washed and eluted by 
the standard procedures described in Section 2.2.3.3. Each 
column was used twice to determine if the column was
reusable. All fractions were collected and aliquots (1 ml) 
were counted for radioactivity in duplicate.
C. Evaporation of methanol fractions eluted from the
affinity column
The columns were packed with affinity gel to a bed 
volume of 0.5 ml. Two sets of samples were loaded; one 
with 2 ng ^h-a f b  ^in uncontaminated urine (2 ml) the other
with 5 ng -^H-AFB^ in uncontaminated urine (5 ml). Columns
were washed and eluted by the standard affinity column
procedures (see Section 2.2.3.3). Radioactivity in each 
fraction was counted. From methanol fractions, samples 
(500 ul) were injected directly into the HPLC and the 
radioactivity present in the AFBi peak (retention time of 
12 min) was determined. Then aliquots (7ml) of these 
methanol fractions were evaporated to 0.5 ml and 
reconstituted to 7 ml with PBS before samples (500 /il) were 
injected into the HPLC. Radioactivity present in the HPLC 
fractions was determined.
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D. Routine testing of the capacity of the affinity gel
The columns were packed with affinity gel suspension 
(1.5 ml) in 2 ml disposable plastic syringes giving a 1 ml 
bed volume. Two columns were used; one for standard 
^H-AFBi 10 and 20 ng/ml in PBS containing 10° dpm/ml; the 
other for standard 3h _a FBi 1 and 5 ng/ml in uncontaminated 
urine (10^ dpm/ml). The column was loaded with 20 ng 
%-AFB^/ml in PBS (1 ml) and the standard affinity column 
elution procedures followed (see Section 2.2.3.3), before 
the column was reloaded with 10 ng ^H-AFB^/ml in PBS (1 
ml). Fractions from each loading were collected and 
duplicate samples (1 ml) were counted for radioactivity. 
Total dpm in each fraction was calculated and the 
percentage distributions of radioactivity between the 
fractions were determined. In the case of the urine 
samples, the procedures adopted were essentially the same 
as for PBS samples except that the column was loaded with 5 
ng ^H-AFBi (1 ml) followed by 1 ng ^H-AFB^ (i ml). All 
fractions were counted for radioactivity.
2.3.4.3 Evaluation of overall clean-up procedures
A . Monitoring of ^H-AFBy in uncontaminated urine samples 
Urine sample (10 ml), spiked with 20 ng ^H-AFB^/ml was 
loaded onto a Sep-Pak cartridge and the ^n-AFB^ eluted
with methanol (see Section 2.2.3.2). The same Sep-Pak 
cartridge was then reloaded with a further 10 ml aliquot of 
the original urine sample and the elution procedure 
repeated. The comparable fractions from the two Sep-Pak
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loadings were combined and counted for radioactivity. 
Aliquots (500 ;ul) of the methanol fraction were directly 
injected into the HPLC to determine radioactivity 
associated with AFBi peak. Then the methanol fraction 
(7 ml), with water (0.5 ml) added, was evaporated to 
0.5 ml and reconstituted to 7 ml with PBS. Recovery after 
evaporation was determined by radioactive counting before 
the samples (500 ;ul) were injected into the HPLC to check 
radioactivity associated with AFBi peak. Then 0.1, 0.2 and
0.5 ml of this fraction were diluted to 5 ml with PBS 
before loading onto the affinity columns. Unretained, 
washing and methanol fractions from the affinity columns
were collected and counted for radioactivity. In this
\
experiment the methanol eluate from the affinity column was 
collected in 2 different fractions; an initial 10 ml and a 
subsequent 5 ml fraction. The overall recovery of the 
procedure was calculated.
B. Monitoring of AFBi in spiked urine samples using ELISA 
Urine samples, spiked with 0.1, 0.5 and 1 ng/ml of
AFB^ were prepared using a stock solution of 10 ug AFB^/ml 
in PBS. The samples (10 ml) were loaded on the Sep-Pak 
cartridge. Fractions of the methanol eluates were 
collected and aliquots (4 ml) evaporated and reconstituted 
to 5 ml with PBS before loading on the affinity columns 
with 1 ml bed volume and elution with methanol. The first 
10 ml of the methanol eluates were collected and aliquots 
were evaporated and then reconstituted in 2 ml PBS. 
Samples (100 ,ul) were analysed for AFB^ by ELISA using
58
five replicate assays with six wells per assay. The 
results were expressed in terms of ng AFB^/ml. An 
'unspiked' urine sample was included in the experiment to 
determine the background level or UALS in the sample. It 
was subjected to the same procedure as those applied to the 
'spiked' urine samples.
2.3.5 Urinary aflatoxin-like substances (UALS)
2.3.5.1 Validation of the use of the 'clean-up' procedures 
Uncontaminated urine samples from 3 Western male 
subjects were used. Each sample (1 ml) was loaded onto a 
Sep-Pak cartridge and the methanol eluates after
evaporation and reconstitution in PBS (see Section 2.2.4) 
were loaded onto the affinity columns. The unretained and 
washing fractions from the affinity columns were combined 
and desalted by reloading onto a Sep-Pak cartridge. 
Possible inhibitory substances (UALS) present in the 
fraction were then eluted from the Sep-Pak with methanol. 
Methanol eluates from the Sep-Pak were collected and water 
(0.5 ml) added, followed by evaporation to 0.5 ml and 
reconstitution to 1 ml with PBS. Methanol eluates from the 
affinity column were evaporated to 0.5 ml, without passing 
through Sep-Pak, and reconstituted in 1 ml with PBS. The 
samples (100 /Ul) were diluted 1:1 with PBS before using in 
ELISA. Three replicate assays were performed per sample.
2.3.5.2 Attempts to fractionate UALS by HPLC
Uncontaminated urine samples (1 ml) from 3 Western
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people were evaporated to dryness using the Speedvac 
Concentrator and redissolved in 50% methanol in water (100 
Ail). The samples were then centrifuged for 10 min and 
aliquots (20 pi) of supernatant were injected into the 
HPLC. Fractions (1 min/l.2 ml) were collected and 
evaporated to dryness before reconstitution with PBS (1 
ml). The apparent AFB-^  in each fraction was analysed in 
duplicate by ELISA.
2.3.5.3 Procedures adopted for reduction of UALS prior to 
ELISA
Urine samples from West Germany, 5 males and 5 females 
were analysed for apparent AFB^ concentration by ELISA 
using undiluted samples and the dilutions in PBS of 1:25, 
1:100 and 1:250.
When the 'clean-up1 procedures were used, undiluted 
urine sample (1 ml) were passed through the Sep-Pak 
cartridges and the affinity columns using the standard 
procedure (see Section 2.2.4). The samples were finally 
reconstituted to 1 ml with PBS before analysing by ELISA 
in triplicate.
The creatinine level in each sample was also analysed 
using method described in Section 2.2.3.7.
2.4 RESULTS AND DISCUSSION
2.4.1 Rabbit anti-AFBi serum
Rabbit serum samples, diluted 1:5,000 and 1:10,000
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with PBS-gelatine, were tested for the presence of 
anti-AFBi antibody using standard AFBi concentrations 
(0.01-100 ng/ml) in the competitive ELISA. The results are 
shown in Figure 2.5. When using a dilution of 1:5,000, the 
competition curve obtained exhibited no region of "steep 
slope" over any concentration of AFBi, and, therefore, was 
not suitable for precise quantitation. In contrast, at the 
dilution of 1:10,000 the curve exhibited a "steep slope" 
over the range 0.03-1.00 ng AFBi/ml and, therefore, this 
dilution was used in further experiments.
When fresh serum was required, a booster dose of 
immunogen was injected into the rabbit, a small sample of 
serum was removed and tested by using a 1:10,000 dilution 
and a concentration range of 0.01 to 100 ng AFBi/ml. T^e 
competition curve observed was compared with that obtained 
from a previous "standard" serum sample.
2.4.2 BSA-AFBi conjugate
The presumed structure of BSA-AFBi conjugate is shown 
in Figure 2.6. Theoretically, 1 mole of AFBi in i litre 
solution would have the absorption of 20,000 at 405 nm;
i.e. 1 nmole of AFBi in i mi solution would have the 
absorption of 0.02. From spectrum shown in Figure 2.7, the 
absorption was 0.153 which was equivalent to 7.65 nmoles 
AFBi • This spectrum came from 250 ,ul solution, hence, 
the total nmoles of AFBi in i mi solution was 30.6 nmoles. 
The protein content of the conjugate was found to be 300 
ug/ml. Molecular weight of BSA is 66,200 so the protein 
content in 1 ml solution was equivalent to 4.5 nmoles.
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Figure 2.6 Presumed structure of BSA-AFB^ 
conjugate
o o
BSA
(From Sizaret et al_. , 1982 )
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Therefore the .ratio of AFB^ molecule : BSA molecule was
7:1.
2.4.3 Antibody recognition of structural analogues to 
AFBi
It was shown from the results in Figures 2.8 and 2.9 
that rabbit anti-AFB^ serum could detect various 
metabolites of AFB^ with different sensitivities. The 
concentration of each analogue at 50% inhibition was 
determined and the ratio of sensitivity relative to AFB^ 
was calculated as shown in Table 2.1. The data indicated 
that rabbit anti-AFB^ serum could detect AFB^-NAcCys, 
AFBi-GSH, AFB^-FAPy, AFBx-Cys, AFiM1# AFB]_-CysGly and AFB2 
with approximately the same sensitivity as it detected
AFB^, which gave 50% inhibition of the ELISA at 0.25 
ng/ml. The 50% inhibition concentrations for these 
analogues were 0.14, 0.32, 0.36, 0.42, 0.44, 0.69 and 0.70 
ng/ml respectively. This antibody could also detect AFL, 
AFPi and AFQ]_ but with lower sensitivity. The 50% 
inhibition concentrations were 7.50, 8.40 and 12.80 ng/ml
respectively. AFB^-Gua could be detected with the
sensitivity intermediate between these two groups with 50% 
inhibition at 2.45 ng/ml. AFG^ and AFG2 were detected with 
much lower sensitivity with 50% inhibition of 50ng/ml.
These data clearly indicate that the major epitope for
antibody recognition of aflatoxin lies in the cournarin and
cyclopentenone rings of the aflatoxin molecule. From this 
hypothesis, it could be predicted that the antibody would 
detect AFB^-Gua and AFB^-FAPy at a similar sensitivity but
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Table 2.1
Concentration of aflatoxin metabolites which showed 
50% inhibition in ELISA
Aflatoxins
Concentration 
for 50% inhibition 
ng/ml
Ratio of sensitivity 
relative to AFB^
AFBX 0.25 1 .0
a f b 2 0.70 2.9
AFGi 50.00 204.1
a f g2 50.00 204.1
AFMX 0.44 1.8
AFPX 8.40 34.3
AFQX 12.80 52.2
AFL 7.50 30.6
AFB^-Gua 2.45 10.0
AFBx-FAPy 0.36 1. 5
AFB]_-NAcCys 0.14 0.6
AFBX-GSH 0.32 1.3
AFBx-Cys-Gly 0.69 2.8
AFB^-Cys 0.42 1.7
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it was found that the 50% inhibition values for AFB-^-Gua 
and AFB^-FAPy were 2.45 and 0.36 ng/ml respectively. These 
data indicate that the antibody is about 7 times more 
sensitive in detecting the AFB^-FAPy adduct than the 
AFB^-Gua adduct. This finding was unanticipated since the 
aflatoxin moiety is identical in these adducts when 
compared to the parent molecule (Figure 2.4). These 
observations suggest that the epitope for the antibody may 
be partially obstructed in these DNA adducts due to the 
stereochemistry of covalent binding of aflatoxin to 
guanine.
When this polyclonal rabbit anti-AFB]_ serum was 
compared with the monoclonal antibody raised by Groopman et 
al. (1984) against AFB^-bovine gamma globulin and having
the major epitope for aflatoxin recognition in the coumarin 
and cyclopentenone rings of the aflatoxin molecule, it 
was found that both antibodies could detect AFB^, AFB2 and
AFMi much more sensitively than AFG^, AFG2 and AFQ^. The
sensitivities of both antibodies against AFB^-FAPy were 
much higher than that of AFB^-Gua. The results indicate 
that as the major epitope for antibody recognition is in 
the same area of the antigen molecule for both the 
monoclonal and polyclonal antibodies, they would detect the 
range of aflatoxin metabolites with a similar order of
sensitivities.
2.4.4 Standard AFBi inhibition curves in PBS and in 
urine samples
Since human urine was the sample of interest, standard
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ELISA competition curves for AFB^ in PBS and in spiked 
urine samples were compared. It was found that the 
percentage inhibition of an unspiked control urine sample 
compared with control PBS was 72% (Table 2.2). This was 
equivalent to 1 ng AFB^/ml in PBS. When the percentage 
inhibitions at the same concentrations of AFB^ in PBS and 
in 'spiked' control urine sample were compared, the values 
obtained from 'spiked' urine sample were consistently 
higher than those obtained from PBS. This was due to the 
fact that unspiked urine samples already had high 
percentage inhibition which was the result of the presence 
of interfering substances in the urine.
The data in Table 2.3 indicate that when an 
uncontaminated urine sample (urine 1) was passed through 
the 'clean-up' procedures before spiking with known 
concentrations of AFB^, similar percentage inhibitions to 
'spiked' PBS were obtained. When urine samples were spiked 
with known concentrations of AFBj before passing through 
the 'clean-up' procedures (urine samples 2-4), the 
percentage inhibitions at the lower concentration of AFB^ 
(0.01 ng/ml) were higher than the corresponding one in PBS 
solution. There were no differences in the percentage 
inhibitions when using higher concentrations of AFB^ in PBS 
and in urine samples.
When the percentage inhibitions of the 'spiked' urine 
samples were calculated by comparison with the 
corresponding 'unspiked' urine samples (Table 2.4), the 
percentage inhibitions at each concentration of AFB^ in
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Table 2.2
Percentage inhibition of various concentrations of AFB^ 
in PBS and in undiluted control urine sample in ELISA
AFB^ concentration 
(ng/ml)
% Inhibition 
PBS
in the ELISA 
urine
0 - 71.7
r—
1
o
•
o
15.8 73.3
0.10 43.1 80.0
1.0 70.9 85.8
10.0 82.4 91.9
100.0 84.6 92.6
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Table 2.3
Percentage inhibitions of various concentrations of AFBj as compared 
to PBS in uncontaminated human urine samples after passing through the 
clean-up procedures
AFBi
concentration
(ng/ml)
% Inhibition in the ELISA compared with control PBS
PBS urine 1 urine 2 urine 3 urine 4 urine 5
0 - 2. i 34.1 38.7 53.8 34.6
0.01 3.3 4.6 35.9 44.1 60.0 41.9
0.10 41.5 50.2 38.9 61.2 74.8 57.6
1.0 72.5 76.9 72.3 70.7 79.0 74.9
10.0 87.2 85.3 84.4 86.1 90.5 86.2
100.0 91.9 88.0 84.7 87.8 92.4 90.5
N.B. - Urine 1 was passed through the clean-up procedures before 
spiking with known concentrations of AFB^
- Urine 2-5 were spiked with known concentrations of AFB^ before 
passing through the 'clean-up' procedures
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Table 2.4
Percentage inhibitions of ELISA in PBS and in urine samples
AFBi
concentration
(ng/ml)
% Inhibition in the ELISA
PBS* urine 1+ urine 2+ urine 3+ urine 4+ urine 5+
0.01 3.3 2.6 3.0 16.5 13.4 11.2
0.10 41.5 49.1 8.1 43.4 45.5 35.1
1.0 72.5 76.4 63.7 58.4 54.5 61.7
10.0 87.2 85.0 84.0 82.8 79.4 79.0
100.0 91.9 87.8 84.6 85.4 83.6 85.4
N.B. - Urine 1 was passed through the ’clean-up’ procedures before 
spiking with known concentrations of AFB^
- Urine 2-5 were spiked with known concentrations of AFB^ before 
passing through the 'clean-up' procedures
* Percentage inhibition in PBS was calculated by reference to 
control PBS
+ Percentage inhibition in 'spiked' urine samples were calculated 
by reference to the corresponding unspiked urine samples
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urine samples were similar to those observed in the PBS 
samples. The values obtained were slightly higher at 0.01 
AFB^/ml than those seen in the PBS samples. The pattern of 
the standard inhibition curves, however, was similar.
Although in these preliminary spiking experiments, a 
range of AFB^ concentrations up to 100 ng/ml was used, a 
limiting factor in the subsequent assays was the capacity 
of the affinity column (20ng AFB^) using a 1 ml bed volume 
(see Section 2.4.6.3). When samples containing 100 ng AFB^ 
were loaded onto the columns, the columns were overloaded 
and only 10-20% of AFB^ loaded was recovered in the 
methanol eluates. But in the subsequent ELISA, even giving 
this lower level of recovery from the column, the 
inhibition obtained was in the plateau part of the 
curves. Therefore, in order to obtain ELISA inhibitions in 
the proportionate (steep) part of the curves which is in 
the range of 50% inhibition, it is desirable to start with 
concentration of AFBj in the sample of not more than 20 
ng/ml. Anything in excess of this would be in the 
non-proportionate (plateau) part of the inhibition curves.
When uncontaminated urine samples were directly 
assayed for apparent AFB^ concentration, there were some 
inhibitory substances present in the samples which reacted 
with rabbit anti-AFBi serum in ELISA giving high percentage 
inhibitions. These inhibitions could be reduced by passing 
the samples through the preliminary 'clean-up1 procedures 
(Sep-Pak and affinity column). These substances were 
referred to in one study as urinary aflatoxin-like
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substances (UALS) (Dragsted et al. , 1988). It is widely
accepted that even in the Western urine samples, which are 
presumed to be free of aflatoxin contamination, from France 
(Martin et al. , 1984), USA (Groopman et al^ ., 1984) and
Denmark (Dragsted et al., 1988) there are these UALS which 
often gave positive results for aflatoxins. These
substances can be reduced by using Sep-Pak and 
immunoaffinity column (Groopman et aJL., 1984) but they
cannot be totally removed from the samples as shown in
Table 2.3. Due to the presence of these UALS in the 
uncontaminated urine samples, it is possible that when 
these samples were 'spiked1 with AFB^, the percentage 
inhibitions would be higher than those obtained in PBS. 
All these percentage inhibitions were calculated by 
comparing with 'unspiked' PBS which was free of any
inhibitory substances. When the percentage inhibitions of 
'spiked'urine samples in ELISA were calculated from the 
corresponding 'unspiked' urine samples, similar percentage 
inhibitions to those seen from comparing 'spiked' with
'unspiked' PBS were obtained (Table 2.4).
In practice, it is not possible to achieve the ideal 
situation in which the percentage inhibitions are
calculated by comparing contaminated samples with
uncontaminated samples from the same individual because one 
cannot find uncontaminated urine samples to serve as 
controls before obtaining another sample from the same 
source which is contaminated with aflatoxins. However, the 
protocol adopted in which urine samples from a presumably
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unexposed population such as Western people are used to 
serve as controls and then to monitor the exposure in 
people from a different part of the world is not entirely 
satisfactory. It was observed that not only did the 
control Western urine samples contain inhibitory substances 
(UALS), but these varied between individuals (Table 2.16). 
There is evidence that the UALS present in the urine 
samples of Western people vary according to the food being 
eaten (Dragsted et al., 1988), so it is not appropriate to 
compare people from different parts of the world because 
the dietary pattern varies from country to country.
One theoretical possibility would be to establish 
standard UALS inhibitory level for each population to be 
studied. However, this could only be achieved using large 
numbers of samples, and even then only a range of 
inhibitory level would be established. So a compromise 
solution for monitoring aflatoxin exposure is to calculate 
the percentage inhibitions in urine samples by reference to 
PBS controls.
2.4.5 The effect of methanol on ELISA
Since all the procedures used in the preliminary 
'clean-up' of urine samples involved the use of methanol, 
it was of interest to study the effect of this solvent on 
the competitive ELISA. In 50% methanol solution, the 
standard ELISA curve of AFB^ was less steep than the one 
obtained using PBS (Figure 2.10). In the presence of 50% 
methanol, the percentage inhibitions at AFB^ concentrations
76
F
i
g
u
r
e 
2»
10
 
Ef
fe
ct
 
of
 
me
th
an
ol
 
on
 
th
e 
AF
B^
 
co
mp
et
it
io
n 
as o
toCQ
O . 60
CO
O
O
uomqiMUl *
77
ng
/m
l 
AF
Bj
less than 0.1 ng/ml were higher than those seen in PBS, 
while at the higher concentrations the percentage
inhibitions were lower. In 85% methanol solution, there
was a 'flat* competition ELISA curve and even at the lowest
concentration of AFB^ (0.01 ng/ml) the percentage 
inhibition was 60% compared with the PBS control.
From these results, it can be seen that methanol 
solutions of 50% or more were not suitable for ELISA 
because they not only gave high percentage inhibition at 
low concentrations of AFB^, but also the competition curves 
were "shallow" when compared with the curves obtained in 
PBS.
It had already been shown that uncontaminated urine
samples could give high percentage inhibition in 
competitive ELISA due to UALS. If these two factors 
(methanol and UALS) acted additively in the ELISA, high 
percentage inhibitions compared with PBS could be 
obtained. As a result of this experiment, it was decided 
that methanol would be removed from the samples prior to 
their assays by ELISA.
2.4.6 Methods developed to monitor aflatoxins excreted 
in human urine samples
It had been a common experience of people working in 
this field that monitoring of aflatoxin levels in human 
urine samples was not straightforward (Groopman et al. , 
1985, 1986; Garner et al. , 1985). The samples could not
be used directly in ELISA because they always had high and 
variable background levels of inhibitory substances. The
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suggestion had been made to use some 'clean-up' procedures 
to remove non-aflatoxin substances or UALS that might react 
with the antibody in ELISA. The use of Sep-Pak C^g 
cartridges and immunoaffinity columns had been suggested 
(Groopman et al. , 1984). In order to establish a suitable 
method for use in monitoring aflatoxin levels in human 
urine samples, all the 'clean-up' procedures had to be 
validated. They were divided into each individual step and 
were tested separately.
2.4.6.1 Capacity of Sep-Pak Cia Cartridge
The data given in Table 2.5 clearly show that when 1 
ml of a solution containing up to 100 ng of ^H-AFB^ in 
either PBS or 'spiked' urine sample was loaded onto a 
Sep-Pak cartridge, more than 90% of the ^H-AFB^ was
retained on the cartridge and could subsequently be eluted
with methanol.
Table 2.6 shows that when up to 200 ng of ^H-AFBi 
in uririe was loaded onto a Sep-Pak cartridge, 90% of the 
radioactivity was retained and subsequently could be eluted 
with methanol. About 9% of the radioactivity was in the 
unretained and the washing fractions. When these two 
fractions were combined and injected into the HPLC, most of 
the radioactivity eluted in the first few fractions. When 
the methanol fractions from the Sep-Pak cartridge were 
subjected to the HPLC, peaks which corresponded to those
obtained by injection of standard ^H-AFB^ were observed
(Figure 2.11).
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Table 2.5
Radioactivity in fractions from Sep-Pak Cjg cartridge after loading 
with various concentrations of 3H-AFBi in PBS and in urine sample
Radioactivity in fractions
3H-AFB1
(ng/ml) unretained washing methanol
dpm %* dpm %* dpm %*
in PBS 
0.1 280 1.9 830 5.7 13570 92.4
1.0 560 4.0 550 3.9 12960 92.1
10.0 270 1.9 630 4.4 13580 93.8
100.0 260 1.8 800 5.5 13500 92.7
in urine
0.1 380 3.0 980 7.6 11500 89.4
1.0 550 3.4 880 5.4 14770 91.2
10.0 370 2.6 800 5.5 13280 91.9
100.0 360 2.7 1040 7*9 11860 89.4
* Percentage of total radioactivity recovered in all fractions
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Table 2.6
Radioactivity in fractions from Sep-Pak C^g cartridge 
after loading with 10 ml of urine sample containing 
200 ng 3H-AFB!
Fraction from 
Sep-Pak total dpm
Radioactivity
%*
unretained 48,210 4.9
washing 36,735 3.7
methanol 896,630 91.4
* Percentage of total radioactivity recovered in all 
fractions
81
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When the methanol samples eluted from the Sep-Pak were 
evaporated and reconstituted to the original volume in PBS, 
the percentage recovery of radioactivity was .92%. A 
similar percentage of the radioactivity in the 
AFB^-associated HPLC peak was observed using the methanol 
fraction either directly or after evaporation and 
reconstitution in PBS.
From the data shown in Tables 2.5 and 2.6 it could be 
concluded that when ^H-AFBi was loaded onto a Sep-Pak C^g 
cartridge up to the amount of 200 ng, 90% of the 
radioactivity was retained on the cartridge and 
subsequently eluted with methanol but this corresponded 
with 100% retention of AFB]_. It was demonstrated by the 
correspondence with the AFB^-associated peak in the HPLC 
fractions of the label present in the methanol eluate from 
the Sep-Pak, in contrast to the radioactivity in the 
unretained and the washing fractions which eluted early 
from the HPLC. The label present in the unretained and the 
washing fractions of the Sep-Pak represented tritium 
exchange from the AFB^. Therefore, these unretained and 
washing fractions from Sep-Pak were subsequently discarded 
and only the methanol eluate was used in further analysis. 
The evaporation process to remove methanol was proved to be 
effective and more than 90% of the radioactivity could be 
recovered following this process.
However, it must be pointed out that these experiments 
represented an early stage in the development of monitoring 
protocol and subsequently when actual biological samples
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containing AFBi metabolites were to be examined, the 
distribution of these metabolites among the Sep-Pak 
fractions would need to be reassessed.
2.4.6.2 Capacity of affinity gel
The results from a non-immune column loaded with 1 ml 
of 1 ng in PBS (Table 2.7) showed that the column
did not retain ^H-AFBi . All the radioactivity came out in 
the unretained and the PBS washing fractions. The slight 
retardation observed in the emergence of the ^H-AFBi was 
presumably the result of normal chromatographic action.
When the immune column was loaded with 1 ml of PBS 
containing 1 ng ^jj-AFBi, the results indicated that the 
column strongly retained ^H-AFBi* Only 18% of the 
radioactivity was eluted in the unretained and the washing 
fractions and as had already been demonstrated by the HPLC, 
these samples of ^h-a f b  ^ contained at least 10% of tritium 
exchange. The data indicated that with 0.5 ml bed volume, 
the immune column was capable of retaining 1 ng ^H-AFBi in 
PBS and the immunoaffinity column had potential for 
"cleaning-up" the samples prior to ELISA.
2.4.6.3 Characteristics of the immunoaffinity columns
Immunoaffinity columns with 0.5 ml bed volume were 
tested. The results shown in Table 2.8 are divided into 
two parts depending on the nature of the samples used (PBS 
or urine).
When using standard concentrations of ^H-AFBi in PBS,
84
Table 2.7
Radioactivity in fractions from immune and non-immune 
affinity column loaded with 1 ng
Fraction from 
affinity column
non-immune 
total dpm
Radioactivity
column immune column
%* total dpm %*
unretained 2435 19.0 587 5.1
washing 10244 79.9 1452 12.7
methanol 142 1.1 9393 82.6
total dpm 12821 11432
* Percentage of total radioactivity recovered in all 
fractions
85
the volumes loaded varied from 0.2 ml to 10.0 ml and the 
amounts of loaded were 1 to 100 ng. The
percentages of radioactivity in the eluted methanol 
fractions following replicate loadings of ^H-AFBx were: 
from 1 ng AFB^ loaded, 84, 84 and 75%; from 7 ng, 82%; from 
20 ng 67, and 69%; from 75 ng, 22 and 10%; and from 100 ng, 
18%.
When urine samples 'spiked' with various 
concentrations of ^h -a FBx were used, the volumes loaded did 
not exceed 2 ml. The percentages of radioactivity in the 
methanol fractions from 1 ng AFB^ loaded were 72% in two 
replicates; from 10 ng, 68%; and from 20 ng, 59 and 69%. 
It should be noted that when samples containing 20 ng 
^H-AFBx were used, the samples volumes loaded differed by a 
factor of 10 times (0.2 and 2 ml). This difference in the 
sample volumes loaded resulted in differing retentions of 
the radioactivity on the column.
It was clearly shown from these results that in using 
PBS solution, the capacity of the column was 20 ng AFB^ 
with 0.5 ml bed volume and the column could be reused. The 
volumes of samples loaded did not affect the capacity of 
the column, as when 2.0 and 0.2 ml of PBS containing the 
same amount of ^h-aFB^ (20 ng) were loaded onto the column, 
the amounts of radioactivity retained on the column were 
the same. And when 1 and 10 ml of PBS containing 1 ng of 
^H-AFBx were loaded, similar percentages of radioactivity 
were retained on the column, and it was also shown that the 
column was reusable.
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When urine samples were used, less radioactive AFBi 
was retained on the column when compared with loading the 
same amount of ^H-AFBi in p b s . The amount of ^H-AFB^ 
loaded should not exceed 20 ng using 0.2 ml urine samples 
with a column bed volume of 0.5 ml. The capacity of the 
column was lower than when PBS solutions were used. The 
volume of urine samples used affected the capacity of the 
column; when small volumes of urine samples were used, the 
column was capable of retaining more ^H-AFBi. The 
possibility of reusing the columns depended on the volume 
of urine loaded.
From these preliminary studies it was evident that 
loading higher amounts of AFB^ in either PBS or urine 
samples resulted in decreasing percentages of the samples 
being retained. Comparison of loading 1 ng of AFB^ in PBS 
or in urine indicated that more radioactivity was retained 
on the column when AFB^ was in PBS. The percentage of 
tritium found in the unretained and the washing fractions 
when samples were applied in PBS, and presumably due to 
exchange was round 16-25% but in the urine samples, the 
exchange was higher. It is also possible that there are 
some substance(s) in the urine samples that might interfere 
with the binding of ^H-AFBi onto the column.
These results applied only to sample loading which did 
not exceed the AFB^ capacity of the column (20 ng AFBi for 
a 0.5 ml bed volume). When higher sample loadings were 
attempted, radioactivity in the unretained and the washing 
fraction were due to both tritium exchange and also 
unretained AFB^.
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When 2 ng ^H-AFBi were loaded onto the column in a 2 
ml urine sample, 60% of the radioactivity was retained on 
the column, while when 5 ng were loaded in a 5 ml
urine sample only 27% was retained (Table 2.9). The 
percentage radioactivity in the unretained fraction 
following 5 ng AFB^ loading was nearly twice that found in 
the comparable fraction following 2 ng loading. Since this 
difference is not due to tritium exchange it can be 
concluded that the capacity of the column (20 ng AFB^ in 
PBS) is effectively reduced when samples are applied in 
urine. This could be due to substance(s) in the urine
which prevented the binding of AFB^ onto the column.
When the samples from the methanol eluates were 
injected into the HPLC either directly or after 
evaporation, the percentage radioactivity in the
AFBi-associated peak was more than 80% as shown in Table 
2.10. And the recoveries of radioactivity after
evaporation of methanol column eluates following 2 and 5 ng 
loadings were 55 and 102% respectively. The low 55%
recovery might be due to the fact that this sample was
taken down to dryness. In order to clarify this point, a 
further experiment was carried out in which 2 ng of ^H-AFBi 
in 2 ml urine sample was loaded onto an affinity column and 
the whole procedures repeated except that the sample was 
not evaporated to dryness but only to a low volume (0.5 ml) 
before reconstitution. In this case 97.5% of the 
radioactivity was recovered.
The data demonstrate that recovery of ^H-AFB^ after
89
Table 2.9
Radioactivity in fractions from affinity columns after 
loading with 2 and 5 ng ^H-AFB^ in 2 and 5 ml urine 
respectively
Fraction from 
affinity column
% Radioactivity 
2 ng loaded 5 ng loaded
unretained 36.9 64.8
washing 3.1 8.3
methanol 60.0 26.9
Overall % recovery of 
radioactivity loaded* 106.1 100.3
+ Essentially all recoveries approximately 100%
Variation due to radioactive counting using 1 ml aliquots 
of samples
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Table 2.10
Radioactivity in the AFB],-associated peak on HPLC after 
injection of methanol fractions from affinity column 
loaded with 2 and 5ng ^H-AFB^
HPLC fraction
% Radioactivity 
APB^-associated
in the 
peak
2 ng loaded 5 ng loaded
directly injected 81 100
after evaporation 90 94
% recovery after 
evaporation 55 102
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evaporation of the methanol fractions from affinity column 
exceeded 90% and were similar to the percentage recovery of 
radioactivity found using methanol eluates from the Sep-Pak 
C^q cartridges. It was also shown that methanol samples 
should not be evaporated to dryness because this reduced 
the recovery of ^H-AFBi.
2.4.6.4 Routine testing results of the capacity of the 
affinity gel
The routine standard testing of the capacity of the 
affinity gel was developed in order to test each new batch 
of gel prepared using different samples of antisera, either 
from the same or from different rabbits. The results had 
to be in the range of the data shown in Table 2.11, 
otherwise the gel was classified as not suitable for 
further analysis. With 1 ml column bed volume, the 
retention of ^h-a f b  ^ on the column was approximately 93% 
with the capacity of up to 20 ng AFB^ in PBS. Whereas 
using urine samples the radioactivity retained on the 
column was approximately 90%, with the capacity in the 
order of 5 ng AFB^. This may be due to the presence of 
some interfering substances which could prevent the binding 
of AFB^ on the column. In order to avoid possible problems 
associated with this factor when using samples of unknown 
AFB^ content, it was decided to restrict the volume of the 
sample to 1 ml and to increase the column bed volume to 1 
ml.
It had to be borne in mind that the urine samples used
92
Table 2.11
Radioactivity in fractions from affinity column in routine testing 
with standard AFB^ concentration in both PBS and urine sample
3h-afb1
concentration
(ng/ml)
unretained 
dpm %*
Radioactivity in
washing 
dpm %*
methanol 
dpm %*
PBS
20 3,310 0.5 39,945 6.4 579,840 93.1
10 4,466 0.7 50,430 8.0 572,445 91.3
Urine
5 5,522 0.9 51,315 8.5 548,805 90.6
1 12,968 2.7 49,215 10.1 426,495 87.3
* Percentage of total radioactivity recovered
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in the column evaluation studies were untreated samples 
which meant they were not subjected to any previous 
'clean-up' procedures. So it was anticipated that when 
samples were subjected to prior 'clean-up' procedures and 1 
ml of these samples were subsequently loaded onto 1 ml bed 
volume of the affinity column, it would be possible for 
amounts of AFB^ in excess of 5 ng AFBi to be retained onto 
the column.
When each batch of affinity gel was prepared, these 
routine tests were carried out. If the results of the 
tests were not in the acceptable range of the gel capacity, 
the decision had to be made whether the gel was suitable 
for use or not. If the gel retained ^H-AFBi but a little 
less than anticipated, by adjusting the column bed volume 
the capacity of the column used could be in the acceptable 
range. But if the retention was much lower than it should 
be, the gel was discarded.
2.4.6.5 Recovery of the overall 'clean-up' procedures
The study was aimed to evaluate the recovery of 
^H-AFBi in urine samples after passing through the Sep-Pak 
Cis cartridge and the immunoaffinity column by monitoring 
radioactivity and using ELISA techniques to check the 
levels of AFB^ in the samples.
When 20 ml of urine sample containing 20 ng 
^H-AFBi/ml was loaded on a Sep-Pak cartridge (a total 
loading of 400 ng ^h-a FB^ ), 89% of the radioactivity was
retained on the cartridge (Table 2.12). When the methanol
94
Table 2.12
Radioactivity in fractions from Sep-Pak 
cartridge after loading with 20 ml of urine 
containing 20 ng ^H-AFB^/ml
Fraction Volume (ml) % Radioactivity
unretained 20 10.0
washing 6 1.0
methanol 10 88.9
Overall % recovery of 
radioactivity loaded*
109.3
+ Essentially all recoveries approximately 100%
Variation due to radioactive counting using 1 ml aliquots 
of samples
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eluate from the Sep-Pak was directly injected into the 
HPLC, 93% of the radioactivity was in the AFB^-associated 
peak. After evaporation (not to dryness), the radioactive 
recovery was 92% and on subsequent HPLC chromatography the 
radioactivity in the AFBi-associated peak was 90%. So the 
overall recovery from the Sep-Pak procedure and subsequent 
reconstitution to 5 ml with PBS was 82%, hence the amount 
of ^H-AFBi in the solution according to radioactivity 
should be 324 ng. When 0.1, 0.2 and 0.5 ml aliquots of
this methanol fraction from the Sep-Pak were loaded onto
the affinity column with 1 ml bed volume, the amount of 
AFBi loaded should have been 3.24, 6.48 and 16.20 ng
respectively.
The methanol eluate from the affinity column was 
collected in two fractions; the first fraction was 10 ml of 
the eluate and the second fraction was 5 ml eluate. As 
shown in Table 2.13, most of the radioactivity in the 
methanol fractions was in the first 10 ml and that the 
radioactivity in this fraction was more than 80% of the 
total radioactive present in all the affinity column 
fractions, hence this elution volume was sufficient for 
subsequent use in ELISA. A total methanol eluate volume of
10 ml was very convenient for the subsequent evaporation in
the Speedvac Concentrator which had tubes of 10 ml 
capacity.
The average recovery from the affinity column was 
86%. Therefore, the overall recovery of radioactivity 
using ^H-AFB^ in the complete 'clean-up' procedures of a
96
Table 2.13
Radioactivity in fractions obtained from affinity 
columns following loading with different volumes 
of a 'spiked' urine sample pre-purified by Sep-Pak 
cartridge*
Fraction from 
affinity column
% Radioactivity 
0.1 ml 0.2 ml 0.5 ml
unretained 2.5 5.7 9.0
washing 0.1 3.8 6.2
10 ml methanol 92.1 85.9 80.6
5 ml methanol 5.3 4.6 4.2
Overall % recovery of 115.1 94.4 103.1
radioactivity loaded*
* 20 ml of a urine sample 'spiked' with 400 ng ^H-AFBi was 
loaded onto Sep-Pak cartridge, washed and eluted with
10 ml methanol.x Sample (7 ml) was evaporated (not to 
dryness) and reconstituted in 7 ml PBS. Different 
volumes of this sample were then applied to the affinity 
column.
+ Essentially all recoveries approximately 100%
Variation due to radioactive counting using 1 ml aliquots 
of samples
x See Table 2.12
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Sep-Pak Ci8 cartridge followed by an affinity column was 
71%. This recovery was deemed to be of an acceptable 
level.
From Table 2.13, although the percentage radioactivity 
recoveries using the 3 sample volumes did not differ 
greatly, nevertheless, there was a trend for a lower 
recovery, in the first 10 ml methanol eluate, the larger 
the sample volume applied. This suggested that the volume 
of urine samples applied to the column should be kept as 
low as possible, consistent with obtaining significant 
results in the subsequent ELISA.
An experiment was carried out in which 'unspiked1 or 
AFB^-spiked urine samples were subjected to the 'clean-up' 
protocols and finally the AFB^ content assayed by ELISA. 
The data given in Table 2.14 show that for a 10 ml unspiked 
control urine sample, an apparent AFB^ content of 1.77 ng 
(0.177 ng/ml) was found. This level (0.177 ng apparent 
AFB^/ml) was consistent with other experiments carried out 
in this study using unspiked urine samples with the 
'clean-up' procedures (see Table 2.16).
In the AFB^-spiked urine samples, the amounts of AFB^ 
determined by ELISA were 2.95, 4.34 and 9.47 ng for the 1,
5 and 10 ng AFB^ level respectively. The results were 
reproducible in 5 separate assays. The amounts of AFB^ 
obtained in the ELISA were similar to the known amounts of 
AFBi added to the samples. But the apparent level of 1.77 
ng AFB^ in 10 ml unspiked urine sample should be subtracted 
from the values obtained using the 'spiked' samples.
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Following this correction, the amounts of AFBi present in 
each sample would be 1.18, 2.57 and 7.70 ng AFBi
respectively.
When using ^H-AFBi in the 'clean-up' procedures, the 
results presented in Tables 2.12 and 2.13 show an overall 
radioactive recovery for the procedures of approximately 
71%. Therefore, the results of the ELISA and radioactive 
assays for the 'clean-up' procedures are essentially in 
agreement.
2.4.7 Urinary aflatoxin-like substance (UALS)
2.4.7.1 Apparent AFBi concentrations in uncontaminated 
human urine samples
When uncontaminated human urine samples were loaded 
onto the affinity columns, the apparent AFBi concentrations 
were higher in the combined unretained and washing 
fractions from the affinity column than in the methanol
eluate fractions (Table 2.15). The values in the washing 
fractions were 0.70, 1.06 and 1.88 ng apparent AFBi/ml,
with the average of 1.21 ng/ml. While in the methanol 
fractions, the apparent AFBi values were 0.24, 0.40 and
0.78 ng/ml, with the average of 0.47 ng/ml. These results 
indicate that the apparent AFBi concentration in the
washing fractions of the affinity column was nearly 3 times 
higher than that obtained using the methanol fractions. 
Since the urine samples used were presumed to be free of 
aflatoxin contamination, the level of aflatoxin found in 
the samples should represent the background level
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or the interfering substances that could react with the 
antibody used in the ELISA. Therefore, it appeared that 
the methanol eluate from the affinity column was the 
appropriate fraction to use in ELISA to detect aflatoxins 
in human urine samples.
When the uncontaminated urine samples were 
fractionated by HPLC before subjecting to the ELISA, the 
apparent AFBi was very high in fraction 2 of the HPLC 
(Figure 2.12). All the other fractions nearly had the same 
apparent AFBi concentration of 0.2 ng/fraction. The 
results also show that the substances present in the 
uncontaminated human urine samples which were reactive in 
the ELISA system could be separated chromatographically and 
were eluted in the first 4 fractions. Even if the level of 
interfering substances was as low as 0.2 ng/fraction it 
would be desirable to remove them before analysing the 
actual potentially contaminated samples. This is the point 
why the 'clean-up' procedures should be used. It had 
already been demonstrated that the background level in the 
methanol fraction of the affinity column was much lower 
than in the washing fraction (Table 2.15). This meant that 
the majority of the reactive substances had already been 
removed by the washing procedure. However there was still 
some reactive material present in the methanol fraction 
which gave a background reading in the ELISA.
2.4.7.2 Reduction of UALS in uncontaminated human urine 
samples
From the previous experiment it was found that the
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inteference in the uncontaminated urine sample could be 
reduced by using a Sep-Pak C^q cartridge and an immuno- 
affinity column. Comparisons of the apparent AFBi
concentrations in the samples before and after the 
'clean-up' procedures were made.
When undiluted urine samples were used directly in 
ELISA, they gave very high inhibitions of approximately 90% 
and when the 1:250 dilutions were used they gave very low 
inhibitions of approximately 10%. The appropriate dilution 
of human urine samples to be used directly in ELISA was 
1:25 because this dilution gave inhibitions compatable with 
the proportional range of ELISA. The results show that the 
very high inhibitions of neat urine samples could be 
reduced by dilution, but this would not be a practical 
solution when using potentially contaminated samples since 
aflatoxins in the samples would be diluted as well.
When human urine samples diluted 1:25 were analysed by 
ELISA, the apparent AFBi content of the samples ranged from 
1 to 12 ng/ml (Table 2.16). The variation in apparent 
background concentration between individual samples might 
be due in part to differences in the urine
concentrations. Creatinine concentration can be used as a 
reference point to correct for these differences, and 
apparent AFBi can be expressed as ng AFBi/mg creatinine? in 
this case, they ranged from 1.6 to 10.7 ng/mg.
When the samples were passed through the 'clean-up' 
procedures, the background or apparent AFBi levels were 
reduced. They ranged from 0.08 to 0.44 ng/ml or 0.04 to
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0.24 ng/mg creatinine. Therefore, the interference could 
be reduced by 97% (Table 2.16). From these data using 10 
subjects the average apparent AFB^ was 0.14 ng/mg 
creatinine with a standard deviation of 0.07. If the mean 
background level plus one standard deviation is considered 
to be the lower limit of significant detection for the 
presence of aflatoxins assayed by this system, this gives a 
value of 0.2 ng AFB]_/mg creatinine. If the samples being 
analysed had the level of AFB^ equivalent lower than 0.2 
ng/mg creatinine, no firm conclusion could be made as to 
the presence of aflatoxins in these samples. Since the 
number of subjects used in determining this lower limit of 
significant detection was small, it would be possible that 
if more subjects were used, this limit of detection would 
be changed. But from all the data obtained from
uncontaminated urine samples analysed so far it appears 
that this limit is an appropriate one to use.
2.5 SUMMARY
A method to monitor aflatoxins excreted in human urine 
samples has been developed using the ELISA technique. It 
was found that urine samples cannot be used directly in 
ELISA because of a high interference due to unknown 
substances (UALS) present in the urine. These UALS can be 
reduced by the 'clean-up' procedures of a Sep-Pak C^g 
cartridge and an immunoaffinity column. When the presumed 
uncontaminated human urine samples were spiked with ^H-AFB^
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and the 'clean-up' procedures were carried out, the overall 
percentage recovery of the radiolabelled AFBi was 71%.
The antibody used in the preparation of the 
immunoaffinity columns and in the ELISA is polyclonal and 
has as its major epitope for antibody recognition, the
coumarin and cyclopentenone rings of the aflatoxin 
molecule. This antibody can be diluted 10,000 times before 
using in ELISA analysis. When immunoaffinity columns with 
1 ml bed volume were prepared, their capacity was 20 ng
AFBi/ml PBS or 5ng AFBi/ml urine (without any 'clean-up' of
the samples). It is suggested that UALS may obstruct the 
binding of aflatoxin onto the column. Therefore, the
volume of urine loaded should be kept as low as possible, 
but consistent with obtaining significant results in the 
subsequent ELISA.
The general procedures for analysing aflatoxins 
excreted in human urine samples developed in this chapter 
should be further validated using the actual aflatoxin 
metabolites excreted in the appropriate animal model 
system.
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CHAPTER 3
Marmoset. Monkey as an Animal Model to Validate 
the Methods Developed for Monitoring Human 
Exposure to Aflatoxins
108
3.1 INTRODUCTION
In order to monitor the levels of aflatoxin exposure 
using human urine samples, methods employing an ELISA 
technique with preliminary 'clean-up' procedures on Sep-Pak 
C^q cartridge and immunoaffinity column have been 
developed. These methods have been validated step by step 
using 'spiked' ^H-AFBi in either PBS or uncontaminated 
human urine samples. Only AFBi was used in developing 
these monitoring procedures, however, AFBi is unlikely to 
be found in human urine samples because it will be 
metabolized in the body by microsomal enzyme system to 
various metabolites (see Section 1.3). In view of this, it 
would have been desirable to validate the methods using 
known contaminated human urine samples. Since it is not 
possible to conduct this type of study in human beings, an 
appropriate animal model which has similar pathways of AFBi 
metabolism to humans should be used.
Primates are considered to be the animal species which 
have metabolic pathways of many xenobiotic compounds 
similar to man. Several studies have suggested that AFQi 
is the major metabolites of AFBi in the monkey and man 
(Biichi et al. , 1974; Hsieh et al. , 1977; Moss and Neal,
1985; Yourtee et al. , 1987). AFQi is identified as an
hydroxylated product of AFBi with the hydroxyl on the 
carbon atom p to the carbonyl of cyclopentenone ring 
(Figure 2.4) (Masri et al., 1974). In one study, 33% of 
AFBi was metabolized by human liver microsomal fractions in
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75 min to a variety of metabolites, of which AFQi made up 
8.5% of the total, while using monkey liver microsomes 48% 
of AFBi was metabolized and 10.1% was AFQi (Hsieh et al. , 
1977). In a recent study using human liver microsomes, 
AFQi comprised 70-90% of soluble, detectable metabolites 
and 15-20% of the added AFBi (Moss an<3 Neal, 1985). It is 
thought that AFQi is metabolized further to water-soluble 
conjugates such as glucuronides, which are difficult to 
detect (Wei et al., 1985).
The formation of AFQi s considered to be a 
detoxifying step, although the fate of the AFQi produced is 
unclear (Moss and Neal, 1985). It was not detected in the 
urine of monkeys dosed with AFBi (Dalezois and Wogan, 1972; 
Dalezois et al., 1973) nor in the urine of humans ingesting 
aflatoxin-contaminated diet (Campbell et al., 1970). In
both instances, however, the analytical methods employed 
would have detected only unconjugated derivatives, because 
the chloroform soluble fraction of the urine was examined, 
and it is possible therefore that conjugated AFQi may, in 
fact, have been present.
Marmoset monkey is the animal of choice because 
preliminary in vitro studies in this laboratory using the 
liver microsomal fraction from the animals showed that the 
major metabolite obtained (AFQi) is similar to that 
obtained from human liver microsomes (Moss and Neal, 
1985). AFQi accounted for at least 30% of metabolites 
produced from both marmoset monkey and man (G.E. Neal, 
D.J. Judah and E.J. Moss, personal communication).
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In competitive ELISA using polyclonal rabbit anti-AFBi 
serum, AFQ^ is detected with a sensitivity 52.2 times less 
than that of AFB^ (Table 2.1). It is most likely that in 
both human and monkey, AFQ^ is excreted mainly in the 
conjugated form. Standards of these AFQi conjugates are 
not available to be tested, but it is expected that they 
would inhibit even less effectively than AFQi. As stated 
in Section 2.4.3, it was found that modification in the 
cyclopentenone ring (AFQi) substantially decreased the 
sensitivity of detection by the polyclonal antibody used in 
this study and so additional modification at this position 
by the conjugating moiety would further reduce the 
sensitivity. Due to the problems being outlined, it was 
necessary to validate the methods developed for monitoring 
the level of aflatoxin exposure in man using the marmoset 
monkey.
The objective of this study was to use marmoset urine 
samples to validate the methods proposed for use in 
monitoring aflatoxin exposure in humans. Male and female 
marmosets were treated with l^C-AFBi to avoid the 
complication due to exchange when ^H-AFBi was used (see 
Section 2.4.6.1). Marmoset urine samples which contained a 
spectrum of metabolites assumed to be representative of 
that expected to be found in human urine samples were 
collected. The AFB^ equivalent concentrations in the 
samples were determined by using both radioactive counting 
and the ELISA technique.
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3.2 MATERIAL AND METHODS
3.2.1 Animals
One male and one female marmoset (Saguinus 
oedipomidas), 2-year old, were made available by the 
Ministry of Defence, Porton Down, Salisbury, and the animal 
procedures were carried out by personnel from that unit at 
the Porton Down site. The body weights of the male and 
female marmosets were 305 and 350 g respectively. They 
were placed in separate metabolism cages in which ^^C-C02 
could be trapped. Animals were allowed to have food and 
water ad libitum. Urine samples were collected over 24 h 
before dosing the animals with l^c-AFBi to serve as control 
samples.
3.2.2 Chemicals
Chemicals used in this study were of analytical or 
HPLC grade.
3*2.3 Preparation of -^C-AFBi solution for injection
l^c-AFBi for injection was prepared from a stock 
unlabelled AFBi solution (2 mg AFBi 1 ml DMSO) and stock 
l^C-AFBi (120 mCi/m mol in methanol). Stock l^C-AFBi (1 ml 
methanol containing 10 ;uCi) was blown with nitrogen gas to 
remove methanol and then redissolved in DMSO (380 /Ul). The 
injection solution was prepared by adding 130 ;ul of the 
unlabelled AFBi solution in DMSO (0.26 mg AFBi) to the 380
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;ul of l^C-AFBi in DMSO (10 pCi). The actual specific 
activity of injection solution was determined
directly using radioactive counting of the AFBi peak from 
the HPLC and the AFBi quantitated from the peak area of the 
UV absorption. It was found that the specific activity of 
l^C-AFBi injection solution was 115.4 dpm/ng AFBi.
3.2.4 Dosing of the marmoset monkeys
Animals were injected with ^-^C-AFBi intraperi- 
toneally. The male marmoset was injected with 200 /Ul DMSO 
solution containing 204 ;ug l^c-AFB^ (2.3 x 10^ dpm) while 
in the case of the female, the injection volume was 250 /Ul 
containing 255 yug l^C-AFBi (2.9 x 10^ dpm). So the dose of 
l^C-AFBi received by male and female was 0.67 and 0.73 mg 
AFBi/kg respectively. Two urine samples were then
collected over the following 2 days; the first samples over 
the period 0-24 h (24 h sample), and the second over the 
period 24-48 h (48 h sample). Animals were sacrificed 48 h 
after dosing. Urine volumes were measured and the samples 
were divided into aliquots (1 ml) and stored at -70°C until 
used. Creatinine concentration was analysed as described 
in Section 2.2.3.7.
3.3 EXPERIMENTAL PROTOCOLS
3.3.1 An examination of l^C-AFBi metabolites excreted in 
marmoset urine samples
Aliquots (20 ;ul) of 24 and 48 h urine samples from
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both male and female marmosets were injected into the HPLC 
in duplicate. The fractions (1 min) from the HPLC were 
collected and radioactivity in each fraction was counted.
3.3.2 Preliminary analysis of aflatoxins in marmoset 
urine samples
The urine samples from both male and female marmosets 
collected as 24 and 48 h samples after dosing with ^C-AFBi 
were analysed without any 'clean-up' procedures for the 
presence of aflatoxins both by radioactive monitoring and 
by competitive ELISA (see Section 2.2.3.1). Aliquots (50 
>ul) of each sample was counted for radioactivity and the 
estimated alfatoxin concentration was calculated from 
specific activity. In addition, the control urine samples 
(i.e. before dosing with l^C-AFB^) were included in the 
study to determine the apparent AFB^ content obtained in 
the ELISA. These samples had to be diluted in order to be 
in the inhibition range required for evaluation by the 
competitive ELISA curve. The aflatoxin concentrations are 
expressed as ng AFB^ equivalent because AFB^ was used in 
the construction of the standard curve.
3.3.3 Validation of the methods used in the 'clean—up1 
procedures of urine samples for aflatoxin 
analysis
3.3.3.1 Sep-Pak Ci a cartridge and immunoaffinity column
Urine samples (1 ml) from 24 and 48 h of both male and 
female marmosets were loaded onto Sep-Pak C±q cartridges,
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washed with water (3 ml) and eluted with 100% methanol (5 
ml). Aliquots (500 /Ul) from each fraction were counted for 
radioactivity and the distribution of radioactivity between 
the fractions was calculated.
For 24 h urine sample, aliquots (1 ml) of the washing 
fractions and samples (50 ;ul) of the methanol fractions 
from the cartridges, diluted with PBS to 5 ml, were loaded 
on the affinity columns (1 ml bed volume). The columns 
were washed with PBS (15 ml) and the retained materials
eluted with 85% methanol in PBS (15 ml). All samples from
each fraction were evaporated down to 1 ml before counting 
for radioactivity. The distribution of radioactivity in 
each fraction was calculated.
For 48 h urine samples, aliquots (2.5 ml) of the
washing fractions and samples (1 ml) of the methanol 
fractions from the Sep-Pak cartridges, diluted with PBS to 
5 ml, were loaded on the affinity columns. The columns 
were washed and eluted in the same way as 24 h urine
samples. Samples were evaporated to 1 ml before counting 
for radioactivity.
3.3.3.2 Radiolabelled metabolites of l^C-AFBi present in 
fractions obtained from the affinity column using 
24 h male marmoset urine sample
Male marmoset 24 h urine samples (1 ml) were loaded 
onto Sep-Pak C^g cartridges, washed with water (3 ml) and 
the retained materials were eluted with methanol (5 ml). 
In view of the high concentration of aflatoxin metabolites 
present in these methanol samples, as seen from their
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radioactive content, it was not necessary to evaporate and 
reconstitute them in PBS. Instead, an aliquot (500 ;ul) of 
the methanol eluate was diluted with PBS (45 ml) which 
ensured that the affinity column was not overloaded with 
either methanol or aflatoxins. The radioactivity present 
in the fractions obtained from the affinity column was 
checked to ensure that there were sufficient counts 
available for the subsequent HPLC assay. It was found to 
be necessary to pool the fractions obtained from 8 
individual loadings onto 8 affinity columns, using aliquots 
(5 ml) of the diluted methanol eluate from the Sep-Pak 
cartridge, to achieve the level of radioactivity required 
for the HPLC. The unretained and the washing fractions 
were bulked, giving a total volume of 160 ml, while the 
total volume of methanol eluate was 120 ml. Because of 
their large volumes and low aflatoxin concentrations, the 
washing fraction was freeze dried and redissolved in water 
(10 ml). The excess salt from PBS was removed by passing 
the sample onto a Sep-Pak cartridge and the methanol eluate 
was collected. The volume of this sample (5 ml) was 
reduced to 100 ;ul using a Speedvac Concentrator at 40°C 
before aliquots (20 >ul) were injected into the HPLC.
For the methanol fraction from the affinity column, 
the sample was evaporated to dryness using a rotary 
evaporator at room temperature and then redissolved in 
water (10 ml). The sample was passed through a Sep-Pak 
cartridge and the methanol eluate (5 ml) was collected and 
the volume was reduced to 100 ;ul before injecting aliquots
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(20 pi) into the HPLC. Fractions (1 min/l.2 ml) from both 
the affinity column samples were collected from the HPLC 
and were counted for their radioactivity.
3.3.3.3 Attempt to remove interfering substances from 
control marmoset urine samples
Control marmoset urine samples (1 ml) from both male 
and female were subjected to the 'clean-up' procedures 
developed for using with human urine samples. The protocol 
was exactly the same as that described in Section 2.3.5.1 
using human samples. The apparent AFBi concentrations in 
both the washing and methanol eluate fractions from the 
affinity column were analysed in triplicate by ELISA using 
6 wells per assay (see Section 2.2.3.1).
3.3.3.4 Extraction of 24 h marmoset urine samples and 
analysis of aflatoxin levels by ELISA
Aliquots (600 pi) of 24 h urine samples from both male 
and female marmosets were made up to 2 ml with 0.2 M sodium 
acetate (pH 5.0) before being extracted with 2 volumes of 
chloroform. The samples were shaken vigorously for a 
couple of minutes before centrifugation at 1000 x g for 10 
min at 4°C to separate chloroform and aqueous phases. The 
aqueous fractions were freeze dried, while the chloroform 
fractions were evaporated to dryness using a rotary 
evaporator. The samples were then redissolved in 50% 
methanol/water (100 pi), and aliquots (20 pi) were injected 
into the HPLC. Fractions (1 min/l.2 ml) were collected, 
and samples (600 pi) were taken to count for radioactivity
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while the remaining samples (600 ,ul) were evaporated to 
dryness, using a Speedvac Concentrator, before 
reconstitution in PBS (1 ml). Fractions 2 to 13 from the 
HPLC were analysed for AFB^ equivalent concentrations using 
the ELISA.
3.3.4 Analysis of aflatoxin levels in marmoset urine 
samples using the 'clean-up' procedures
Urine samples (200 ;ul) from 24 and 48 h of both male
and female marmosets treated with 14c _.AF]3^  were loaded onto
Sep-Pak C^q cartridges, washed with water (3 ml), and the
retained materials eluted with 100% methanol (5 ml).
Aliquots of 150 and 500 /Ul were taken from the methanol
eluates of 24 and 48 h urine samples respectively and
diluted to 5 ml with PBS before loading onto the
immunoaffinity columns. The general procedures for
affinity column were followed (see Section 2.2.3.3).
Methanol eluate fractions from the columns were collected,
and 8 out of 15 ml of these samples were evaporated to 0.5
ml. For 24 h urine samples, they were further diluted 5
times with PBS while 48 h samples were used directly in the
ELISA (see Section 2.2.3.1). AFB^ equivalent levels were
analysed with six and three replicates for 24 and 48 h
urine samples respectively using 6 wells per assay.
3.4 RESULTS AND DISCUSSION
3.4.1 Urine volumes and creatinine concentrations
Urine samples from male and female marmosets were
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collected for 24 h before and for 2 days after dosing with 
l^C-AFB'i. The volumes of male urine were 10 and 9 ml for 
the test 24 and 48 h samples respectively while those of 
the female were 33 and 26 ml (Table 3.1). Creatinine 
concentrations are also given in the Table 3.1.
The volume of urine samples from the male were less 
than those of the female even though the animals were 
allowed free access to water. Creatinine concentrations in 
male urine samples were higher than those of female. These 
may reflect the volume of urine excreted. This difference 
in urine volumes is one factor that has to be considered 
when calculating total excretion of aflatoxins in urine, 
particularly in those cases where the total urine volume is 
not known. Some correction for differences in total volume 
of urine excreted can be applied by expressing the 
concentration of aflatoxins in relation to the creatinine 
concentration, which acts as an internal reference in 
urine; i.e. the concentration of aflatoxins can be 
expressed as ng aflatoxin/mg creatinine. Since the purpose 
of this study was to use the marmoset urine samples, which 
contained a variety of aflatoxin metabolites, to validate 
the methods developed to monitor aflatoxin exposure in 
humans, most of the data in this chapter were still 
expressed as ng AFB^ equivalent/ml.
3.4.2. Pattern of 14c-AFBi metabolites excreted in 
marmoset urine samples
When the distribution of radiolabelled aflatoxin 
metabolites in 24 h urine samples from both male and female
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Table 3.1
Marmoset urine volumes and creatinine concentrations 
after dosing with ^C~AFB^
Urine sample MALE FEMALE
volume creatinine volume creatinine
(ml) (mg/ml) (ml) (mg/ml)
control NM* 0.44 NM* 0.18
24 h 10 0.90 33 0.52
48 h 9 1.28 26 0.63
* not measured
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marmosets was compared (Figure 3.1A), the pattern of 
distribution was similar in that there were major peaks in 
fraction 9 of the HPLC in both male and female. However, 
in the male sample there was an additional minor peak in 
fraction 5. In the 48 h urine samples, there were at least 
3 major peaks which were in fractions 6, 9 and 11 (Figure
3.IB).
The results also indicate that there was no 
s i g n i f i c a n t  d i f f erence in the p a t t e r n  of m e t a b o l i t e s  
e xcreted in both sexes at the same time point. However, 
the major feature was the d i f f e rences in the pa t t e r n s  of 
r a d i o a c t i v i t y  b e t w e e n  the 24 and 48 h samples for b o t h  
the male and female. T h ese results are not c o n c l u s i v e  
be c a u s e  only one male and one female m a r m osets w e r e  used, 
b u t  in order to valid a t e  the m e t hods used in m o n i t o r i n g  
exposure to aflatoxins, these two animals w o u l d  be 
su f f icient to serve the purpose. The ide n t i f i c a t i o n  of all 
the m e t a b o l i t e s  e x c reted in the urine samples was b e y o n d  
the scope of this thesis.
The p r o m i n e n t  feature of the 24 h  urine sample was the 
m a j o r  r adioactive peak in fraction 9, which, al t h o u g h  still 
p r e s e n t  in the 48 h  sample, was m u c h  reduced. The 
ret e n t i o n  time of this p eak is c o n s i s t e n t  w ith AFM^ and 
this is consistent w i t h  p u b l i s h e d  data for urine e x c r e t i o n  
of AFMi shortly after exposure of h u m a n  to AFB^ (Campbell 
et a l . , 1970? Hu et a l . , 1983; Hu  et a l . , 1984? Zhu et a l . , 
1987). This again supports the va l i d i t y  of using m a r m o s e t  
as a model for h u m a n  exposure to aflatoxins.
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Figure 3.1 The distribution of radiolabelled aflatoxin 
metabolites in HPLC fractions of male and 
female marmoset urine samples
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3.4.3 Aflatoxin levels in marmoset, urine samples 
analysed without any 'clean-up' procedures
From the preliminary study using presumed uncontamin­
ated human urine samples, these samples could not be used 
directly in the competitive ELISA (see Section 2.4.4). 
Similar results were observed using undiluted marmoset 
urine samples obtained prior to dosing with l^C-AFBi. 
Different dilutions of the samples were tried. It was 
found that for these uncontaminated (control) urine 
samples, the appropriate dilution for ELISA with 
approximately 50% inhibition was 1:25. The apparent AFBx 
in both male and female urine samples were less than 1 
ng/ml.
For the 24 and 48 h urine samples, the appropriate 
dilutions for the ELISA were 1:5000 and 1:2000 
respectively. This was equivalent to an AFBx concentration 
for male and female 24 h urine samples of 420 and 675 ng 
AFB^/ml while those of 48 h samples were 64 and 49 ng 
AFBx/ml (Table 3.2).
By radioactive monitoring, the counts in 50 /il of male 
and female 24 h samples were 6483 and 7991 dpm 
respectively. Using the specific activity of 115.4 dpm/ng, 
these counts corresponded to aflatoxin concentrations of 
1127 and 1384 ng AFBx/ml respectively, or total aflatoxin 
contents of 11.26 and 47.7 5 /ig. For the 48 h samples, the 
counts in 50 /Ul for male and female were 774 and 443 dpm 
which corresponded to concentrations of 129 and 77 ng
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Table 3.2
A comparison on the concentrations of aflatoxins 
excreted in marmoset 24 and 48h urine samples 
assayed by radioactivity and ELISA
AFB]_ equivalent (ng/ml) 
MALE FEMALE
24 h 48 h 24 h 48 h
ELISA 420 64 675 49
Estimated by 
radioactivity
1127 129 1384 77
ELISA as % of amount 
estimated by 
radioactivity
37.3 49.6 48.7 63.6
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AFBi/ml or total excretions of 1.16 and 1.99 /ug 
respectively (Table 3.2).
The results given by both radiactive counting and 
ELISA indicate that most of the aflatoxin excretion by 
marmoset monkeys treated with l^c-AFB^ takes place in the 
first 24 h after dosing. About 50% of the estimated 
aflatoxins excreted, calculated from radiaoctivity, was 
detected by ELISA (Table 3.2). This discrepancy may be due 
to the fact that a major aflatoxin metabolite in marmosets 
is AFQi (G.E. Neal, D.J. Judah and E.J. Moss, personal 
communication). The antibody used in the ELISA can
recognize AFQi 52.2 times less sensitivity than AFBi (see 
Table 2.1), hence, at the same percentage of inhibition
from competitive ELISA, AFQi give a lower reading when
expressed as AFBi equivalent units. With the additional 
fact that AFQi may excreted in conjugated forms, the
recognition by the antibody will be even lower than AFQi 
itself. With these points in mind, 50% of the estimated 
AFBi from radioactivity detectable by ELISA is in the 
acceptable range.
When the creatinine concentration was taken into 
consideration, the ng AFBi equivalent(from ELISA)/mg 
creatinine for male and female, 24 and 48 h urine samples 
were 468, 1288, 50 and 127 respectively. The female
excreted approximately 2.6 times more aflatoxins than the 
male. When the percentages of the doses of aflatoxin 
excreted in urine samples were calculated from radioactive 
assay,the percentages of aflatoxin excretion in the 24 h
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samples of the male and female were 5.52 and 17.94% 
respectively, while those obtained in the 48 h samples were 
0.57 and 0.78%. The differences in the levels of 
aflatoxins in urine samples may be due to a sex-related 
difference in metabolism. The different sexes may excrete 
different metabolites which are detected with differing 
sensitivities by the antibody. The metabolite profile in 
both sexes may not be the same. This topic will be dealt 
with in more detail in Section 3.4.4.4.
3.4.4. Validation of the methods used in the 'clean-up'
procedures of urine samples for aflatoxin analysis
3.4.4.1 Capacities of the Sep-Pak Cia cartridge and 
immunoaffinity column
When samples (1 ml) of 24 and 48 h urines of both male 
and female marmosets were loaded onto Sep-Pak cartridges, 
more than 95% of the radiolabelled metabolites were 
retained on the cartridges and subsequently eluted with 
100% methanol (Table 3.3).
When the washing fractions from the Sep-Pak cartridges 
were loaded onto the affinity columns, most of the radio­
activity failed to bind. Less than 8% of the radiolabel 
was found in the methanol eluates from the columns. On the 
other hand, when the methanol eluates from the Sep-Pak 
cartridge were loaded onto the affinity columns, more than 
50% of the radiolabel was bound onto the columns and 
subsequently eluted with 85% methanol (Table 3.4). The 
remainder of the radioactivity was evenly distributed
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Table 3.3
The distribution of radioactivity in fractions from Sep-Pak C^g 
cartridge after loading with 24 and 48 h marmoset urine samples
Fraction
MALE
radio­
activity
(dpm)
% total 
radio­
activity*
FEMALE
radio­
activity
(dpm)
% total 
radio­
activity*
24 h urine
unretained 1576 1.2 408 0.3
washing 2144 1.7 3328 2.9
methanol 124,920 97.1 111,760 96.8
48 h urine
unretained 48 0.4 130 1.4
washing 288 2.1 320 3.5
methanol 13,360 97.5 8,680 95.1
* Expressed as the percentage of radioactivity in each fraction when 
compared with the total counts present in all fractions
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Table 3.4
The distribution of radioactivity in affinity column analyses 
obtained by fractionation of samples after treatment of 24 and 
48 h marmoset urine by Sep-Pak cartridge3
Affinity column 
fraction
MALE
washing*5 
dpm %
methanol^ 
dpm %
FEMALE 
washing*5 methanol*5 
dpm % dpm %
24 h urine
unretained 130 20.0 293 23.4 252 17.9 243 20.0
washing 495 76.3 251 20.0 1076 76.5 243 20.0
methanol 24 3.7 708 56.6 78 5.6 929 60.0
48 h urine
unretained 107 48.9 164 25.3 70 34.7 158 28.6
washing 95 43.4 146 22.6 125 61.9 113 20.5
methanol 17 7.7 337 52.1 7 3.4 281 50.9
washing ---» affinity
<
 column
methanol --> affinity
column
b Fractions from Sep-Pak Cjg cartridge
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between the unretained and the washing fractions of the 
affinity columns.
From these experiments, the 'clean-up' procedures 
using Sep-Pak Ciq cartridges did not lead to significant 
loss of radiolabelled aflatoxin metabolites from the urine 
samples because more than 95% of the label was recovered 
from the cartridges in the methanol eluates. It is 
interesting to note that the reverse phase Sep-Pak G^g 
cartridge could retain not only the non-polar aflatoxin 
metabolites but also the polar metabolites of AFBi which 
result from secondary metabolism. To further verify that 
the washing fractions from the Sep-Pak cartridges did not 
contain any significant amount of aflatoxin polar 
metabolites, these fractions were loaded onto the affinity 
columns. More than 92% of the label present in these 
fractions (which comprised 5% of the original 
radioactivity) was not recognized by the antibody. 
Therefore, the washing fractions from the Sep-Pak
cartridge could be discarded and only the methanol eluates 
used for further analyses.
When the methanol eluate fractions from the Sep-Pak 
cartridges were subjected to the affinity columns, 50-60% 
of the radiolabelled metabolites was retained and 
subsequently eluted from the columns using 85% methanol. 
The rest of the radioactivity was in the unretained and the 
washing fractions of the affinity columns. The nature of 
the radioactive compounds present in these unretained and 
washing fractions was further examined by the HPLC.
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In the experiments using 24 and 48 h urine samples 
from marmosets treated with l^C-AFBi# the average 
recoveries of the radioactivity in the methanol eluate 
fractions of the Sep-Pak cartridges and the affinity 
columns were 96.6 and 54.9% respectively. Therefore, the 
overall recovery of the whole 'clean-up' procedure using 
marmoset urine containing a variety of aflatoxin 
metabolites was 53% which compared favourably with the 71% 
obtained from spiked in presumed uncontaminated
human urine samples (see Section 2.4.6.5).
Using this information, one should be aware that by 
analysing aflatoxins in urine samples using ELISA technique 
with the pretreatment of the samples with Sep-Pak Ciq 
cartridge and immunoaffinity column, only 50% of the actual 
value would be observed. Therefore, the levels obtained in 
terms of AFBi equivalent in the samples would be under­
estimated.
3.4.4.2 The HPLC distribution of aflatoxin metabolites 
from the affinity column fractions
The distribution of radioactivity in the fractions 
obtained by HPLC of the washing and the methanol eluate 
fractions from the affinity column are shown in Figure 3.2. 
The radiolabelled metabolites in the washing fractions 
were more polar than those in the methanol eluates from the 
affinity column. However, the major peak present in the 
methanol eluate corresponded with the major peak of 
radioactivity obtained when the urine sample was directly
130
Fi
gu
re
 
3.
2 
Th
e 
HP
LC
 
di
st
ri
bu
ti
on
 
of
 
ra
di
ol
ab
el
le
d 
af
la
to
xi
n 
me
ta
bo
li
te
s 
ob
ta
in
ed
 
by 
ch
ro
ma
to
gr
ap
hi
ng
 
th
e 
af
fi
ni
ty
 
co
lu
mn
 
fr
ac
ti
on
s
CD
c
</>
n: o
ro Q)
I I
/i//
oo
vO
_ LO
- CM
■'
/
■
■ •
o oi—i c
- o
- oo
- r~-
- vO 
in
- CO
-  CM
c
o
o
CO
CD
CO
o
CM
nr
CD
”1
O
* A}!A|peo!peJ %
>1
■P
•H
>
• H
+ j
u
fd
0
-rH
b
fd CO
P C
0
•H
fd ■P
-P O
0 fd
-P p
m
<D
t: h
-p 0c
fd
0  b
Pc cu
0 S
•rH■p po 0
fd
p tnC
• H
^ £
u CO
fd fda)
C 0)
•H  £
(0 •p
0
• tnp
fd 0
•P A
c ■p
Q) •rH
O Q)
P
0) e
f t  0
p
(1) M-l
P
fd b
0
(0 p
■P 0
rH >
3 0
CO 0
0 0
PS p
•K
131
injected into the HPLC (Figure 3.1A). The probable 
identity of this metabolite as AFM^ has already been 
referred to (see Section 3.4.2). The results also implied 
that the antibody used in the immunoaffinity column failed 
to recognize or recognized the polar metabolites with only 
low affinity. Since the radioactive compound used in these 
experiments was 14c-AFB]_, in place of ^h -a f b  ^ as used in 
the earlier experiments (see Chapter 2), there would not be 
any isotope exchange and the radioactivity in the polar 
region of the washing fraction from the affinity column 
should, therefore, be associated with actual aflatoxin 
metabolites. However, it is possible that 14c from the 
aflatoxins could be reincorporated into non-aflatoxin 
metabolites, e.g. O-demethylation of AFBi leads to the 
formation of the phenol AFPi. It is not known in what form 
the methyl group is released but the label associated with 
14qH3 is believed to be largely expired as 14cc>2. However, 
it is possible that some of this one carbon unit is 
reincorporated and is accounted for by some of the 
radiolabel not recognized by the affinity column used in 
this study. But, despite all of the possible
complications, the recovery of the radiolabelled materials 
after loading on the immunoaffinity column was 50% as shown 
in Table 3.4, which is an acceptable level for the 
monitoring assays proposed.
3.4.4.3 Apparent AFBi concentrations in control marmoset 
urine samples
The ELISA determinations (Table 3.5) showed .that in 
both male and female marmoset urine samples, the apparent
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Table 3.5
Apparent AFBj concentrations obtained by ELISA in control marmoset 
urine samples following fractionation on affinity columns
Assay No.
washing
Apparent AFBi
MALE
methanol
(ng/ml)
FEMALE
washing methanol
1 6.4 0.36 9.0 0.78
2 8.0 0.39 9.6 0.78
3 6. 6 0.56 5.4 0.82
mean 7.0 0.44 8.0 0.77
S.D. 0.9 0.11 2.3 0.02
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AFBi concentrations were higher in the washing fractions 
than in the methanol fractions from the affinity column. 
The average level in the washing fractions was 7-8 ng/ml, 
while in the methanol fractions, it was less than 0.8 
ng/ml. Since the samples being used were the control 
samples (from untreated animals),it was assumed that the 
apparent AFBi level was due to either the background level 
of the system or interfering substances present in the 
urine samples. These results, using control marmoset urine 
samples, were in agreement with those of uncontaminated 
human urine samples (Table 2.15) in which the interfering 
substances or UALS were in the washing fractions obtained 
from the affinity columns. Therefore, based on the results 
of these two systems, it is apparent that the methanol 
eluate fraction from the affinity column represents the 
appropriate fraction for subsequent analysis using ELISA. 
Although the unretained and washing fractions from the 
affinity column contain the same level of radiolabelled 
metabolites (approximately 50%) as that present in the 
methanol eluate, the presence of the inhibitory substances 
in the unretained and washing fractions means that 
analysing these fractions by ELISA, for samples of unknown 
contamination with aflatoxins, would be difficult to 
interpret.
3.4.4.4 A comparison of the estimations by ELISA and 
radioactivity of the aflatoxin present in marmoset 
urine samples extracted by chloroform
In order to further clarify the capacity of the 
antibody to detect aflatoxin metabolites, 24 h urine
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samples from both male and female marmosets were e x t racted 
w it h  c h l o r o f o r m  to separate p o l a r  and non-polar m e t a b o l i t e s  
of aflatoxin. The p a t terns of meta b o l i t e s  de t e c t e d  were 
compared using both radi o a c t i v e  counting and E L I S A  
techniques.
F r o m  r adioactive counting, the counts in the 
c h l o r o f o r m  and aqueous phases of male urine sample were 
1304 and 1900 dpm respectively, w h i l e  those of female wer e  
929 and 3173 dpm. Mos t  of the r a d i o a c t i v i t y  was in the 
aqueous phase, and the ratio of radio a c t i v i t y  in 
c h l o r o f o r m : a q u e o u s  phase in male and female were 1:1.5 and 
1:3.4 respectively. It is suggested from these
experiments, and the results shown in Section 3.4.3, that 
the p a t t e r n  of m e t a bolites in m a r m o s e t  urine samples 24 h 
after d o sing wit h  l^c-AFBj. was d i f f e r e n t  in the m a l e  and 
female ma r m o s e t  monkeys. The female animal excreted mor e  
afl a t o x i n  m e t a b o l i t e s  in the urine and a high e r  a m o u n t  of 
p o l a r  m e t a b o l i t e s  w h e n  compared to the male sample. But 
these results were not conclusive since they come from only 
one animal of each sex. However, fro m  Figu r e  3. 1A, the 
pa t t e r n s  of ra d i o l a b e l l e d  m e t a b o l i t e s  ob t a i n e d  w h e n  urine 
samples from bot h  sexes w ere injected into the HPLC wer e  
similar. In these HPL C  analyses of total urine samples 
the g r e a t e r  e x c r etion of p o lar m e t a b o l i t e s  by the female 
m a r m o s e t  was not apparent (Figure 3.1A). However, w h e n  the 
c h l o r o f o r m  and aqueous fractions of these urine samples 
w e r e  subjected to H P L C  individually, the greater content of 
p o l a r  aflatoxin meta b o l i t e s  in the female urine sample was
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clear (see also Figure 3.3A). Therefore, in order to have 
more conclusive evidence regarding metabolism of aflatoxins 
in different sexes of marmoset monkey, more animals would 
be needed. However, this was outside the scope of this 
study.
The distribution of radiolabelled metabolites in the 
fractions from HPLC (Figure 3.3) showed that in chloroform 
phases of both the male and female samples, there was one 
major peak in fraction 9 and a minor peak in fraction 11. 
In the aqueous phases, the major peaks were in fractions 2 
and 7 but radioactivity was also distributed in fractions 5 
to 11 without evidence of individual peaks. The pattern of 
distribution in both sexes was similar.
In parallel with the aflatoxin estimation of the HPLC 
fractions by radioactivity, aliquots of fractions 2-13 were 
also analysed by ELISA. The results given in Figure 3.4 
showed that the total aflatoxin metabolites (expressed as 
AFBi equivalent/fraction) in the chloroform phases of urine 
samples from both sexes were appreciably greater than the 
values obtained in the aqueous phases. This result 
contrasted with the result from the radioactive counting 
from the HPLC. It was evident from the ELISA analysis of 
the HPLC fractions that good correlation between the ELISA 
and radioactive counting existed for the chloroform phase. 
This would be consistent with this fraction containing 
primary metabolites of aflatoxin, in which the epitope 
would have undergone the least modification compared with 
secondary conjugated metabolites. The peak observed in
136
Figure 3.3 The distribution of radiolabelled aflatoxin 
metabolites in chloroform and aqueous phases 
of male and female marmoset urine samples 
fractionated by HPLC
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Figure 3.4 The levels of AFB^ equivalent by ELISA in the
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fraction 9 for both ELISA and radioactivity is consistent 
with this fraction being largely comprised of AFM^# which 
was recognized as sensitively as AFB^ (see Table 2.1). 
However, in the case of the aqueous phase metabolites, it 
is evident that the ELISA did not recognize these as 
sensitively as the radioactivity and, furthermore, for the 
most polar metabolites in fractions 1-4, the ELISA failed 
to detect the presence of any aflatoxin metabolites. These 
HPLC experiments were carried out using total urine samples 
and, therefore, if similar phenomena applied to the 
prepurification by immunoaffinity columns, it is likely 
that these polar metabolites would be lost during the 
'clean-up' procedures. This is proved to be the case as 
demonstrated in Figure 3.2, where the polar metabolites are 
removed in the washing fraction of the affinity column, and 
only the more non-polar metabolites are retained and 
subsequently eluted with methanol.
3.4.5 Aflatoxin levels in marmoset urine samples after 
the 'clean-up* procedures
From the results of the previous experiments, it was 
concluded that the amounts of AFB^ loaded onto the affinity 
column should not exceed 20 ng in 1 ml PBS or 5 ng in 1 ml 
urine samples (see Section 2.4.6.4). In order not to 
overload the column, 200 /ul aliquots of the original 
marmoset urine samples were used. This level of loading 
was based on the results of the radioactivity assays shown 
in Table 3.2, and the dilution being calculated to result
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in appropriate final amounts of aflatoxin loaded onto the 
column.
The results of aflatoxin levels in marmoset urine 
samples (Table 3.6) were expressed as ng AFBi equivalent/ml 
sample. The concentrations of AFB^ equivalents in the 
original samples were calculated from the volumes being 
used in each step. The concentrations in the male 24 and 
48 h urine samples were 281.7 and 40.5 ng/ml, while those 
of the female were 343.4 and 35.5 ng/ml respectively (Table 
3.6).
The data indicate that the majority of aflatoxfh^ in 
the urine samples were excreted in the first 24 h after 
dosing. When these results were compared with those 
obtained without any 'clean-up' procedures (Table 3.2)/ 
the values obtained using ELISA with the 'clean-up' 
procedures were approximately 36% lower. The explanation 
for these differences in AFB^ equivalents may be due to the 
fact that when the urine samples were analysed directly in 
ELISA, interfering substances (UALS) would react with the 
antibody giving a high level of AFB^ equivalents. 
Furthermore from the previous results (Section 3.4.4.1), 
the overall recovery from the 'clean-up' procedures assayed 
by radioactivity was 53%. In view of these complicating 
factors, the results obtained were considered to be in the 
acceptable range.
3.5 SUMMARY
The results obtained in this chapter indicate that for
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the system developed, it is possible to detect aflatoxin 
metabolites in marmoset urine samples. In the 'clean-up' 
procedure the Sep-Pak Cqg cartridge retained most of the 
metabolites excreted in the urine samples with more than 
96% recovery of radioactivity. The reverse phase Sep-Pak 
g cartridge could retain not only the non-polar but also 
the polar metabolites of AFB^. The capacity of the Sep-Pak 
cartridge in this study was not significantly different 
from that used with urine samples. The
immunoaffinity column retained 50-60% of the radioabelled 
metabolites which subsequently could be eluted with 
methanol. The overall recovery of the 'clean-up'
procedures was 53% compared to 71% when ^h -a fBi was being 
used in uncontaminated human urine samples. The lower 
percentage recovery is in part, at least, due to the fact 
that the sensitivity of the antibody used for some 
metabolites and their conjugates is low, especially with 
AFQi and its conjugate which are the most likely major 
metabolites excreted in marmoset urine samples. The 
antibody also has low sensitivity in recognizing all the 
polar metabolites in chloroform-insoluble fractions. 
However, if all these points are borne in mind, it is 
possible to conclude that the levels of aflatoxins obtained 
in the samples in term of AFB^ equivalents using ELISA with 
these 'clean-up' procedures will be underestimated.
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CHAPTER 4
Urinary Excretion of Aflatoxins in Hamsters 
Infected with Liver Fluke, 
Opisthorchis viverrini
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4.1 INTRODUCTION
Differences in liver cancer incidence have been 
reported in different parts of the world (Parkin et al. , 
1984). This is believed to be due to the presence or 
absence of environmental factors responsible for liver 
carcinogenesis. In Thailand, liver cancer is the most 
common fatal neoplasm and is ranked third as a cause of 
death (Srivatanakul et al. , 1988). Liver cancer was the
cancer with the highest incidence recorded by the Cancer 
Registry in 1980-1982 for males and third for females, 
after cervical and breast cancers. According to histo­
logical diagnoses, hepatocellular carcinoma was found more 
frequently than cholangiocarcinoma in both males and 
females. The geographical variations in the incidence of 
hepatocellular carcinoma in Thailand are rather small, in 
contrast to the frequency of cholangiocarcinoma which may 
vary as much as 14-fold between regions (Srivatanakul est 
al . , 1988). The areas with high incidence of the latter
cancer are also found to be heavily infested by the liver 
fluke, Opisthorchis viverrini.
Opisthorchiasis, a disease caused by the liver fluke, 
Opisthorchis viverrini, is endemic particular in Northeast 
Thailand (Viranuvatti and Stitnimankarn, 1972; Upatham et 
al. , 1982). In 1980-1982, the prevalence in the North,
Northeast, Centre and South of Thailand was 5.59, 34.60,
6.34 and 0.01% respectively (Harinasuta and Harinasuta, 
1984). The clinical manifestations of the infection range
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from asymptomatic to severe malnourishment, cirrhosis of 
the liver and neoplastic changes of the biliary system of 
the liver (Harinasuta et al./ 1984; Upatham et al., 1984). 
The disease is considered to be a major public health 
problem in Thailand, since about 7 million Thai people are 
suffering from this disease according to a survey carried 
out a few years ago (Preuksaraj, 1984). In some endemic 
areas, prevalence reaches at least 90% of the population, 
and the disease produces clinical symptoms which can be 
correlated with infection intensity (Upatham et' al., 1985).
Development of a complete life cycle of liver fluke 
requires two intermediate hosts. The first intermediate 
hosts are snails (Bithynia tentaculata, B. goniomphalus,
B . funiculata and B . siamensis). The second intermediate 
hosts are freshwater fish that contain encysted 
metacercariae in their gills, flesh and skin. A wide 
variety of fish, e.g. Puritus orphoides, Hampala dispar and 
Cycloheilichthys siaja may be infected (Vichasri et al., 
1982). The adult fluke is a common parasite of the dog, 
cat, fox and pig. Man is an accidental host (Harinasuta 
and Harinasuta, 1984; Sornmani, 1987). The parasites live 
in the distal biliary passage of the definitive hosts 
without invading the liver parenchyma, and occasionally in 
the pancreatic ducts and gall bladder. The worm contains 
both testis and ovary, so self-fertilization is the common 
means of reproduction. The ova are carried down the common 
bile duct and pass through the bowel (Viranuvatti and 
Stitnimankarn, 1972).
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The life cycle of the fluke starts from eggs passing 
out in faeces (Figure 4.1). On reaching the water the eggs 
are eaten hy snails, the first intermediate host. In the 
snail, the miracidia hatch and develop further to the 
stages of sporocysts, rediae and cercariae in six to eight 
weeks. The cercariae then leave the snail, and when the 
mature cercariae come into contact with a suitable species 
of fish, especially cyprinoid fish, they attach themselves 
to the fish scales, lose their tails, penetrate the tissue 
of the fish and encyst. Encysted cercariae mature in about 
six weeks after ingestion by the natural host or the 
accidental host which is man. Excystation takes place in 
the duodenum by the action of gastric and duodenal juices. 
The free metacercariae pass through the ampulla of Vater to 
the bile ducts, pancreatic ducts, gall bladder or bile duct 
tributaries and attach themselves to the epithelial 
lining. They become mature within four weeks and begin to 
produce eggs. The life span of the fluke is 25 to 30 years 
(Viranuvatti and Stitnimankarn, 1972; Harinasuta and 
Harinasuta, 1984; Sornmani, 1987). The flukes usually move 
about in the biliary canals of the hosts and result in 
chronic mechanical irritation of epithelial linings and 
finally in pathological changes of the biliary system. 
Possible toxic secretion by the worms may produce 
additional changes of the canals.
Most infection in man is acquired by eating raw fish 
or inadequately cooked fish containing viable infective 
metacercariae. Eating food by using contaminated hands
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Figure 4.1 Life cycle of Opisthorchis viverrini
Adult worm in 
biliary ducts (Liver)
Dog & Cat 
as reservoir host
Metacercaria ingested 
by eating raw, ,
infected lish '
y) Egg in stool
thynia snail
Cercaria from 
snail penetrates fish
(From Sornmani, 1987)
after handling infected fish may also lead to infection. 
Infection can also occur by drinking contaminated unboiled 
or unfiltered water. The prevalence of liver fluke 
infection in the Northeast of Thailand is due to the fact 
that "Koi Pla" is the most popular raw fish there. This 
consists of raw flesh from small fish chopped with 
vegetables, garlic, lemon juice, fermented fish sauce or 
salt, chilli and roasted ground rice. It is eaten daily by 
villagers.
0. viverrini has also been implicated in the causation 
of cholangiocarcinoma (Chainuvati et al. , 1976; Sonakul et 
al., 1978; Koomprochana et a_l., 1978; Schwartz, 1980;
Kurathong et al., 1985). There were three separate studies 
of necropsy cases at the Siriraj Hospital in Bangkok 
(Bhamarapravati and Viranuvatti, 1966; Stitnimankarn, 1976; 
Koomprochana et al., 1978) which found that opisthorchiasis 
was closely associated with intrahepatic bile duct 
carcinoma. It is interesting that opisthorchiasis-related 
cancers occurred predominantly in the patients who came 
from the Northeast of Thailand. Koomprochana et al. (1978) 
also showed that patients having opisthorchiasis-related 
tumours were much younger than patients in Western 
countries having cholangiocarcinoma and suggested that 
chronic infection with the fluke might play a role in 
carcinogenesis.
It has also been postulated that opisthorchiasis 
infection in the presence of certain chemical carcinogens 
may have a synergistic effect in the induction of cholan-
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giocarcinoma as well as primary hepatocellular carcinoma 
(Flavell, 1981; Flavell and Lucas, 1982; Thamavit et al., 
1987a). Cholangiocarcinoma was found to develop in 100% of 
golden Syrian hamsters experimentally treated with 
opisthorchis metacercariae and dimethylnitrosamine 
(Thamavit et al., 1978; Bhamarapravati and Thamavit, 1978). 
Animals which received either nitrosamine or liver fluke 
alone did not develop cancer. It, thus, seems likely that 
the initial carcinogenic stimulus in cholangiocarcinoma is 
multifactorial, requiring both the presence of the fluke 
and other precipitating factors such as dietary 
carcinogens.
Flavell and Lucas (1983) proposed that 0. viverrini 
infection in the hamsters was capable of promoting 
dimethylnitrosamine-initiated bile duct carcinogenesis. 
While Thamavit et al. (1988) demonstrated the potential of 
infection with liver fluke parasites for promotion of liver 
tumour induction in both hepatocellular and cholangio- 
cellular compartments. They also proposed that liver 
injury caused by parasite and non-specific compensatory 
regeneration might play an important role in generation of 
both hepatocellular carcinoma and cholangiocarcinoma in man 
and hamster (Thamavit et al., 1987b; Thamavit et al. ,
1988).
Several epidemiological studies have suggested a close 
geographical relationship between food contaminated with 
aflatoxins and the incidence of hepatocellular carcinoma 
(Shank et al., 1972c,d; Peers and Linsell, 1973; Shank,
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1977; van Rensburg, 1985). These areas include the 
Northeast of Thailand where opisthorchiasis is endemic. 
AFBi is the most potent liver carcinogen known for the rat 
(Wogan and Newberne, 1967) and is toxic for a wide range of 
species (Newberne and Butler, 1969). The rat is extremely 
sensitive to the carcinogenic action of AFBi whereas the 
hamster is relatively resistant. The pattern of AFB^ 
metabolism in vitro of monkey, hamster and man is similar 
but totally different from rat (Hsieh et al., 1977).
In the Northeast of Thailand, there are many factors 
that may affect the formation of liver cancer, i.e. liver 
fluke infestation, nitrosamine and aflatoxin ingestion, and 
malnutrition. These factors may act synergistically. So 
far only liver fluke infestation and nitrosamine have been 
studied (Thamavit et aJL. , 1978; Flavell and Lucas, 1982).
In order to investigate the additive effects of liver 
fluke infestation and aflatoxin administration, the hamster 
was chosen as the experimental animal model because it was 
very susceptible to infection by the parasite and massive 
data on liver fluke pathogenicity in this species were 
available (Bhamarapravati et al., 1978; Flavell et al.,
1980). The objectives of these experiments were to compare 
the pattern of urinary excretion of aflatoxin metabolites 
and the pathological effects of aflatoxin in hamsters with 
and without liver fluke infection.
150
4.2 MATERIAL AND METHODS
4.2.1 Animals
Golden Syrian hamsters, 8 weeks old, were obtained 
from the Animal Breeding Department, MRC Laboratories, 
Toxicology Unit, (Carshalton, Surrey). They were housed 
six to a cage and allowed a standard diet (from Wm. Lillico 
and Son, Wonham Mill Ltd., Betchworth, Surrey) and water ad 
libitum.
4.2.2 Chemicals
All chemicals used in these experiments were of 
analytical or HPLC grade.
4.2.3 Preparation of metacercariae and experimental
infections
Liver fluke metacercariae were received from 
Thailand. The naturally infected fish were caught in a 
water reservoir in a small village near Khon Kaen, a 
Northeast province of Thailand. They were transported in 
ice from Khon Kaen to Bangkok. Metacercariae were obtained 
by the peptic digestion method described by Flavell (1982) 
at the Department of Pharmacology, Faculty of Science, 
Mahidol University, Bangkok. The metacercariae were placed 
in normal saline and packed in an ice box (but not frozen) 
for transfer to London by air. Upon arrival, they were 
left at room temperature for half an hour before being 
infected into hamsters.
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Metacercariae were administered intragastrically via a 
dosing needle and syringe. The successful infection was 
checked by counting the eggs in the stools 6 weeks after 
the hamsters had been infected.
4.2.4 Preparation of J-^C-AFBi solution for injections
l^c-AFBi, prepared ky growing A. parasiticus in medium 
containing l ^ C - a c e t a t e ,  was used in the study of the 
effects of AFBi 10 mg/kg on hamsters with or without liver 
fluke infection. The solution was prepared by dissolving 
unlabelled AFB^ (4 mg) in DMSO (400 pi), then an aliquot 
(400 pi) of i^C-AFBi (25 pCi in 2.5 ml methanol) was added. 
The concentration of the solution was 5 mg ^C-AFBi/ml.
4.2.5 Histological studies
Liver tissues from hamsters were fixed in 10% buffered 
formalin and embedded in paraffin. Sections (5p thick) 
were stained with haematoxylin and eosin.
4 .3 EXPERIMENTAL PROTOCOLS
4.3.1 Histological examination of livers of hamsters
with or without liver fluke infection
Male golden Syrian hamsters were divided into 2 groups
of 30 animals each. One served as a control while the
other was infected with liver fluke metacercariae. They
were checked for the successful infection 6 weeks after
metacercariae had been administered. The animals were kept
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for 17 weeks before 2 animals from each group were killed. 
Livers were removed for histological examination.
.4.3.2 Study of the effects of AFBi 5 mg/kg on hamsters 
with or without liver fluke infection
Six male golden Syrian hamsters from the previous 
experiment were used 17 weeks after they had been infected 
with metacercariae. They were injected with 5 mg AFB^/kg 
intraperitoneally. AFB^ solution was prepared at a 
concentration of 5 mg/ml in DMSO. Animals were placed 
individually in metabolism cages. Urine samples were 
collected over 24 h period before and after AFB^ injection. 
The samples were stored at -40°C until used. They were 
analysed for aflatoxin levels using ELISA without any 
'clean-up' procedures. It was observed that the samples 
required dilution before using in ELISA to obtain 
inhibitions in the proportional region of the competition 
curves. Each sample was analysed with 6 replicates using 6 
wells per assay. Animals were killed 7 days after dosing. 
Livers were removed for histological study.
4.3.3 Study of the effects of AFBi 10 mg/kg on hamsters 
with or without liver fluke infection
Female golden Syrian hamsters were used in this set of 
experiments because at the time that this study was due to 
commence, only female hamsters were available and the study 
could not be postponed because the metacercariae were 
arriving shortly. The hamsters were divided into 2 groups 
of 30 animals each. One group was infected with liver
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fluke metacercariae while the other one served as control. 
They were checked for successful infection (see Section 
4.2.3) before AFBi was administered. The animals were kept 
for 15 weeks after infection. Six animals from each group 
were placed individually in metabolism cages 24 h before 
AFBi injection. The urines were collected to serve as 
untreated or control samples. In these experiments, in 
contrast to those described in the previous Section, the 
hamsters were housed in metabolism cages designed for this 
species which ensured maximum collection of urine samples. 
Four animals from each group were injected with 10 mg 
AFBi/kg intraperitoneally, while the other two were 
injected with 10 mg (see Section 4.2.4). The
animals then remained in the metabolism cages and two 24 h 
urine samples were collected. Animals were killed 48 h 
after dosing and the livers were removed for histological 
study. Urine samples were stored at -40°C until used.
4. 3 .3 .1 An examination of -*-4c—ApiS-j metabolites excreted in 
hamster urine samples
Aliquots (20 pi) of 24 h urine samples from 2 hamsters 
with or without liver fluke infection, dosed with 
(10 mg/kg), were injected into the HPLC. The eluates were 
monitored b y ,both UV and fluorescence detection. Fractions 
(1 min/1.2 ml) from the HPLC were collected and radio­
activity was counted. Untreated (control) urine samples 
(20 pi) were also injected into the HPLC and chromatograms 
were recorded.
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4.3.3.2 Aflatoxin analysis by ELISA using hamster urine 
samples fractionated by HPLC
Urine samples (20 pi) from untreated hamsters, and 
24 and 48 h after treatment with AFBi (10 m9/kg), with or 
without liver fluke infection, were injected into HPLC 
using two animals from each group. Fractions from the HPLC 
(1 min/1.2 ml) were collected.
The HPLC fractions (1.2 ml) from untreated (control) 
animals of both groups were evaporated to dryness before 
redissolving in PBS (1 ml), and aliquots (200 pi) were 
analysed for apparent AFBi by ELISA in duplicate using 6 
wells per assay.
In the case of urine samples collected 24 and 48 h
after treatment with AFBi, aliquots (200 pi) from the HPLC
fractions were evaporated to dryness and redissolved in PBS 
(1 ml). The 24 and 48 h samples were diluted 40. and 16 
times with PBS respectively, before aliquots (200 pi) were 
analysed for AFBi equivalents by ELISA in triplicate using 
6 wells per assay.
4.4 RESULTS AND DISCUSSION
4.4.1 Histological comparison of hamsters with or 
without liver fluke infection
Livers in the liver fluke infected group were granular
in appearance. The livers were enlarged and pale in
colour.
Histological findings showed that in liver fluke 
infected animals, there was very extensive biliary
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proliferation with lymphoid infiltration forming follicles. 
This disrupted the normal lobular pattern. In all livers, 
there was a pink extracellular amorphous material localized 
around the central veins and the area of biliary prolif­
eration which was stained by congo red indicating the 
presence of amyloid (Figure 4.2).
4.4.2 Effects of AFBi 5 mg/kg on hamsters with or 
without liver fluke infection
4.4.2.1 Excretion of aflatoxins in urine samples
In collecting the urine samples, it was found in this 
initial experiment that the metabolism cages used in this 
laboratory which were designed for rats were unsuitable for 
use with hamsters. In many cases, little or no urine 
sample was collected which was due, at least in part, to 
the animals being able to enter and remain in the food 
hoppers. Only 3 samples from the non-liver fluke group and 
5 samples from the liver fluke group were obtained.
The urine samples from both groups of hamsters were 
analysed for excretion of aflatoxins without any 'clean-up' 
procedures. This was because this experiment was carried 
out before the final procedures of aflatoxin monitoring 
were developed. Prior to aflatoxin analyses, different 
dilutions were tried and it was found that for control 
urines (before treating the hamsters with AFBi), the 
samples had to be diluted in the range of 20 to 75 times. 
The concentration of apparent AFBi was approximately 3-12
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Figure 4.2A
Liver from untreated control hamster showing 
normal lobular pattern. H & E stain x 120.
Figure 4.2B
Liver from hamster infected with liver fluke 
Opisthorchis viverrini for 17 weeks, showing 
bile duct proliferation and inflammatory 
infiltrate in the portal area.
H & E stain x 120.
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Figure 4. 2A
Figure 4.2B
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ng/ml except one animal in the non-liver fluke group which 
had the apparent AFBi content of 45 ng/ml (Table 4.1). 
However, there was no significant difference in the levels 
of apparent AFBi -*-n both liver fluke infected and non­
infected groups.
For the urine samples from the hamsters treated with 
AFBi at a dose of 5 mg/kg, high concentrations of aflatoxin 
excreted in the urine were expected. The appropriate 
dilutions for the ELISA lay between 1:50,000 and 
1:200,000. The results (Table 4.1) were expressed as AFBi 
equivalent concentration (pg/ml). AFBi equivalents in 
hamsters treated with AFBi were 10^ times higher than the 
apparent AFBi concentrations of the urine samples obtained 
from the same animals prior to treatment with AFBi. In t*ie 
case of one hamster in the non-liver fluke group (animal 
no. C4), which had a high excretion of inhibitory 
substances in the urine prior to dosing with AFBi, after 
dosing, showed levels of AFBi equivalents higher than other 
animals in both AFBi treated groups. However, at the 
dilutions employed, the contribution from the non-aflatoxin 
inhibitory substances present in the urine samples would 
have been negligible.
In order to examine the pathological effect of AFBi on 
hamsters infected or uninfected with liver fluke, it was 
necessary to dose the animals at a comparatively high 
level because the hamster is a species relatively resistant 
to AFBi. When these animals were also used for determining 
aflatoxin excretion in the urine, because of the high level
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of dosing and the rate of excretion of aflatoxin in the 
urine, it is necessary to dilute extensively the samples 
before using in ELISA. This lead to a high level of 
variation in the results when the ELISA were corrected for 
the extensive dilutions employed.
Since this experiment was carried out using non-radio- 
labelled AFBi, t*10 pattern of metabolites excreted in the 
urine samples of hamsters infected with liver fluke cannot 
be compared with the one obtained from non-liver fluke 
group. Moreover, a pitfall of this experiment was the 
urine volumes were not measured because of the variation in 
collection efficiency, for reasons already referred to, so 
comparisons of the total aflatoxin excreted cannot be 
made.
4.4.2.2 Histological observations
Histological findings showed that 7 days after dosing 
with AFBi • tlle liV0ts of non-liver fluke infected hamsters 
dosed with 5 mg AFBi/kg, showed biliary and oval cell 
proliferation with some residual damage to periportal 
hepatocytes (Figure 4.3A).
The livers of hamsters with liver fluke infection, 
dosed with 5 mg AFBi/kg, showed more extensive biliary 
proliferation and lymphoid infiltration (Figure 4.3B). The 
extent of the biliary proliferation and lymphoid 
infiltration was similar in all liver fluke infected 
animals whether or not treated with AFBi. These results 
indicate that the pronounced effects due to liver fluke
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Figure 4.3A
Liver from hamster treated with AFBi 5 mg/kg, 
killed on day 7 after injection, showing 
slight oval cell proliferation. Periportal 
hepatocytes show some vesiculation and 
disruption of the trabecular pattern.
H & E stain x 120.
Figure 4.3B
Liver from hamster infected with liver fluke, 
Opisthorchis viverrini for 17 weeks prior to 
injection with AFBi 5 mg/kg, killed on day 7 
after injection, showing extensive biliary 
proliferation and inflammatory infiltrate 
similar to that seen in Figure 4.2B.
H & E stain x 120.
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Figure 4.3A
Figure 4.3B
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infection are not enhanced by the additional treatment with 
5 mg AFB^/kg.
4.4.3 Effects of AFBi 10 mg/kg on hamsters with or 
without liver fluke infection
Animals no. 1 and 2 in the non-liver fluke infected 
group and no. 7 in the liver fluke group died during the 
period 24-48 h after injection with AFB^, probably due to 
AFB^ acute toxicity . Unfortunately, they were 3 of the 4 
animals treated with radioactive AFB^ and, therefore, no 
48 h radiolabelled urine samples were obtained from these 
animals. The summary of the data on doses and urine 
volumes are shown in Table 4.2.
In this experiment, metabolism cages designed for 
hamsters were used. However, the urine volumes over 24 h 
period were still low (less than 3 ml) and, therefore, it 
appears probable that this is a characteristic of hamsters, 
and that they have a high capacity for water retention.
4.4.3.1 Histological observations
Livers from non-liver fluke infected hamsters 48 h 
after dosing with 10 mg AFB^/kg showed that there was 
slight oval cell proliferation with moderate to extensive 
periportal necrosis. In one animal, the liver showed 
extensive haemorrhagic periportal necrosis (Figure 4.4A).
In the group that had been infected with liver fluke 
and dosed with 10 mg AFB^/kg, the livers showed slight oval 
cell and biliary proliferation with slight to extensive
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Figure 4.4A
Liver from hamster treated with AFB^ 10 mg/kg, 
killed on day 2 after injection, showing biliary 
and oval cell proliferation, and necrosis of 
periportal hepatocyes. H & E stain x 120.
Figure 4.4B
Liver from hamster infected with liver fluke, 
Opisthorchis viverrini, for 15 weeks prior to 
injection with AFB^ 10 mg/kg, killed on day 2 
after injection, showing slight bile duct 
proliferation and extensive necrosis of hepato- 
cytes involving the entire lobule.
H & E stain x 120.
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periportal haemorrhagic necrosis (Figure 4.4B). In two 
animals, there was extensive hydropic change in periportal 
cells and centrilobular haemorrhagic necrosis.
These results indicate that dosing hamsters in the 
non-liver fluke infected group with 10 mg AFB^/kg resulted 
in more extensive damage of the livers than that observed 
using 5 mg AFB^/kg (see Section 4.4.2.2). In addition, in 
the liver fluke infected group, treated with 10 mg AFB^/kg, 
3 out of 5 animals showed very extensive haemorrhagic 
periportal necrosis, suggesting that the toxicity of AFB^ 
is accentuated by liver fluke infection.
4.4.3.2 Pattern of l^C-AFBi metabolites excreted in 
hamster urine samples
Hamsters excreted small volumes of concentrated 
urine. At the same time, the dose of AFB^ given to the 
animals was very high (10 mg/kg), therefore, the amounts of 
aflatoxin metabolites present in the urine samples were 
high. In order to record the chromatograms from UV and 
fluorescence detectors of the HPLC, it was necessary to 
have the detectors at their lowest sensitivity settings. 
Even so, the high fluorescence peak went off scale.
When untreated urine samples (control) from hamsters 
with or without liver fluke infection were injected into 
the HPLC, the chromatograms from these samples showed no 
peaks at the detector sensitivity settings used in 
subsequent examination of the aflatoxin-containing urine 
samples. When 24 h urine samples from both groups treated
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with l^C-AFBi were used, the chromatograms (Figure 4.5) 
showed that there was a variety of highly fluorescent 
substances which could be fractionated by the HPLC and that 
the patterns of chromatograms for the infected and non- 
inf ected hamsters were different. The data given in Figure
4.5 is from a standard injection of 20 pi of urine samples 
and have not been corrected for differences in total urine 
volumes.
When radioactivity present in the HPLC fractions was 
counted, the patterns of metabolites excreted in the liver 
fluke (Figure 4.6A) and the non-liver fluke group (Figure 
4.6B) were different, even though consistent results were 
obtained from the 2 animals within each group. However, in 
both groups there is one peak in common which appears in 
fraction 9. This peak corresponds with AFM^ which is 
found in the urinary excretion shortly after exposure to 
AFBi, as discussed in Section 3.4.2. These results are 
consistent with those of Hsieh et a_l. (1977) who demon­
strated that the in vitro pattern of AFB^ metabolism of 
monkey, hamster and man was similar.
It was, therefore, observed from UV, fluorescence and 
radioactive monitoring of HPLC separations of urine samples 
that the profile of AFB^ metabolites differed between liver 
fluke infected and non-infected animals. Hence, it 
suggests that liver fluke infection has some effect on 
aflatoxin metabolism in hamsters. In both groups treated 
with AFBi, there appears to be excretion of AFMi in the 
first 24 h after dosing but, apart from this, the overall
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Figure 4.5 HPLC chromatograms of UV and fluorescence 
detection of aflatoxin metabolites present 
in the 24 h urine of hamsters treated with 
14C-AFBi (10 mg/kg)
TT Tr -i-- 110 12
TTr
8
Time (minute) Time (minute)
A. Non-liver fluke infected hamster
B. Liver fluke infected hamster
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Figure 4.6 Radioactivity in HPLC fractions from 
chromatographing urine samples 
from hamsters treated with -^C-AFBi 
(10 mg/kg)
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profiles are strikingly different. In view of this result, 
it would be interesting to compare further the pattern of 
metabolism between these two groups of hamsters in more 
detail. However, it was outside the scope of this study.
4.4.3.3 Aflatoxin levels in hamster urine samples
When untreated urine samples from hamsters, either 
with or without liver fluke infection, were fractionated by 
HPLC, and analysed for apparent AFB^ content, there was no 
significant difference in the pattern of apparent AFB^ 
obtained from both groups (Figure 4.7). The levels were 
high in fraction 2 (approximately 3-6 ng/fraction), then 
they decreased to levels less than 0.5 ng apparent AFB^/ 
fraction before, again, increasing in fraction 8 and 
subsequent fractions.
These results show that in urine samples from hamsters 
untreated with AFB^, there are high levels of interfering 
substances that can react with anti-AFB^ serum in ELISA. 
It was unlikely that these animals had been fed with a diet 
contaminated with AFB^. It appears possible that the high 
levels of ELISA interfering susbtances present in the 
hamster urine are due to the concentrated nature of these 
excretions.
When comparing the results obtained with the hamsters 
before treatment with AFB^ with the ones obtained using 
uncontaminated human samples (see Figure 2.12) and marmoset 
control samples (see Section 3.4.3), there was one peak in 
common in fraction 2 of the HPLC separations, in all three
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Figure 4.7 Apparent AFB^ by ELISA in HPLC fractions 
from chromatographing urine samples from 
non-AFB^ injected hamsters
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species, associated with inhibition in the ELISA. This was 
presumably a polar compound from its retention time on 
HPLC. However, a major difference between the hamster and 
human samples was that in the hamster samples there was a 
potent interfering substance which eluted in fraction 8 and 
subsequent fractions from the HPLC. The marmoset
fractionations appeared similar to the human results and 
again indicated the suitability of this animal as a model 
for human exposure.
Dragsted et a^ L. (1988) have carried out similar HPLC 
fractionations of 1 uncontaminated' human urine samples and 
have observed that substantial amounts of ELISA inter­
fering substances are eluted in their HPLC system with a 
retention time similar to that of AFBi* However in the 
present study, this result was only obtained using samples 
from hamsters and not with the human or marmoset urines. 
The reason for the difference between their results and 
the one obtained from this study is not known at present. 
However, our results suggest that hamster may be a good 
animal model system to study UALS.
When hamster urine samples, collected 24 and 48h 
after injection of AFB^ into animals of both the liver 
fluke and non-liver fluke groups, were fractionated by HPLC 
and subsequently analysed for AFB^ equivalents by ELISA 
(Figure 4.8), the patterns of AFB^ equivalents obtained 
from both groups at the same time point (24 or 48 h) were 
similar. The prominent feature of the 24 h urine samples 
of both liver fluke and non-liver fluke groups was the
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Figure 4.8 Equivalent AFBi concentrations by ELISA 
in HPLC fractions from chromatographing 
urine samples from hamsters treated with 
AFBX (10 mg/kg)
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major peak in fraction 9, which although still present in 
the 48 h samples was much reduced. The retention time of 
this peak was consistent with AFM^. This peak was also 
prominent when using radioactive counting (Figure 4.6).
Radioactive monitoring of aflatoxin metabolites 
(Figure 4.6B) using fractions obtained from 24 h urine 
samples of non-liver fluke infected hamsters showed a less 
prominent peak in fraction 5 of the HPLC, and this peak 
could also be detected by ELISA (Figure 4.8A). However, a 
small peak in fraction 2, detected by radioactivity (Figure 
4.6B) was not recognised by the antibody (Figure 4.8A). 
Similar discrepancies between radioactive and ELISA 
detection were observed using 24 h urine samples from the 
liver fluke group. The ELISA technique again detected 
the major radioactive peaks in fractions 9 and 6 but not 
fractions 2 and 3. These results clearly indicate that the 
antibody used is capable of recognising less polar meta­
bolites of aflatoxin which may have less modification at 
the recognition epitope of the antibody than for the more 
polar metabolites which probably result from secondary 
metabolism, and therefore, have greater modification at the 
recognition epitope.
For the urine samples collected 48 h after treatment 
with AFBi, comparisons between radioactivity and ELISA 
monitoring cannot be made because the animals treated with 
l^C-AFBi died between 24 and 48 h after dosing, therefore, 
no 48 h samples were obtained. But from the ELISA 
monitoring of unlabelled urine fractions, the qualitative
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metabolite pattern was similar for. the liver fluke and 
non-liver fluke groups (Figure 4.8B). In the absence of 
quantitation of aflatoxin metabolites by radioactivity, it 
is not possible to compare the total level of metabolites 
using AFB^ equivalent concentrations derived from ELISA. 
As has been clearly demonstrated by comparing the data in 
Figures 4.6 and 4.8, the ELISA technique is not efficient 
in detecting polar metabolites and so, if the samples 
contain high proportion of these metabolites, the aflatoxin 
content would be seriously underestimated. This would be a 
particular drawback in the case of the 48 h samples where 
not only the levels of aflatoxin metabolites decreased but 
also it was most likely that a higher proportion of polar 
metabolites was present and the antibody would not detect 
them. It is suggested from this study, therefore, that the 
pattern of AFB^ metabolism in liver fluke and non-liver 
fluke infected hamsters can best be carried out using 
radiolabelled AFB^, due to the difficulty in assaying polar 
metabolites by ELISA.
4.5 SUMMARY
The results obtained in this Chapter indicate that the 
pattern of aflatoxin metabolites excreted in the urine 
samples of liver fluke and non-liver fluke infected groups 
may not be the same. More animals are required to clarify 
this point. Concerning individual metabolites, it appeared 
that AFMi was a major constituent of the urine of hamsters
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treated with AFB^ and this metabolite was detected 
sensitively by the ELISA. However, it was also found that
the antibody used did not recognise efficiently the polar 
metabolites of AFB^ excreted in the urine.
In the present study hamster urine samples were not 
subjected to the 'clean-up' procedures for aflatoxin
monitoring developed in connection with human and marmoset 
samples, because the main object of the study described in 
this Chapter was to determine whether there was any 
significant differences between the aflatoxin metabolism of 
hamsters with or without liver fluke infection. However, 
from all the data available, it is possible to suggest that 
the level of AFB^ equivalents obtained by ELISA will be
underestimated as in the case of marmoset urine samples.
From histological examination, liver fluke infection 
can cause very extensive biliary proliferation with 
lymphoid infiltration forming follicles. These effects 
were so pronounced that even a dose of 5 mg AFB^/kg body 
weight of hamster did not show any significant difference 
from the effects of the liver fluke alone. But with a dose 
of 10 mg AFBi/kg, infection with liver fluke accentuated, 
the toxicity of AFB^ in the livers of the hamsters. 
However, in the non-liver fluke infected group, a
significant difference between the dose of 5 and 10 mg 
AFB^/kg was clearly seen. A complicating factor in
increasing the dose of AFB^ to 10 mg/kg was the high 
mortality which resulted, but despite this drawback, it was 
necessary to increase the AFB^ dosing to this level in
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order to produce AFBi-related lesion in the liver fluke 
infected group.
One interesting point in this study is that the
hamster may be a good animal model to study the UALS. In
urine samples from animals untreated with AFB^ in both
liver fluke and non-liver fluke infected groups, high
levels of these substances were detected. This is possibly 
related to the small urine volumes excreted by these 
animals which results in the inhibitory substances being 
concentrated.
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CHAPTER 5
Monitoring of urinary aflatoxin excretion in patients 
with liver disease from different areas of Thailand
180
5.1 INTRODUCTION
There is considerable evidence indicating an 
association between aflatoxin ingestion and liver cancer in 
humans (see Section 1.6). Most of the evidence linking 
these two factors is based on correlation between cancer 
incidences and the levels of exposure to aflatoxin 
contamination in food. But the presence of aflatoxin- 
contaminated food in general food surveys does not give 
information concerning specific individual exposures which 
can only be obtained from individual monitoring (Groopman 
and Kensler, 1987). Although epidemiological studies may 
provide evidence for an association, they cannot give 
direct proof of a cause and effect relationship (Munoz and 
Linsell, 1982). In addition, despite providing unique 
information about the responses of humans who have been 
exposed to a suspect agent this is usually retrospective. 
In such circumstances, they can detect only relatively 
large increases in relative risk and huge numbers of 
subjects will be required to evaluate a substance having a 
small risk.
Some of the limitations of cancer epidemiology may be 
overcome by the development of methods which permit the 
monitoring of exposure to a suspected or known carcinogen 
at an individual level. Exposure monitoring provides a 
bridge between laboratory animal and human studies. Human 
risk assessment of a particular substance may be improved 
by correlating data obtained through the biological
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monitoring of the compound in human with the results of 
parallel studies using laboratory animals. The
incorporation of biological monitoring methods into 
conventional epidemiological studies can increase their 
power to detect carcinogenic risk earlier, and at lower 
exposure, as well as to estimate more accurately the 
magnitude of human risk. However, biological monitoring 
may not be straight forward and should be used in parallel 
with environmental monitoring, especially in the case of 
carcinogens, for which the latency between exposure and 
effects may last for decades (Vainio, 1985).
In order to monitor human exposure to any toxic 
substance there are two important considerations to bear in 
mind. Firstly, the methods used must be sensitive and 
specific enough to allow detection of human exposure to any 
substance of interest, which will often be at an extremely 
low level. Secondly, possible modifying and/or confounding 
factors, such as dietary considerations, drinking and 
smoking habits must be taken into account when the results 
of the biological monitoring are being analysed. In the 
present study, the assay methods for detecting aflatoxins 
in human urine samples using ELISA techniques have been 
successfully developed (see Chapters 2 and 3). It was of 
interest, therefore, to apply these techniques to monitor 
human populations in which the risk of aflatoxin exposure 
seems highly likely.
In Thailand, liver cancer is the most common fatal 
neoplasm reported in the National Cancer Registry, and is
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responsible for 16.3% of all new cases in males and 5.5% in 
females (Srivatanakul et a_l. , 1988). This cancer occurs in 
males three times more frequently than in females (Parkin 
et al. , 1988). The overall incidence shows considerable
variation in its frequency in the different regions of the 
country (see Section 4.1).
According to a study carried out in Thailand since
1967, there was a good correlation between the levels of 
aflatoxin contamination in food and incidences of liver 
cancer (Shank et al., 1972c,d). Another similar study was 
reported in 1984 (Anukarahanonta et al. , 1984), the results 
obtained were in accordance with the previous reports.
Various foodstuffs available in the local markets in 
Thailand have been shown to be contaminated with 
aflatoxins (Table 5.1). The frequency as well as the 
severity of aflatoxin contamination were found not to vary 
with the seasons of the year (Shank £t al., 1972b;
Anukarahanonta et al., 1984). There were two different
geographical locations of great interest. The first one is 
Songkhla where low levels of aflatoxin contamination in 
food and low incidence of liver cancer were observed, and 
the second one, Ratburi, with high contamination of 
aflatoxins in food and high incidence of liver cancer.
Even though the survey studies were carried out several 
years ago, the pattern of diet consumed and the levels of 
aflatoxin contamination in foodstuffs have not altered 
substantially in the intervening period (Anukarahanonta et 
al. , 1984). In the present study, patients with liver
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Table 5.1
Alfatoxin contamination in market food in Thailand
Commodity No. of 
sample
Percent
positive
Contamination levels* (jig/kg)
test + 
samples
contaminated
sample
maximum
Corn 62 35 140 (93) 400 2,730
Rice 364 2 <1 20 98
Wheat and barley 44 11 7 (4) 67 248
Peanut 216 49 750 (426) 1,530 12,256
Sesame seeds 75 3 <1 <1 <1
Mung beans 140 5 1 16 112
Other beans 322 3 6 (3) 213 1,620
Fresh vegetables 140 1 <1 30 46
Onions and garlic 58 3 2 67 N . A . W
Cassava starch 65 3 5 (2) 150 294
Peppers, chili 106 11 14 (9) 125 966
Fish and shrimp 
dried 139 5 8 (5) 166 772
* Contamination levels were expressed as average total aflatoxins 
+ Numbers in parenthesis represented average level of AFB^
(x) N.A. = data not available
(Adapted from Shank et^  al., 1972b)
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disease from these two areas were monitored for aflatoxin 
exposure. The other area, namely Khon Kaen, was also 
selected due to the fact that there were high levels of 
aflatoxin contamination, high incidence of liver cancer and 
also high incidence of liver fluke infestation. This 
latter area was not chosen in the study of Shank and his 
coworkers because they did not want to complicate their 
study with extra aetiological factors in liver 
carcinogenesis (Shank et a_l., 1972d) . However, the hamster 
studies (see Chapter 4) indicated alterations in aflatoxin 
excretion in the urine due to the presence of liver fluke 
infestation. Therefore, the effect of liver fluke 
infestation on aflatoxin disposition may also be observed 
by monitoring patients with liver disease in this area.
The objective of this study was to compare the levels 
of aflatoxin excreted in urine specimens of patients with 
and without liver disease in three different areas of 
Thailand, i.e. Ratburi, Songkhla and Khon Kaen. Since it 
is well established that cancer is a disease with a very 
long latent period, it is not to be expected that the 
presence of aflatoxins in the samples or the levels of 
aflatoxin found, would have any particular relevance in 
terms of the carcinogenic process in any individual 
patient. But giving that food consumption of Thai people 
has not drastically changed during the last decade 
(Anukarahanonta et ajL., 1984), the data obtained may
provide additional information on human risk assessment of 
aflatoxin. In any case, the results obtained would
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indicate the possibility of using the assay methods 
developed in monitoring the level of human exposure to 
aflatoxin which could be of value in a prospective study of 
liver cancer.
5.2 MATERIALS AND METHODS
5.2.1 Subjects
Patients were selected from major hospitals with good 
medical facilities and recording systems. The hospitals 
which participated in this study are located in different 
geographical areas with respect to differences in levels of 
aflatoxin contamination as being surveyed by Shank et al. 
(1972b, c). The hospitals are in Ratburi (area with high 
aflatoxin contamination and high incidence of liver 
cancer), Songkhla (area with low aflatoxin contamination 
and low incidence of liver cancer), and Khon Kaen (area 
with high aflatoxin contamination and high incidences of 
liver cancer and liver fluke infestation). All these 
hospitals are regional hospitals where patients from 
central, southern and northeastern parts of Thailand are 
referred to respectively.
Newly admitted patients with liver disease were 
recruited in the study during the period of April-December 
1986. All the patients were diagnosed clinically by having 
the symptoms of hepatomegaly and jaundice with or without 
ascites. Patients without liver disease who were admitted 
within the same period as the patients with liver disease
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were also recruited for comparison. Patients in both 
groups were matched with respect to their sex and age (± 5 
years).
5.2.2 Sample Collections
Morning urine specimens from patients with or without 
liver disease were collected on the day following 
admission. Aliquots (15 ml) of urine samples were stored 
in glass bottles with screw caps and kept frozen at -20 °C 
prior to and during transportation to Bangkok by air, 
except from Ratburi where the samples were sent by car 
(approximately one hour drive).
At the end of the field study, all urine samples were 
sent frozen to England by air in an ice box packed with dry 
ice. Upon arrival, the samples were immediately stored at 
-70°C until required.
5.2.3 Aflatoxin analysis
Urine samples (1 ml) were used in the assays for 
aflatoxin contamination. They were subjected to the 
'clean-up' procedures before analysing for AFBi equivalents 
by ELISA (using 4 replicates) as described in Section 
2.2.4.
5.2.4 Creatinine analysis
The samples were analysed for creatinine concentra­
tions as described in Section 2.2.3.7.
5.2.5 Statistical analysis
Because of the unequal number of the patients with and
187
without liver disease in each hospital, it was not possible 
to carry out a combined two-way analysis of variance 
(Snedecor and Cochran, 1980). Individual statistical 
analyses were, therefore, performed as follows. Within 
each hospital, the levels of aflatoxin per creatinine unit 
in both groups of patients were compared by student t-test 
using the statistical package (Minitab, Inc., University 
Park, Pennsylvania). All values obtained for samples from 
each individual hospital were also pooled to allow a 
comparison between hospitals using one-way analysis of 
variance.
5.3 RESULTS AND DISCUSSION
The age and sex of patients with or without liver 
disease in the three different areas are shown in Table 
5.2. In some particular cases of liver disease patients, 
liver biopsies or liver scans were carried out. In Ratburi 
only 15% (4 cases) of patients with liver disease was
confirmed as hepatocellular carcinoma. In Songkhla and 
Khon Kaen, there were 11% (1 case) and 31% (4 cases) 
respectively. The highest percentage of liver cancer among 
liver disease patients was in Khon Kaen which is the area 
with a high incidences of liver fluke infection and 
aflatoxin contamination. The presumptive diagnosis of the 
other patients with liver disease was cirrhosis. All the 
patients with non-liver disease were suffering from chronic 
medical diseases such as asthma, hypertension and
188
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congestive heart failure. Since the number of patients in 
the groups selected were proportional to the number of 
people admitted with liver disease it can be seen that 
there were more male patients presenting with liver disease 
than female patients in all three areas (Table 5.2).
The mean ages of patients presenting with liver 
disease in the case of the males in the three different 
areas were in their 50's, but in the female groups, it was 
46 years in Khon Kaen, whilst in the other two areas they 
were in their 60's. The results given in Table 5.2 are 
consistent with the national survey of liver cancer that 
males tend to have liver cancer at an earlier age than 
females (Srivatanakul et al., 1988). However, in the case 
of the female group in Khon Kaen, they presented at an 
earlier age than the other two female groups and also 
earlier than all the male groups. The reason for this is 
not known but it could be associated with the high 
incidence of cholangiocarcinoma in the case of Khon Kaen 
which is probably related to the high incidence of liver 
fluke infection.
The sizes of the three selected hospitals in this 
study are the same. From Table 5.2, therefore, it might 
appear that there was a higher incidence of liver disease 
in Ratburi compared with the other two regions. However, 
the figures may not reflect the actual incidences of liver 
disease in these regions during the period of study. 
Firstly, because some cases may not have been recruited
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into the study due to the absence of responsible research 
assistance during the period of their admission ,and 
secondly, because the referral system in Thailand, in which 
patients are allowed to be treated in any hospital of their 
choice without having to go through their local general 
practitioners, often resulted in people entering hospitals 
other than those in their own regions. For these reasons a 
valid comparison between the actual incidence of liver 
disease in the three areas was not attempted.
In this study, the number of patients with non-liver 
disease is higher than the number of liver disease cases. 
This is due to the fact that all non-liver disease patients 
matching patients in liver disease group were recruited.
Morning urine specimens from both groups of patients 
collected on the day after their admissions were chosen as 
the protocol for urine sample collections because in 
Thailand, the average temperature is 32 °C which promotes 
the growth of bacteria and other microorganisms. If 24 h 
urine samples were collected, some form of preservative 
would have to be added to them which could interfere with 
the subsequent ELISA detection system. In the case of the 
morning urine samples, the total daily urine volumes 
excreted were not recorded. Creatinine concentration in 
each sample was determined to serve as a reference point or 
internal standard for the comparison of aflatoxin levels 
excreted in the different urine samples. Hence, the 
concentrations of aflatoxin were expressed as ng AFB^ 
equivalent/mg creatinine.
The AFBi equivalents in the urine samples obtained
from patients with or without liver disease in the three
different areas are shown in Tables 5.3-5.8 along with
their sex, age and creatinine levels. When the individual 
levels of AFB^ equivalent/mg creatinine were compared 
between patients with or without liver disease in any one 
hospital, there was no significant difference observed in 
the case of any of the hospitals studied. When the levels 
of aflatoxin excreted in the urine samples of similar
disease-status patients in the three different areas were
compared, no significant differences were found. When the 
values obtained from all patients in each individual
hospital were compared with the other two hospitals, no 
significant differences were also observed.
Inspection of the data in Figure 5.1 shows a skewed 
distribution, in the case of all the groups studied, with 
most values clustering around 0-0.2 ng AFB^/mg creatinine 
with several high value outliers. In order to avoid any 
bias for the non-normal distribution, the above statistical 
tests were also carried out on the log transformation of 
the data, however, there was still no significant 
difference.
When the results for each area were analysed in more 
detail; in Ratburi, 4 (15%) out of 26 patients with liver 
disease had liver cancer (urine sample nos. 142, 196, 197
and 199; Table 5.3). Three of them were over 50 years old 
while the other (sample no. 196) was only 18 years. This 
man had suffered from chronic viral hepatitis B infection
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Table 5.3
AFBi equivalents in urine samples obtained from patients with
liver disease from Ratburi+
Sample
no.
Sex Age Creatinine
(mg/ml)
AFBi equivalent 
(ng/ml)
AFB]/creatinine 
(ng/mg)
80 F 60 1.40 0.17 0.12
93 F 65 1.81 0.25 0.14
107 F 59 2.20 0.37 0.17
164 F 62 4.02 0.20 0.05
76 M 47 5.54 0.31 0.06
78 M 48 1.36 0.23 0.17
79 M 42 1.07 0.26 0.24
84 M 62 2.05 0.37 0.18
113 M 58 4.60 0.48 0.10
127 M 51 4.29 0.19 0.04
135 M 54 1.60 1.35 0.84
142* M 52 2.08 0.25 0.12
144 M 46 1.52 0.44 0.29
146 M 31 2.18 0.19 0.09
149 M 63 2.40 0.21 0.09
155 M 65 3.30 0.30 0.09
165 M 57 1.43 0.16 0.11
167 M 68 0.63 0.38 0.61
172 M 39 7.33 0.76 0.10
184 M 46 7.21 0.40 0.06
186 M 45 0.27 0.14 0.52
196* M 18 2.87 0.12 0.04
197* M 60 8.43 0.18 0.02
199* M 50 6.40 0.65 0.10
201 M 44 0.40 0.08 0.21
206 M 55 2.04 0.23 0.11
Mean 53 3.00 0.33 0.18
S.D. 12 2.27 0.26 0.19
+ Area with high aflatoxin contamination and high incidence of liver 
cancer
* Patients with liver cancer
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Table 5.4
AFBi equivalents in urine samples obtained from patients with
non-liver disease from Ratburi+
Sample
no.
Sex Age Creatinine 
(mg/ml)
AFBi equivalent 
(ng/ml)
AFB]/ creatinine 
(ng/mg)
83 F 60 1.33 0.15 0.11
137 F 65 4.79 0.16 0.03
145 F 63 0.93 0.33 0.36
86 M 39 1.74 0.18 0.10
91 M 59 1.40 0.18 0.13
99 M 20 3.23 0.32 0.10
105 M 20 3.13 0.16 0.05
106 M 60 2.10 2.69 1.28
114 M 61 0.29 0.11 0.39
121 M 72 2.28 0.35 0.16
123 M 44 0.97 0.29 0.30
129 M 56 1.79 0.12 0.07
133 M 30 0.81 0.17 0.21
139 M 69 2.23 0.12 0.05
140 M 50 0.06 0.07 1.17
143 M 49 0.20 0.06 0.31
148 M 54 1.97 0.11 0.05
168 M 57 1.39 0.13 0.09
169 M 72 1.44 0.26 0.18
182 M 48 2.50 0.53 0.21
198 M 31 1.43 0.03 0.02
202 M 58 1.73 0.15 0.09
203 M 52 0.79 0.25 0.31
204 M 41 0.79 0.53 0.68
205 M 47 0.63 0.08 0.12
207 M 45 1.72 0.18 0.11
Mean 51 1.60 0.30 0.26
S.D. 14 1.04 0.50 0.33
+ Area with high aflatoxin contamination and high incidence of liver 
cancer
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since the age of 10. In these liver cancer patients, their 
levels of AFB^ equivalents, expressed per unit creatinine, 
were all in the range of 0.02-0.12 ng/mg, compared with the 
range of 0.05-0.84 ng/mg creatinine in other patients with 
liver disease. In the patients with non-liver disease, 
there were two cases (sample nos. 106 and 140; Table 5.4) 
which had high levels of AFB^ equivalents of 1.28 and 1.17
ng/mg creatinine respectively. These patients were both
/
suffering from asthmatic attack. In one case (sample no. 
140), the urine sample was extremely dilute, with a 
creatinine level of only 0.06 mg/ml, and even though the 
patient had a low level of AFB^ equivalents (0.07 ng/ml) in 
his urine, when the aflatoxin excretion was corrected for 
the creatinine level, the aflatoxin excretion was high. In 
contrast, sample no. 106 had a creatinine level in the 
normal range but a very high level of AFB^ equivalents, 
resulting in a high level of AFB^ equivalent per unit 
creatinine. The ranges of AFB^ equivalent/mg creatinine in 
patients with or without liver disease in this area were 
0.02-0.84 and 0.02-1.28 ng/mg respectively.
In Songkhla, there were 9 liver disease cases (Table 
5.5), of which 1 case (11%) had liver cancer (sample no. 
183). He was 36 years old with the level of AFB^ 
equivalents of 0.07 ng/mg creatinine. This level was low 
when compared with the levels obtained from other patients 
with liver disease in the same hospital, in which the range 
was 0.03-0.41 ng/mg creatinine. In the patients with 
non-liver disease (Table 5.6), the range of AFB^
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Table 5.5
AFBi equivalents in urine samples obtained from patients with
liver disease from Songkhla+
Sample
no.
Sex Age Creatinine
(mg/ml)
AFBj equivalent 
(ng/ral)
AFB]/ creatinine 
(ng/mg)
102 F 54 1.38 0.19 0.14
175 F 67 1.84 0.26 0.14
103 M 49 2.20 0.21 0.10
173 M 64 12.26 1.14 0.09
178 M 48 0.39 0.16 0.41
180 M 66 3.80 0.22 0.06
183* M 36 4.46 0.32 0.07
187 M 58 8.81 . 0.28 0.03
189 M 61 1.76 0.33 0.18
Mean 56 4.1 0.35 0.14
S.D. 10 3.9 0.30 0.11
+ Area with low aflatoxin contamination and low incidence of liver 
cancer
* Patient with liver cancer
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Table 5.6
AFBi equivalents in urine samples obtained from patients with
non-liver disease from Songkhla+
Sample
no.
Sex Age Creatinine
(mg/ml)
AFBj equivalent 
(ng/ml)
AFBj/creatinine 
(ng/mg)
118 F 50 1.65 0.18 0.11
157 F 58 0.77 0.04 0.05
174 F 53 3.16 0.23 0.07
181 F 60 1.57 0.58 0.37
188 F 55 5.73 0.37 0.07
196 F 68 1.99 0.20 0.10
92 M 36 3.03 0.62 0.20
94 M 46 2.16 0.33 0.15
95 M 41 1.86 0.04 0.02
96 M 46 2.33 0.20 0.09
98 M 51 1.09 0.29 0.26
100 M 56 2.43 0.12 0.05
115 M 54 1.55 0.14 0.09
119 M 52 6.55 0.71 0.11
131 M 52 2.03 0.26 0.13
151 M 26 2.44 0.16 0.07
163 M 52 4.58 0.29 0.06
176 M 60 2.16 0.22 0.10
177 M 57 1.38 1.35 0.98
179 M 60 3.27 0.26 0.08
190 M 61 1.76 0.33 0.18
191 M 51 7.53 0.16 0.02
192 M 43 1.57 0.13 0.08
193 M 42 0.69 0.12 0.18
Mean 51 2.64 0.31 0.15
S.D. 9 1.77 0.28 0.19
Area with low aflatoxin contamination and low incidence of liver 
cancer
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equivalents was 0.02-0.98 ng/mg creatinine. The highest 
level of AFBi equivalents in this group of patients (0.98 
ng/mg) was found in a 57 years old man (sample no. 177) who 
suffered from urinary tract infection and had a urinary 
creatinine content in the normal range.
In Khon Kaen, there were 13 cases of liver disease 
(Table 5.7), of which 4 cases (31%) had liver cancer 
(sample nos. 152, 162, 111 and 209). These were two women 
who were in their 30' s and two men who were over 50 years. 
The range of AFBi equivalents for these cancer patients was 
0.06-0.17 ng/mg creatinine which was nearly the same as the 
range obtained for the other liver disease (non-cancer) 
patients (0.04-0.23 ng/mg). In the patients with non-liver 
disease (Table 5.8), the range of AFB^ equivalents was 
0.03-1.69 ng/mg creatinine. The highest level (1.69 ng/mg) 
was observed in sample no. 81 which was obtained from a 54 
year old man, suffering from congestive heart failure. 
This high result was due to the fact that his urine sample 
was extremely dilute with a creatinine concentration of 
only 0.09 mg/ml.
In Khon Kaen hospital, all the patients were screened 
for liver fluke ova in the stools. They were positive in 4 
(31%) and 3 (17%) cases of patients with and without liver 
disease respectively. There was one case (sample no. 161) 
who had both liver fluke infection and liver cancer. The 
levels of AFBi equivalents in the patients with liver fluke 
infection were higher in the non-liver disease group than 
in the liver disease patients. There is no clear
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Table 5.7
AFBi equivalents in urine samples obtained from patients with
liver disease from Khon Kaen+
Sample
no.
Sex Age Creatinine
(mg/ml)
AFBj equivalent 
(ng/ml)
AFBj/creatinine 
(ng/mg)
88 F 74 1.26 0.25 0.20
152* F 39 2.76 0.35 0.13
158 F 35 3.48 0.17 0.05
161*x F 37 1.59 0.22 0.14
77 M 52 0.58 0.13 0.23
104 M 58 2.79 0.33 0.12
108x M 54 4.53 0.19 0.04
109x M 63 3.08 0.35 0.11
111* M 65 0.63 0.11 0.17
138 M 46 2.62 0.11 0.05
147X M 57 2.52 0.22 0.09
170 M 52 3.67 0.17 0.05
209* M 53 2.53 1.62 0.06
Mean 53 2.46 0.32 0.11
S.D. 11 1.17 0.40 0.06
+ Area with high aflatoxin, high incidence of liver cancer and high 
incidence of liver fluke infestation
* Patients with liver cancer
x Patients with liver fluke infection
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Table 5.8
AFB^ equivalents in urine samples obtained from patients with
non-liver disease from Khon Kaen+
Sample
no.
Sex Age Creatinine
(mg/ml)
AFBj equivalent 
(ng/ml)
AFBj/creatinine 
(ng/mg)
87 F 40 0.87 0.33 0.38
125 F 36 4.48 0.37 0.08
141 F 63 0.66 0.08 0.12
81x M 54 0.09 0.15 1.69
82 M 55 2.78 0.22 0.08
85 M 65 2.23 0.28 0.13
89 M 63 2.72 0.67 0.25
112 M 54 2.48 0.16 0.06
124 M 63 0.45 0.21 0.45
130x M 54 0.53 0.18 0.34
136 M 51 1.40 0.22 0.16
153 M 61 1.47 0.91 0.13
154 M 63 0.22 0.15 0.66
156x M . 45 3.67 0.11 0.03
159 M 60 5.88 0.58 0.10
160 M 54 9.89 0.25 0.03
162 M 48 4.49 0.24 0.05
171 M 53 1.72 0.11 0.07
Mean 55 2.56 0.29 0.27
S.D. 8 2.47 0.22 0.39
+ Area with high aflatoxin contamination, high incidence of liver cancer 
and high incidence of liver fluke infestation
x Patients with liver fluke infection
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explanation for this difference but one point that is worth 
noting is that the urine samples obtained from 2 out of the 
3 liver fluke infected patients without liver disease were 
dilute with creatinine concentrations less than 0.6 mg/ml.
From these data, it appeared that correcting for 
creatinine concentration in the case of several dilute 
urine samples resulted in apparent significantly high 
levels of aflatoxin content where the actual aflatoxin 
assays themselves gave results in the normal range. 
Therefore, the validity of correcting the samples on the 
basis of the creatinine content warrants further 
investigation.
When the results from the three areas are combined 
(Figure 5.1), there appears to be a trend towards a wider 
distribution in the levels of AFB^ equivalents in samples 
obtained from the non-liver disease patients. When the 
'background' level of 0.2 ng AFB^ equivalent/mg creatinine, 
obtained from presumably uncontaminated Western urine 
samples, was applied as the lower limit of detection of 
significant aflatoxin contamination (see Section 2.4.7.2), 
there were 5 (8%) and 10 (38%) cases of the patients with 
and without liver disease respectively in Ratburi who had 
levels of AFB^ equivalents higher than 0.2 ng/mg 
creatinine. While in Songkhla and Khon Kaen, there were 1 
case (11%) and 1 case (8%) of liver disease and 4 cases 
(17%) and 6 cases (33%) of the non-liver disease group 
respectively exhibiting significant levels of aflatoxin in 
their urines. These higher levels in patients with
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non-liver disease may toe due to the fact that the patients
with liver disease came to the hospitals when they were
very sick. From medical records, most of them were
suffering from their symptoms at least one week toefore
admission to the hospitals, therefore, their dietary 
patterns might have completely changed during this period, 
and the levels of aflatoxin excreted in the urine might not 
represent the normal level of exposure. In contrast, the 
patients with non-liver disease came to the hospitals 
because of their acute symptoms such as asthmatic attack. 
In these cases, the nature of their ailments were probably 
such as not to have had a significant effect on their
dietary habits. Thus, there was a possibility that they 
had consumed theirnormal diet which contained aflatoxin 
and, therefore, their urine samples would be more likely to
reflect the aflatoxin contamination of this food.
When the levels of aflatoxin excreted in urine samples 
of patients with non-liver disease from the three different 
areas were compared, the levels of AFBi equivalents, higher 
than 0.2 ng/mg creatinine in Ratburi, Songkhla and Khon 
Kaen were 38, 11 and 33% of cases respectively. If these 
numbers represent the levels of exposure, the results are 
consistent with the survey of aflatoxin contamination in 
food (Shank et al. , 1972b), i.e. there is a high level of 
aflatoxin contamination in Ratburi and Khon Kaen and a 
relatively low contamination in Songkhla.
Even though the numbers of patients participating in 
this study were too small to make any valid statistical
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comparisons, nevertheless a trend in the levels of 
aflatoxin excreted in human urine samples is indicated. 
These levels are in agreement with the levels of aflatoxin- 
contaminated food for each area. This study also shows 
that the methods developed to monitor aflatoxin excretion 
in human urine samples are able to detect variations in the 
levels of contamination. It also provides useful
information for designing further epidemiological studies.
5.4 SUMMARY
The methods for monitoring aflatoxin excretion in 
human urine samples were applied to samples obtained from 
patients with or without liver disease from three different 
areas of Thailand. These areas differ in terms of the 
levels of aflatoxin contamination in food and incidences of 
liver cancer and liver fluke infestation. The results 
obtained show that the methods can detect variations in the 
levels of aflatoxin in urine samples. However, there is no 
statistically significant difference between the aflatoxin 
content of samples obtained from patients with or without 
liver disease in the same areas, or between the levels 
found in samples obtained from the different areas. This 
may be due to the small number of samples analysed. This 
study also suggests that patients with liver disease may 
not be the group that should be monitored for urinary 
aflatoxin levels, because their dietary patterns may have
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changed as a result of their illness prior to their 
admission to hospitals. However, when samples obtained 
from patients with non-liver disease were compared, a trend 
in the levels of aflatoxin found in the urine samples was 
observed which was consistent with the known levels of food 
contamination in each area.
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CHAPTER 6
Monitoring of urinary aflatoxin excretion 
in Thai vegetarians
206
6.1 INTRODUCTION
Studies of the geographical distribution of cancer 
have demonstrated a variation in the incidences of specific 
cancers (Parkin et al. , 1988). It is estimated that 80% of 
human cancers are environmentally determined and only a 
small part can be attributed to genetic factors (Doll, 
1986). The wide variation in incidence of cancers of 
various sites in the gastrointestinal tract and the liver 
may be due to carcinogenic factors in the diet. In some 
parts of Thailand, human foodstuffs have been found to be 
contaminated with small amounts of aflatoxins and this is 
believed to contribute to a high incidence of hepato­
cellular carcinoma in some areas (Shank et a_l., 1972d).
Aflatoxins have been reported to contaminate mainly 
vegetarian products (see Table 5.1) such as peanuts, rice 
and maize (Shank et al., 1972b,c; Anukarahanonta et al.,
1984). Since the vegetarians consume more of these 
products than the meat-eaters, it is likely that the former 
have a higher risk of exposure to aflatoxins than the 
latter. Starting from the early 1970's, there has been a 
surge of interest in vegetarianism as an alternative food 
pattern (Guthrie, 1975). In Thailand, as in other parts of 
the world, increasing numbers of people are turning to 
vegetarianism for a variety of reasons. To some it
represents a form of religion or spiritual release through 
which they hope to purify their bodies. For others,
vegetarian diets are an alternative food to relatively
costly animal proteins. There are two major types of
vegetarianism, namely the true vegetarian and ovolacto- 
vegetarian (Guthrie, 1975; Davidson et al., 1977). The
former relies exclusively on vegetable proteins whereas the 
latter has milk, eggs and other dairy products in addition 
to vegetables. Thai vegetarians usually consume rice, 
peanuts, beans and maize daily.
Evidence has been advanced suggesting a significant 
difference in drug metabolism between vegetarians and 
meat-eaters. Asian vegetarians were shown to metabolize 
antipyrine more slowly than Asians or Europeans who ate 
meat regularly (Fraser et al., 1978; Mucklow et al., 1979; 
Wilmana et al. , 1979). Half-lives of antipyrine and
paracetamol were slightly longer in the vegetarians than 
non-vegetarians (Dollery et al. , 1979; Brodie et al., 
1980). The low protein content of the Asian vegetarian 
diet may be responsible for the differences in drug 
handling between Asian and European vegetarians. However, 
a study of antipyrine metabolism has suggested that a 
significant difference in antipyrine clearance between 
lactovegetarians and meat-eaters appears to be related to 
differences in consumption of animal fat rather than 
protein (Fraser et al., 1978).
There is little doubt that dietary factors influence 
the development of cancer in humans (Rogers, 1978) and 
animals (Newberne, 1976). The complexities of dietary 
interactions with chemical carcinogens, especially 
aflatoxin, in animal models, are evident from many studies
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(Boyd et al. , 1982; Emerole et al_. , 1984; Llewellyn et al., 
1985; Chang and Bjeldanes, 1978; Baldwin and Parker, 1987; 
Bailey et al., 1987), and the situation very probably is no 
less complicated in the case of human cancer. In some 
parts of the world, especially in the developing countries, 
primary liver cancer is a major problem, particularly in 
males (Parkin et al^ . , 1988; Srivatanakul et al.-, 1988). In 
most populations, the livers of hepatic cancer patients are 
usually fatty and often cirrhotic, although the populations 
generally do not consume excessive levels of »fat. It 
should be noted, however, that the fat that they do consume 
is often unsaturated (fish or vegetable) and that their 
diets frequently are contaminated with mycotoxins, 
nitrosamines or other hepatic carcinogens. They also 
suffer from a high incidence of viral hepatitis and, in 
some cases, liver parasitism. Any or all of these factors 
may interact with dietary nutrients to enhance liver cancer 
(Newberne et a_l. , 1979).
In view of the above evidence, vegetarians would 
appear to be a high risk group of the population for 
aflatoxin carcinogenicity, although there is, at present, 
no epidemiological evidence to support this hypothesis. It 
is also possible that the handling of aflatoxins in the 
body may be different between the vegetarians and 
non-vegetarians.
The objective of this study was to compare the levels 
of aflatoxins excreted in urine of these two groups of the 
population. A well-established vegetarian community in
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Bangkok was selected for this study. In this community, 
they follow the same doctrine of Buddhism that believes in 
a very modest style of living. They tend to follow the 
same activities and patterns of eating throughout the 
year. They usually consume rice, peanuts, beans and maize 
which are transported from areas where high levels of 
contamination with aflatoxins have been reported.
6.2 MATERIALS AND METHODS
6.2.1 Subjects
The subjects in this study consisted of vegetarians 
and non-vegetarians who live in Bangkok. The
non-vegetarians were third-year medical students at Mahidol 
University while the vegetarians were from one vegetarian 
community, Santi Asoke. Forty-five people from each group
participated in the study. They were told about the
objective of the study. The vegetarians had been on a 
strict vegetarian diet for more than 3 months. None of 
the subject in either group was a regular smoker or
drinker.
6.2.2 Sample collections
Single voided urine samples were collected from these 
two groups of people in August 1987. For the
non-vegetarian group, the urine samples were collected in 
50 ml plastic containers at Mahidol University. The data 
on their age and sex were also collected. The samples
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(15 ml) were transferred into glass bottles with screw caps 
and stored at -20°C before sending to England.
For the vegetarian group, the urine samples were 
collected at their community in 50 ml plastic containers. 
Then they were placed in ice boxes and brought back to 
Mahidol University. The samples (15 ml) were also
transferred into glass bottles and stored at -20°C. All
the pertinent data were collected.
All the samples were sent frozen to England in a box 
with dry ice. Upon arrival, they were stored at -70°C 
until required.
6.2.3 Aflatoxin analysis
Urine samples (1 ml) were used in the assay for 
aflatoxin contamination. They were subjected to the 
'clean-up' procedures before analysing for AFB^ 
equivalents by ELISA (using 4 replicates) as described in 
Section 2.2.4.
6.2.4 Creatinine analysis
The samples were analysed for creatinine 
concentrations as described in Section 2.2.3.7.
6.2.5 Statistical analysis
Results were analysed comparing the levels of 
aflatoxin per creatinine unit in urine samples from the 
various groups by student t-test.
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6.3 RESULTS AND DISCUSSION
The age and sex of the subjects participating in this 
study are summarized in Table 6.1. There was a wide 
variation between the means of the ages of the vegetarians 
and the non-vegetarians. The mean age of the non­
vegetarians was 20 while that of the vegetarians was around 
40 years. This was due to the fact that the non­
vegetarians were medical students who were in their 20's, 
while in the case of the vegetarian group, they were a 
mixed population of all ages. Comparison between the sexes 
within each group were possible because the mean ages in 
both sexes of each group were similar.
Single voided urine samples were chosen as the method 
of collection for the reasons stated in Section 5.3, and 
creatinine levels were expressed as mg/ml. For the purpose 
of comparison, aflatoxin levels, analysed by ELISA, were 
expressed as ng AFB^ equivalent/mg creatinine. In the 
vegetarian group, the levels of aflatoxin in the male and 
female ranged from 0.04-0.39 and 0.04-3.22 ng AFB^ 
equivalent/mg creatinine respectively, with the mean values 
of 0.14 and 0.31 ng/mg (Tables 6.2-6.3). The levels in 
the female samples were higher but these values did not 
reach statistical significance. In the non-vegetarians, 
the ranges were 0.02-1.82 and 0.04-1.85 ng AFBi 
equivalent/mg creatinine for male and female, with mean 
values of 0.20 and 0.24 ng/mg respectively (Tables 
6.4-6.5). When the data obtained from the male and female
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Table 6.1
Age and sex distribution in vegetarian and non-vegetarian populations
MALE FEMALE
non­
vegetarian vegetarian
non­
vegetarian vegetarian
number 25 19 20 26
mean age (year) 20.12 38.47 20.25 39.42
standard deviation 1.01 13.46 1.21 16.46
range of ages (year) 18-23 26-64 18-24 20-78
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Table 6.2
Urinary aflatoxin levels in male vegetarians
Sample No. Age Creatinine
(mg/ml)
AFBi equivalent 
(ng/ml)
AFBi/Creatinine 
(ng/mg)
304 53 2.34 0.11 0.05
307 40 2.34 0.62 0.26
311 26 1.16 0.19 0.16
313 53 1.93 0.36 0.19
314 58 3.32 0.52 0.16
319 33 0.99 0.17 0.17
320 30 3.17 0.27 0.09
321 30 2.91 0.17 0.06
322 60 2.71 0.21 0.08
324 29 0.26 0.07 0.27
325 52 0.61 0.24 0.39
326 30 0.88 0.09 0.10
329 26 2.34 0.29 0.12
330 27 4.14 0.54 0.13
335 28 2.74 0.25 0.09
341 24 2.56 0.12 0.05
342 31 2.12 0.32 0.15
343 37 1.42 0.18 0.13
344 ' 64 2.79 0.11 0.04
mean 38.47 2.14 0.25 0.14
S.D. 13.46 1.02 0.16 0.09
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Table 6.3
Urinary aflatoxin levels in female vegetarians
Sample No. Age Creatinine 
(mg/ml)
AFBi equivalent 
(ng/ml)
AFBi/Creatinine
(ng/mg)
300 28 2.36 0.38 0.16
301 24 3.85 0.37 0.10
302 20 3.71 0.54 0.15
303 30 1.81 0.24 0.13
305 52 2.37 0.68 0.29
308 . 34 5.28 0.28 0.05
309 48 2.37 0.29 0.12
310 56 0.69 0.30 0.43
312 61 2.36 0.41 0.17
315 39 1.63 0.17 0.10
316 34 0.85 0.21 0.25
317 31 1.52 1.25 0.82
318 49 2.98 0.19 0.06
323 32 0.90 2.90 3.22
327 43 1.66 0.15 0.09
331 23 5.02 0.18 0.04
332 78 4.20 0.19 0.05
333 66 1.92 0.44 0.23
334 36 1.48 0.45 0.30
336 26 1.40 0.14 0.10
337 26 3.41 0.22 0.06
338 35 1.89 0.12 0.06
339 26 2.37 0.16 0.07
340 31 0.18 0.09 0.50
345 22 1.80 0.50 0.28
346 75 0.04 0.13 0.33
Mean 39.42 2.25 0.42 0.31
S.D. 16.46 1.33 0.56 0.62
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Table 6.4
Urinary aflatoxin levels in male non-vegetarians
Sample No. Age Creatinine 
(mg/ml)
AFBi equivalent 
(ng/ml)
AFBi/Creatinine 
(ng/mg)
216 20 0.99 0.23 0.23
217 19 1.10 0.24 0.22
218 20 1.49 0.12 0.08
221 18 2.21 0.10 0.05
222 20 1.46 0.07 0.05
223 20 1.71 1.65 0.96
226 20 1.63 0.12 0.07
227 21 2.05 0.09 0.04
228 20 5.19 0.17 0.03
233 21 1.76 3.21 1.82
234 20 2.91 0.17 0.06
235 21 3.51 0.06 0.02
236 20 2.67 0.51 0.19
238 21 2.69 0.08 0.03
239 20 2.23 0.15 0.08
262 20 3.20 0.13 0.04
263 18 2.22 0.06 0.03
265 20 2.02 0.17 0.08
266 21 1.52 0.11 0.07
267 20 3.58 0.11 0.03
269 20 0.57 0.11 0.19
271 21 4.10 0.20 0.05
273 19 2.62 0.31 0.12
274 20 0.90 0.20 0.22
284 23 3.87 0.46 0.12
Mean 20.12 2.33 0.35 0.20
S.D. 1.01 1.12 0.67 0.39
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Table 6.5
Urinary aflatoxin levels in female non-vegetarians
Sample No. Age Creatinine 
(mg/ml)
AFBj equivalent 
(ng/ml)
AFBi/Creatinine 
(ng/mg)
210 18 0.73 0.26 0.36
211 21 2.19 0.09 0.04
212 20 0.40 0.74 1.85
213 20 3.08 0.46 0.15
214 19 1.16 0.07 0.06
215 20 1.89 0.24 0.13
219 20 0.92 0.04 0.04
224 21 0.65 0.34 0.52
225 20 2.82 0.79 0.28
229 20 0.36 0.09 0.25
230 20 5.24 0.23 0.04
231 20 0.82 0.09 0.11
232 20 3.08 0.17 0.06
260 21 1.26 0.10 0.08
261 21 2.65 0.12 0.05
264 21 1.23 0.08 0.07
268 19 1.89 0.23 0.12
272 19 1.38 0.20 0.14
275 21 0.56 0.13 0.23
279 24 1.38 0.19 0.14
Mean 20.25 1.68 0.23 0.24
S.D. 1.21 1.21 0.21 0.40
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urine samples were analysed statistically, no significant 
differences were found either within or between vegetarians 
and non-vegetarians. This might be due to the small number 
of samples being analysed. If the number of subjects was 
increased, a statistically significant difference might 
possibly be observed.
However, the trend that vegetarians appear to excrete 
higher level of AFB^ equivalents than the non-vegetarians 
is further illustrated when the data are plotted as in 
Figure 6.1. In addition, the levels obtained in the female 
samples of both vegetarians and non-vegetarians appear to 
be higher than those found in the males of comparable 
groups. These data raise the possibility that the 
metabolism of aflatoxin in males and females is different, 
and that females seem to excrete higher levels of
aflatoxin. Higher excretion in females could also result 
from higher intake. However, it would appear that females 
excrete more of a given dose than males based on the 
results of the marmoset experiments. In the marmoset, the 
level of aflatoxin in the female urine sample (as a 
percentage of dose) was higher than that observed in the 
male sample (see Section 3.4.4.4). However, the effect of 
sex difference on aflatoxin metabolism, especially in
humans, needs to be further investigated.
From the study using samples from non-exposed European 
people, the lower limit of significant detection of
aflatoxin in the urine was set at 0.2 ng/mg creatinine (see 
Section 2.4.7.2). When this limit was applied to the data
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obtained in this study, 13 samples (29%) of the vegetarians 
were positive compared with 11 samples (24%) in the case of 
the non-vegetarians. However, within the levels detected 
below the limit of significance of 0.2 ng/mg creatinine, 
there was a difference between the vegetarian and 
non-vegetarian samples. In the case of the vegetarians, 
6 samples (13%) had values less than 0.05 ng/mg creatinine 
whereas in the non-vegetarians, there were 14 samples 
(31%). This may indicate that the level of significant 
detection deduced from the European samples may not be 
appropriate to use with samples from Thai people, possibly 
because the dietary patterns of the Thais and the Western 
people are different. It has been suggested that the 
amounts of UALS present in the urine samples, which are 
used to set a level of significance of aflatoxins 
detection, depend on the dietary intake of the subjects 
(Dragsted et a^ L. , 1988). However, this limit cannot easily 
be set using samples from Thai people, because it is 
usually unknown if they have consumed aflatoxin- 
contaminated food. In other words, on the evidence of the 
results from ELISA detection, the relative contribution 
from UALS and actual aflatoxins is difficult to assess. 
When the results of the Thai samples were compared with 
those obtained using presumed uncontaminated urine samples 
from Western people, the levels observed in the Thai 
samples were actually much lower than the values obtained 
using the Western samples even though the Thai samples were 
obtained from an area where high levels of aflatoxin-
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contaminated food were found. This discrepancy cannot be 
explained on the basis of the level of aflatoxin 
contamination, but it appears possible that the limit of 
significance of 0.2 ng/mg creatinine set on the basis of 
the Western samples may not be appropriate to the Thai
samples and that dietary patterns may, at least in part,
play an important role.
In the case of the vegetarians, there is one point
that is worth mentioning. Since their sources of diet are
entirely vegetables and fruit, if they do not choose their 
diet carefully, they may experience some degree of 
malnutrition. It has been shown that vegetarians may not 
have protein deficiency if they eat a correct diet but they 
will probably have some kind of fat deficiency due to the 
difficulty in substituting for animal fats (Frazer et al., 
1978). This could result in an alteration in metabolism. 
Such a difference has been shown for the metabolism of 
antipyrine between vegetarian and non-vegetarian groups 
(Fraser et al. , 1978; Dollery et a_l., 1979; Brodie et al., 
1980). Therefore, it is possible that the metabolic 
pathways of many other xenobiotics may differ between 
vegetarians and non-vegetarians. If this is the case,, the 
aflatoxin metabolites excreted by these two groups of 
people may be different. Because the same antibody was 
used to detect the aflatoxin in the urine of the two 
groups, differences in the nature of metabolites excreted 
by them could have a considerable effect on the results 
obtained. This could lead to a non-significant difference
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in the levels of aflatoxins excreted, because the antibody- 
used may not be able to detect them. However, this subject 
needs further investigation which was beyond the scope of 
this thesis.
6.4 SUMMARY
From these results, it is confirmed that the methods 
developed for monitoring aflatoxin excretion can be used in 
the case of actual human samples. It can detect wide 
variations in the levels of aflatoxins in the urine. In 
this study, vegetarian people were selected as the study 
population because they were a high risk group who were 
more likely to consume aflatoxin-contaminated food. But 
when the results were compard with a non-vegetarian group, 
the statistical analyses failed to show any significant 
difference. However, it is possible to suggest that 
vegetarians may excrete different forms of metabolites from 
non-vegetarians. This factor needs to be investigated 
thoroughly.
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CHAPTER 7
General Discussion
223
7.1 GENERAL CONSIDERATIONS
The aim of this study was to develop a method for 
monitoring individual exposure to aflatoxin. The method
should be able to be used in large scale epidemiological 
studies without requiring any expensive equipment. It 
should be sensitive enough to detect a very low level of 
aflatoxin exposure with reliable results. The system 
should not be too complicated to perform and ideally it
should be able to be used in field studies; i.e. in the 
areas where there is a high level of contamination with 
aflatoxins. In order to monitor aflatoxin exposure at an 
individual level, urine is the easiest material to collect 
and the technique is non-invasive. The method for 
monitoring urinary aflatoxin excretion has been developed 
with a 'clean-up' procedure to be applied to the samples
prior to the aflatoxin analysis by ELISA. The method was
validated in the conventional way by using uncontaminated 
urine samples from European people spiked with 
radiolabelled AFB^. In addition, the marmoset monkey, an 
animal model which has similar pathways of aflatoxin 
metabolism to human (Hsieh et all. , 1977; Yourtee et al. ,
1987), was also used to validate the method because it is 
probable that their urine, after treating the animals with 
AFBi, would contain a spectrum of aflatoxin metabolites 
similar to that expected to be present in urine samples of 
exposed humans. The details of the development of the 
method will be discussed in Section 7.2.
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After the method had been successfully developed, it 
was used to examine human exposure in samples collected 
from different areas of Thailand where there is 
considerable evidence of aflatoxin contamination in 
foodstuffs (Shank et. al. , 1972b; Anukarahanonta et al. ,
1984). Two groups of people were monitored. In the first 
group, the objective was to compare the urinary aflatoxin 
excretion in patients with or without liver disease in the 
areas where there are high and low aflatoxin contamination 
of aflatoxins in food which correlate with high and low 
incidence of liver cancer respectively.
In one of the areas being studied, in addition to 
high incidences of aflatoxin contamination of foodstuffs
and liver cancer, there is also a prevalence of liver 
infection with Opisthorchis viverrini, which presents a 
serious health problem and which is believed to be involved 
in the development of cholangiocarcinoma (Harinasuta and 
Harinasuta, 1984; Thamavit €Jt al_. , 1988). It was not known 
whether or not infection with liver fluke would result in 
any change in the metabolic pathway of aflatoxin. In order 
to examine this point, the hamster was used as an animal 
model system to study this interaction because it is a
species that is susceptible to infection with the human
liver fluke, 0j_ viverrini. The second group of people
monitored were vegetarians because they would have a very 
high probability of consuming aflatoxin-contaminated food. 
The details of the human monitoring will be discussed in 
Section 7.4.
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7.2 METHOD FOR ANALYSING AFLATOXINS IN HUMAN 
URINE SAMPLES
ELISA techniques are considered to be suitable methods 
for measuring the levels of aflatoxins in human body fluids 
especially in epidemiological studies (Garner et al.,
1985). When the techniques were applied to human urine 
samples, it was found that some substances were present in 
control, presumed uncontaminated, urine samples which 
precluded their direct use in ELISA (see Section 2.4.4.). 
These results are in agreement with other studies (Martin 
et al., 1984; Groopman et a_l., 1984). A 'clean-up'
procedure for the urine samples was introduced by Groopman 
et al. (1984) which included the use of a Sep-Pak
cartridge and an immunoaffinity column. In the present 
study a method for analysing aflatoxins in human urine 
samples using ELISA techniques with some prior 'clean-up' 
of the samples was successfully developed (see Chapters 2 
and 3). The individual steps in the method developed will 
be discussed in detail.
7.2.1 The antibody
The crucial factor in the development of the method 
used was the antibody. In this study, it was a rabbit
anti-AFBi serum which was a polyclonal antibody raised 
against an AFB^-antigen. The antibody had as its major
epitope for antibody recognition, in the coumarin and
cyclopentenone rings of the aflatoxin molecule (see Section 
2.4.3). The anti-serum showed cross-reactivity with
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various aflatoxin metabolites but with differing degrees of 
sensitivity (Table 2.1). A polyclonal antibody was used in 
order to obtain an overall estimation of exposure to 
aflatoxin since a range of metabolites would be involved. 
However when the polyclonal antibody used is compared with 
a monoclonal antibody raised against AFBi, for example, 
that raised by Groopman et al. (1984), it is seen that both 
antibodies detect a range of AFB^ metabolites, such as 
AFMi, AFQi, AFBi-Gua and AFB^-FAPy, with a similar order of 
sensitivities. It is apparent that a monoclonal antibody 
does not necessarily possess a higher degree of specificity 
than a polyclonal antibody, and since it is more difficult 
to raise, the polyclonal antibody used in this study is 
suitable for screening urine samples for aflatoxin 
contamination.
However, the use of the polyclonal antibody, raised 
against AFB^, in the present study also has several 
drawbacks. Firstly, the sensitivity for detecting AFQi and 
its conjugates, which are the most likely metabolites 
excreted in human urine, is low. These metabolites have 
been shown to account for more than 30% of the total 
metabolites in in vitro system using human liver microsomes 
(Moss and Neal, 1985). This means that the level of 
aflatoxin detected by this antibody would be
underestimated. On the other hand, the antibody can detect 
AFMi with a high sensitivity (Table 2.1). AFM^ has been 
found in human urine samples by many investigators 
(Campbell et al., 1970; Sun et al_. # 1983; Zhu et al.,
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1987), immediately after exposure to aflatoxin-contaminated 
food. AFM^ excreted in human urine samples represents 1-4% 
of the dose received. Despite the low level of conversion 
of AFBi consumed to AFM^ excreted, the sensitivity with 
which this metabolite is detected by the antibody used 
gives a sensitive indication of actual exposure to 
aflatoxins. Secondly, when urine samples from marmoset 
monkeys, treated with 14C-AFBi , were used in validating the 
capacity of the antibody in detecting the actual 
metabolites excreted, the antibody had a very low capacity 
for most of the polar metabolites (see Section 3.4.4.4), 
even though it was capable of detecting AFB^-NAcCys with 
high sensitivity (Table 2.1). This demonstrates that it is 
not the polarity of the compounds which determine the 
sensitivity of the antibody, but it is the modification at 
some specific parts of the molecule, especially in the 
coumarin and cyclopentenone rings, which plays an important 
role.
In order to increase the sensitivity of the method, 
further investigations particularly regarding the polar 
metabolites of aflatoxin need to be carried out in detail. 
It is most likely that, most if not all of the polar 
metabolites are in the form of conjugates. One way to 
increase the sensitivity of the ELISA in detecting 
conjugated materials in urine samples would, theoretically, 
be to pretreat them with hydrolytic enzymes in order to 
cleave the conjugates. This would appear to offer the 
possibility of increasing the sensitivity of the aflatoxin
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ELISA analysis using urine samples. However, in some 
preliminary experiments (results not given), it appeared 
that even if the polar aflatoxin metabolites were 
glucuronide or sulphate conjugates, they were not capable 
of easy cleavage with p-glucuronidase or sulphatase. 
Treatment of these polar metabolites with these enzymes did 
not significantly increase the sensitivity of the ELISA or 
result in the release of chloroform-soluble metabolites. 
Some of thepolar metabolites might be of considerable 
significance in relation to long-term exposure to 
aflatoxins. It is possible that in long-term exposure, 
aflatoxin which has been metabolized and bound to protein 
or other macromolecules could subsequently be released by 
repair systems or turnover of macromolecules, followed by 
entry into the bloodstream and excretion in the urine.
In this study, six rabbits were used for antibody 
production. The ELISA and immunoaffinity gel both depend 
on an antigen-antibody reaction and hence, an antibody 
which has the capacity to bind an AFB^ antigen in the ELISA 
should be usable in the preparation of immunoaffinity 
gels. In some cases in the present study, the antibody 
detected aflatoxin in ELISA with a high degree of 
sensitivity, but did not form active immunoaffinity gels. 
No explanation is readily apparent for this phenomenon. 
Presumably there was some factor which affected the ability 
of the IgG fractions to bind to the gel. This point 
requires further investigation. Therefore, in this study 
the antibody used in the ELISA and in preparing the
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immunoaffinity gel came from different rabbits but both 
antibodies were tested in ELISA and were shown to have 
similar capacities and sensitivities for AFBi and its 
metabolites.
7.2.2 The 'clean-up' procedures
The 'clean-up' procedures used in this study involved 
the use of Sep-Pak C^g cartridges and immunoaffinity 
columns which are now standard procedures used by many 
investigators (Groopman et aJL.,1986; Zhu et al., 1987;
C.P. Wild, personal communication). The advantages and 
disadvantages of these procedures are discussed step by 
step.
7.2.2.1 Sep-Pak Cia cartridge
Sep-Pak C^g cartridges have been used for collecting 
and concentrating urine samples for aflatoxin analysis 
since 1983 (Autrup et al., 1983). Apart from being used as 
the preliminary 'clean-up' procedure, the cartridge have 
also been used to transfer the samples from Third World 
countries where most of the field studies were carried out 
(Autrup et al. , 1983; Groopman et al., 1985; Dragsted et
al. , 1986). In these studies, not all the samples were
collected as 24 h total urines, so it was not possible to 
obtain the total volumes of urine excreted. To overcome 
this problem, creatinine concentrations were determined in 
samples collected at single time points to correct for 
individual variation in volume voided and allow the
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comparison of aflatoxin excreted from each individual 
(Garner et al. , 1985). If the cartridges are used as the 
means of sample transportation, creatinine is not retained 
and comparisons between each individual cannot be 
performed. This problem may be solved either by sending 
untreated urine samples or by analysing them for their 
creatinine content before absorbing them onto the Sep-Pak 
cartridges.
From the results of the experiments performed in the 
present study using marmoset urine samples, absorption onto 
Sep-Pak C^g cartridges provided a suitable system for 
removing some of the substances which interfere with the 
ELISA, whilst at the same time retaining not only the 
non-polar but also the polar metabolites of aflatoxin (see 
Section 3.4.4.1). More than 95% of the radiolabelled 
metabolites, excreted in marmoset urine, were retained by 
the cartridge and . subsequently could be eluted with 
methanol. This demonstrated that this step in the 'clean­
up' procedures did not cause any significant loss of 
aflatoxin metabolites and also that, some of the 
interfering substances could be removed,suggesting that 
they were polar in nature.
7.2.2.2 Immunoaffinity column
The objective of using the immunoaffinity column is to 
concentrate and purify the samples based on the antigen- 
antibody reaction. Substances which are not recognized by 
the antibody will not be retained, regardless of their
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polarity, only substances of interest will be retained in 
the concentrated samples. The affinity characteristics of 
the antibodies used in the preparation of the affinity gels 
determine the range of metabolites which will be retained. 
Groopman et al. (1984) was the first group who suggested 
the use of such columns in the assay of aflatoxin, and 
later reported that the columns were reusable (Groopman jst 
al., 1985, 1986). When the immunoaffinity column was
adapted for the present study, apart from the problem 
encountered in the preparation of immumoaffinity gels with 
some samples of immune serum as discussed in Section 7.2.1, 
the columns were found to be reusable only under certain 
circumstances. When AFB^ was applied to the column in PBS, 
the column could be reused at least 4 times without losing 
any capacity. In contrast, when AFB^ was added in 
uncontaminated human urine samples, no loss of efficiency 
was observed using the column for two sample assays, but 
when subsequent column loadings were attempted quantitative 
binding of AFB^ onto the column did not take place and so 
the effective use of the column was limited to two 
preparations. The interfering substances which limited the 
use of the columns could be partly removed by passage 
through the Sep-Pak C^g cartridges. These results are 
similar to those reported in other studies, for example 
Groopman et al. (1984) had reported that 60% of the 
radiolabelled AFBi in spiked urine samples applied directly 
to the affinity column failed to bind, but when the 
samples were pre-purified by absorption onto Sep-Pak
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cartridges, quantitative absorption of AFB^ subsequently 
took place on the affinity column. The results from the 
present study indicated that the volume of urine loaded 
onto the affinity column should be kept as low as possible 
consistent with the level of contamination with aflatoxin 
which determined the probability of obtaining significant 
results in the subsequent ELISA. It was decided that 
routinely only 1 ml of urine samples would be used and the 
column would not be used more than twice.
The capacity of a column, having a 1 ml bed volume, 
to retain AFB^ was found to be 20 ng/ml PBS or 5 ng/ml
urine. This capacity was quite low when compared with 
1-1.3 jag AFBi from 10 ml PBS (100-130 ng AFBi/ml PBS), also 
using a 1 ml column bed volume as reported by Groopman et 
al. (1984). The reason for this may be that when a
monoclonal antibody, such as that used by Groopman et al. 
(1984), is used in the preparation of affinity gel, there 
is a greater concentration of specific binding sites 
attached to the gel than in the case of polyclonal
antibody, even if a purified IgG is used. Furthermore in
the present case whole serum was used to bind to the gel.
If necessary, the capacity of the gel could be increased by
purifying the IgG fraction from the serum to remove serum 
protein not involved in the antigenic response. This
purification step was not attempted in this study because
the columns were designed as disposable after two sample 
loadings and the capacity of the column appeared adequate 
for the requirement of the study.
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When the binding characteristics of the column were 
examined, using urine samples from marmoset monkeys treated 
with only 50% of the radiolabelled metabolites
was retained on the column and most of the polar 
metabolites were removed in the washing fraction. This is 
due to the lack of sensitivity of the antibody for the 
polar metabolites present in the urine as discussed in 
Section 7.2.1. This study appears to be the first one 
reported examining the retention on affinity gels of those 
metabolites most likely to be found in human urine. It 
provides an assurance that the system being developed is 
suitable for detecting actual aflatoxin metabolites in 
urine rather than just AFBi.
7.2.2.3 Evaporation process
Since methanol is used at almost every step of the 
procedures and it had been found that it affected the 
analysis of aflatoxin in ELISA (see Section 2.4.5), it was 
necessary to examine the efficiency of methods for its 
removal. Various evaporation processes were tried and the 
results indicated that the Speedvac Concentrator was the 
most efficient and reliable method which gave more than 90% 
recovery (based on radiochemical recovery) after 
evaporation at 40°C. Recoveries using some of the other 
evaporation techniques examined were found to be as low as 
20-50% for as yet unknown reasons. The limitation of the 
chosen method is that it takes a long time to process 
samples with large volumes, for example, 5 h to concentrate
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10 ml samples, containing 85% methanol, to 0.5 ml at 40°C, 
and only 8 samples can be run at a time. When large 
volumes of methanol-containing samples needed to be 
evaporated, rotary evaporation was used, but it required 
great care to avoid any loss of the samples, and much more 
careful attention than the Speedvac Concentrator.
When samples were fractionated by HPLC, different 
fractions contained different concentrations of methanol 
due to the gradient elution used. In order to remove these 
differences in methanol concentration, the samples were 
evaporated to dryness in the Speedvac Concentrator at 
40 °C. The practice of evaporation to complete dryness 
whilst suitable for the quantitative HPLC analyses 
performed, was not advisable when samples from the Sep-Pak 
and affinity column were used in subsequent ELISA analysis 
because of very variable recoveries. But in the case of 
the HPLC fractionating it was used since absolute 
quantitation was not the object of these experiments.
7,2.3 ELISA
The ELISA technique proved to be sensitive and 
reliable in analysing aflatoxin in human urine samples and 
the results were reproducible. It detected a level of AFB^ 
as low as 10 pg/ml in PBS. However, when the actual urine 
samples were used after passing through all the 'clean-up' 
procedures, they were diluted with PBS in order to achieve 
a content of AFB^ equivalents in the range of 0.03- 
1.00 ng/ml which was in the proportionate part of the
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standard ELISA inhibition curves. The actual dilution 
required depended on the level of aflatoxin contamination 
of the individual urine samples. At the outset, this
level, of course, was not known and so the dilution
required was determined as the results of the preliminary 
experiments using a range of dilutions. The samples were 
always analysed in triplicate using 6 wells per assay and 
the results obtained were reproducible (within ± one 
standard deviation). When the levels of aflatoxin in
individual samples were compared, AFBi equivalents were
expressed per creatinine unit as has been discussed (see 
Section 5.3). However, all of these aflatoxin values were 
underestimates, due to the lack of sensitivity of the 
antibody in recognizing some of the aflatoxin metabolites. 
But as far as the monitoring system is concerned, ■ the 
absolute level of contamination may not be crucial. The 
most important objective is to correlate the relative 
levels of contamination with the relative incidences of 
liver cancer in the different regions. It will be valuable 
in future to gather more information on the level of 
individual exposure in many parts of the world and relate 
them to food contamination and liver cancer incidence.
7 .3 URINARY AFLATOXIN-LIKE SUBSTANCES (UALS)
There is considerable evidence that urine samples 
cannot be used directly in the immunoassays due to the 
presence of UALS (Martin et al. , 1984? Groopman £t al_. ,
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1984; Dragsted et al. , 1988). In the present study using
10 presumed uncontaminated urine samples from West Germany, 
the levels of UALS detected varied in the range of 
1.63-10.69 ng apparent AFBi/mg creatinine. These levels 
could be reduced by 97% by passing the samples through 
Sep-Pak C iq cartridges and immunoaffinity columns, when the 
levels were substantially reduced to 0.04-0.24 ng apparent 
AFBi/mg creatinine (Table 2.16). These results indicate 
that there are some substances in the urine that can react 
with antibody and interfere with ELISA. However, even 
after the 'clean-up1 procedures, although the levels are 
reduced, the materials remaining in the samples react in 
the ELISA giving measurable blank values. These findings 
are essentially in agreement with the study of Martin et 
al. (1984) who found that human urine samples collected in
France were positive for aflatoxins in an ELISA using a
polyclonal antibody against AFB^, and with the study of 
Groopman et a_l. (1984, 1986) who noted that materials
present in human urine samples collected in the USA, 
inhibited the binding of AFBi to an affinity column which 
was prepared using a monoclonal antibody against AFB-l . The 
interference due to these substances could be abolished by
extraction or dilution (Martin et al., 1984), or
effectively removed by concentration of the urine samples 
on Sep-Pak C^g cartridges (Groopman et al. , 1986).
However, in a more recent study using Danish urine samples, 
Dragsted et al. (1988), who found levels of 0.0-6.5 ng AFB^ 
equivalent/mg creatinine analysed by ELISA using a
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monoclonal antibody against AFB^, reported that a 
non-specific inhibitor from some urine samples could be 
removed in the purification step using a Sep-Pak C^g 
cartridge, but however, a competitive component for the 
antibody still remained. This finding is consistent with 
the results from the present study that UALS can be 
partially, but not completely, removed by the 'clean-up' 
procedures using a Sep-Pak and an affinity column.
An attempt has been made to isolate and characterize 
the structure of UALS (Dragsted et al., 1988). They found 
that excretion of UALS showed inter- and intra-individual 
variations and indicated that dietary components, 
especially beer, dairy products and meat, were responsible 
for the high level of UALS present in the Danish samples. 
They also suggested that different aflatoxin-like compounds 
may be present in the different dietary sources. It is 
obvious that dietary patterns vary considerably in 
different parts of the world and since they appear to be 
highly correlated with the excretion of UALS, therefore, 
this subject requires thorough investigation in different 
populations. However, this may not be practical in areas 
with high contamination with aflatoxins because of 
difficulties in differentiating between the relative 
contributions of UALS and actual contamination with 
aflatoxins in the ELISA. To solve this problem, monitoring 
of UALS levels and aflatoxin contamination in food have to 
be carried out in parallel, and the levels of UALS could be 
established using the samples obtained from people known to
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consume aflatoxin-free food. However, a great number of 
samples would have to be analysed.
In order to infer the possible chemical structures of 
UALS, Dragsted et ajL. (1988) used a map of epitopes, 
recognized by the antibody, to conduct an on-line computer 
search and came up with strong evidence that UALS contain 
an aflatoxin-like structure, possibly with modification at 
the 8,9-position. The UALS can be resolved into several 
peaks by HPLC, indicating that they represent a group of 
compounds with retention times similar to or slightly 
longer than that of AFB^. By comparison with the results 
of Dragsted et al. (1988) it appears that the hamster may 
be a good animal model system to study the UALS because in 
HPLC separations of control urine samples before treating 
with AFBi (Figure 4.7), the apparent AFBj was present in 
fractions having retention time corresponding to the 
retention time of AFB^ itself. Since hamsters produce 
relatively concentrated urine, no preliminary evaporation 
processes are required and so they should provide a 
suitable source of UALS for characterization.
7.4 STRATEGY FOR MONITORING AFLATOXIN EXPOSURE USING
HUMAN URINE
The purpose of aflatoxin monitoring in human body 
fluids is to provide useful information on the risk 
assessment of this compound with regard to the development 
of liver cancer. In this study urine samples from patients 
with or without liver disease from different parts of
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Thailand were monitored. It was found that the use of 
hospitalized people as the study group, especially patients 
with liver disease, was not ideal for monitoring aflatoxin 
exposure. Although it is relatively easy to collect 
biological fluids from these people, it is possible that 
they may be too sick to have their normal dietary 
patterns. By changing from their normal diet even for a 
short period of time, aflatoxin will be readily removed 
from their bodies. In humans, similar to the marmoset 
monkey, most of the aflatoxin metabolites will be excreted 
within the first 48 h of exposure (see Section 3.4.5). 
Therefore, monitoring the levels of aflatoxin excretion 
after admission to hospital is unlikely to be 
representative of their previous exposure because the 
majority of the aflatoxin detected represents immediate 
pre-exposure only. From this viewpoint, the target 
population for urinary aflatoxin monitoring should be 
normal healthy people in the high risk areas since they are 
likely to have their normal dietary patterns. By
monitoring this population, more useful information 
regarding exposure should be obtained.
When patient populations are monitored for aflatoxin 
excretion, one point which should be considered is the 
status of their drug metabolizing systems. Any condition 
that has an affect on aflatoxin metabolism may lead to 
alterations in the metabolites excreted. It was clearly 
shown in this study, using hamsters infected with liver 
fluke, Opisthorchis viverrini, that the pattern of
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aflatoxin metabolites excreted in the urine was different 
from the non-infected animals. If this is also the case in 
humans, comparison of aflatoxin excretion by ELISA 
monitoring of urine samples between people with or without 
liver fluke infection, may be invalid because the results 
of the monitoring method are dependent on the relative 
antibody recognition of specific aflatoxin metabolites. 
Alteration of the pattern of metabolites excreted to 
compounds that are not recognized by the antibody or which 
are more poorly recognized will lead’ to a further under­
estimation of exposure levels. It is quite clear therefore 
that any condition which may affect or alter the pathways 
of aflatoxin metabolism should be investigated in detail. 
This could be carried out by examining the changed pattern 
of metabolites excreted and, in addition, by using a 
variety of antibodies with differing specificities toward 
aflatoxin metabolites. This would provide a better 
understanding of the aflatoxin excretion pattern.
However, it was found from this study that there was 
some evidence of a correlation between the level of 
aflatoxin excreted in urine samples by patients with 
non-liver disease and the level of aflatoxin-contaminated 
food in those areas of study, although the correlation did 
not achieve statistical significance. These patients, even 
though they do not have liver disease, may not be an ideal 
population for aflatoxin monitoring but, at least, they 
indicate that using the methods developed, it is possible 
to obtain valid results using actual urine samples obtained
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from areas of differing aflatoxin contamination. In a 
future study, it would be preferable to compare groups of 
normal healthy people living in those areas.
In the study on vegetarians, there is a trend that
they may excrete higher levels of aflatoxin in their 
urine (Figure 6.1), but more samples need to be analysed. 
In addition, it was also found in this study that females 
tend to excrete higher levels of aflatoxin than males. The 
higher levels of aflatoxin found in urine samples may 
indicate that they are exposed to higher levels of
aflatoxin in food, or alternatively that they may excrete 
more aflatoxin from a comparable level of exposure. From 
the marmoset monkey study which is consistent with other 
animal studies, the female excretes a higher percentage of 
the aflatoxin dosed and is less susceptible to the toxic 
effects of AFBi than the male (Busby and Wogan, 1984). 
High initial excretion of aflatoxin metabolites in urine 
may indicate that AFB^ is metabolized to less toxic 
compounds which are then more readily excreted, without 
binding to any biologically active macromolecule. However, 
monitoring of food intake is necessary before any firm 
conclusion could be drawn.
In order to monitor aflatoxins in the community more 
precisely, surveys of exposure in the general population 
need to be carried out. Howver, this will pose some
problems. The first problem is concerned with the
logistics as it is not an easy task to monitor a large 
group of population living in a widespread community and it
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would require a large number of staff to collect the 
appropriate urine specimens for aflatoxin analysis. The 
other important scientific consideration is the well known 
fact that the latent period of cancer is very long and it 
may take several years before cancers developed after 
exposure to the causative carcinogenic agent. Therefore, 
the level of aflatoxin exposure observed at any one time 
may not reflect the actual situation at the time of the 
carcinogenic induction. Providing that the life style, 
eating habits and levels of contamination are relatively 
constant, as appears to be the case in Thailand
(Anukarahanonta et a_l., 1984), the monitoring of aflatoxin 
exposure will be appropriate. However, it is still quite 
difficult to establish the link between aflatoxin
contamination in food and level of excretion if only a 
single time point sample is collected. This is because the 
levels of aflatoxin found in the urine samples will 
represent only the immediately previous exposure. 
Therefore, pilot studies may be needed using a stable 
community in which patterns of diet are constant. Food and 
urine samples should be collected for at least 7
consecutive days to determine whether there is a variation 
within a week. This study would need to be repeated to
determine seasonal variation. If the variations within a 
week and also between the seasons are low, samples
collected at any single time point would be appropriate, 
otherwise the study design has to take all of these 
variations into account. In addition, the number of
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samples collected should be large enough to allow 
statistical analysis to be performed, especially when there 
are multiple factors involved in the study.
7.5 CONSIDERATIONS IN THE APPLICATION OF THE
MONITORING SYSTEM TO AFLATOXIN EXPOSURE IN HUMAN
The monitoring of urinary aflatoxin excretion should 
be applied to prospective studies in order to prevent liver 
cancer. However, there are some points that need to be 
borne in mind.
1. There is strong evidence supporting the hypothesis of 
multifactorial aetiology of human liver cancer in 
which aflatoxin and HBV both play important roles (see 
Section 1.5). In order to study the effect of 
aflatoxins in the development of liver cancer, 
confounding factors should be taken into 
consideration,especially those which may alter the 
pattern of metabolites excreted in urine. The results 
of the present study indicate such a role for 
infection with liver fluke in the hamster animal model 
system. Clearly a similar situation could exist in 
the case of infection with HBV and this aspect should 
be considered in any aetiological studies.
2. The UALS present in samples from different parts of 
the world may differ because of the patterns of diet 
consumed. The UALS levels may differ between children 
and adults, and also between males and females, 
aspects which require further investigation.
244
3. Concerning the metabolic aspect of aflatoxin action, 
it is quite obvious that with any alteration in liver 
status, e.g. as a result of liver parasitism, the 
patterns of aflatoxin metabolites could be changed as 
indicated in the hamster study. Thus liver fluke 
infection and other conditions that may affect the 
drug metabolism systems should be borne in mind when 
carrying out monitoring of aflatoxin in urine. The 
results of the study using urine samples from the 
Philippine children show a wide range of AFBi 
equivalents (0.19-5.50 ng/mg creatinine) (D.W. 
Denning, personal communication). This may be due to 
differences in aflatoxin metabolism between adults and 
children. It would be very interesting to study the 
levels of aflatoxin excretion in children of various 
ages because, from experimental studies, young animals 
appear to be more susceptible to the carcinogenic and/ 
or toxic effects of many substances (Vesselinovitch 
and Mihailovich, 1968). In addition, for the purpose 
of prospective monitoring, children would be the 
appropriate group to start with.
4. The results of urinary aflatoxin monitoring very much 
depend on the antibody used, and therefore it would be 
desirable to have a range of antibodies which could 
recognize the appropriate metabolites present in urine 
samples from different conditions such as infection 
with liver fluke, vegetarians as well as 'control' 
people.
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5. Many studies monitoring urinary aflatoxin levels are 
concerned with the presence of primary metabolites 
formed principally in the liver or other organs. 
These aflatoxin metabolites only reflect acute 
exposure. Other metabolites present in the urine or 
perhaps blood which are more indicative of chronic 
exposure, such as aflatoxin-protein or DNA adducts 
should be considered in future studies. In this 
connection, the average life-time in human of e.g. 
albumin (20 days) and haemoglobin (120 days) render 
these molecules better candidates for monitoring 
chronic exposure than e.g. AFM^ which is excreted 
within 48 h of exposure to aflatoxin. The influence 
of adduct formation in proteins on the life-time of 
these compounds is also largely unknown. The
possibility of shorter or extended life-time should be 
investigated. In addition, the pattern of metabolites 
excreted by people exposed to chronic low doses of 
aflatoxin may not be the same as those resulting from 
acute high doses. In this study, the urine samples 
from marmoset monkeys used in the validation of the 
methods developed, represent only acute high dosing in 
which the antibody used could not detect most of the 
polar metabolites excreted. In the chronic situation, 
it is most likely that more polar metabolites would be 
excreted. This is indicated by the results of the 
marmoset study in which 48 h post-dosing, samples 
contained a higher percentage of polar metabolites
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than the 24 h samples (see Section 3.4.2). Therefore, 
it is necessary to develop antibodies capable of 
detecting these polar metabolites to achieve higher 
sensitivities in monitoring for chronic exposure.
7.6 SUMMARY
The immunological methods necessary for monitoring 
aflatoxin excretion in human urine samples were 
successfully developed using ELISA techniques with 
prepurification of the samples with Sep-Pak C^q cartridges 
and immunoaffinity columns. The crucial part of these 
procedures is the antibody used in ELISA and in the 
preparation of the immunoaffinity gel. The antibody used 
has as its major epitope, the coumarin and cyclopentenone 
rings of the aflatoxin molecule. The overall recoveries of 
the procedures developed, validated using urine samples 
from aflatoxin-treated marmoset monkeys were approximately 
50%. This low recovery was apparently due to the inability 
of the antibody to recognize most of the polar metabolites 
excreted. These methods have been used to monitor the 
levels of aflatoxin excretion in urine samples from various 
groups of people from Thailand. The results indicate that 
the methods developed are capable of detecting a wide range 
of aflatoxin excretion and, therefore, are suitable for use 
in epidemiological studies provided that certain modifying 
factors, e.g. differences in patterns of metabolite 
excretion, are borne in mind.
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